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ABSTRACT 
 
The acute phase response is implemented by infected hosts in response to exposure to 
pathogens, including bacteria and viruses. Acute phase responses comprise physiological 
and behavioural changes, such as fever and a range of “sickness behaviours”, including 
lethargy and anorexia as well as impairment in learning and memory. Similar to other 
sickness behaviours, the effect of infection on learning and memory processes has been 
attributed to the release of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and 
interleukin-6 (IL-6). However, the exact role of IL-1β and IL-6 in mediating infection-induced 
cognitive impairment is not clear. Unlike fever, anorexia and lethargy, which may benefit an 
infected host, the physiological benefit of cognitive impairment during illness is doubtful.  
 
To initiate an acute phase response experimentally, moieties of typical bacteria (Gram-
negative and Gram-positive) and viruses frequently are employed. Moieties from the atypical 
Mycoplasmas seldom have been used. Consequently, there is a dearth of information on the 
physiological mechanisms that underlie acute phase responses following Mycoplasma 
infection, despite the prevalence of the disease in the general population. Mycoplasma 
pneumoniae frequently causes community-acquired pneumonia, which may have serious 
extra-pulmonary complications, including cognitive deficits. Therefore, I investigated fever 
and sickness behaviours as well as cytokine responses in simulated, atypical Mycoplasma 
infection. 
 
I implemented an animal model of simulated Mycoplasma infection and characterised fever 
and sickness behaviours, including lethargy and anorexia as well as impairment in learning 
and memory during acute and recurrent acute simulated infection. I also characterized the 
response in the periphery and in the brain of individual pro-inflammatory cytokines, IL-1β 
and IL-6, to administration of fibroblast-stimulating lipopeptide-1 (FSL-1), which simulates 
vi 
 
Mycoplasma infection. Using rats, I recorded fever and lethargy with biotelemetry and 
assessed effects of simulated Mycoplasma infection on learning and memory using a Morris 
Water Maze. In addition, I examined the histology of tissue from the hippocampus, a key 
brain area involved in spatial learning and memory, to assess residual effects of simulated 
Mycoplasma infection on learning and memory.  
 
I showed that bolus administration of a pyrogenic moiety from Mycoplasma, fibroblast-
stimulating lipopeptide-1 (FSL-1), dose-dependently induced fever, lethargy, anorexia and 
body mass stunting in rats. However, FSL-1 administration did not induce concomitant 
impairment in spatial learning and memory. Importantly, at the time of testing in the Maze, I 
found the concentrations of IL-1β to be up-regulated in both the hypothalamus and the 
hippocampus, while the concentrations of IL-6 were unaffected. I also showed that recurrent 
acute injections of FSL-1, at 10 d intervals, induced recurrent fevers, lethargy and anorexia 
without the development of pyrogenic tolerance to any of the sickness responses measured. 
However, there was no residual body mass stunting in rats and also no growth retardation, 
despite the recurrent simulated infection. Equally importantly, there were neither lasting 
detrimental effects on spatial learning and memory nor any residual histological damage to 
the hippocampus of rats. 
 
My findings in simulated Mycoplasma infection are important, firstly because Mycoplasma 
infection is prevalent in both developing and developed countries and frequently causes 
outbreaks, and secondly because Mycoplasma infection affects children and adolescents of 
school-going age. My findings also are encouraging: although lasting detrimental effects, 
including impairment in learning and memory as well as body mass stunting may occur in 
other infections, these appear not to be inevitable outcomes in Mycoplasma infection. 
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PREFACE 
 
In the context of the field of ‘host-pathogen interaction’, approaches into the pathology of 
various infections have elucidated new pathways that we can explore to better understand 
and treat debilitating illness-induced symptoms of the host. Fever and ‘sickness behaviours,’ 
a well-coordinated set of behavioural responses, accompany most if not all types of infection 
and may compromise the sick individual’s quality of life. In spite of the prevalence, sickness 
behaviour in Mycoplasma infections is under-researched, particularly the sickness behaviour 
of impairment in learning and memory. In addition to being a causative agent for community-
acquired pneumonia, the atypical bacterium, Mycoplasma pneumoniae, has been linked to 
various life-threatening, extra-pulmonary infections and memory deficits. Infections with M. 
pneumoniae often present asymptomatically giving the infection the nickname of “walking 
pneumonia”. However, the general perception that Mycoplasma infection is self-limiting is 
not true. The possibility of detrimental consequences, including residual impairment in 
learning and memory, often is overlooked. 
 
Studying the effects of Mycoplasma-induced activation of the innate immune system 
experimentally has been hampered by a lack of an adequate experimental model that does 
not involve the live pathogen. Recently, it was discovered that a pyrogenic moiety from 
Mycoplasma salivarium, namely fibroblast-stimulating lipopeptide-1 (FSL-1), induces fever 
and sickness behaviour in rats. However, there has been no investigation of the effects of 
FSL-1, which simulates Mycoplasma infection, on the sickness behaviour of impaired 
learning and memory. There also has been no investigation into the long-term 
consequences of simulated Mycopolasma infection, including residual detrimental effects on 
learning and memory, residual histological changes in the brain or residual physical 
impairment. 
xxi 
 
Therefore, the aim of my thesis was to investigate systematically both physiological and 
behavioural responses, including fever, lethargy, growth and anorexia as well as impairment 
in learning and memory, in acute (Chapter 3) and recurrent (Chapter 5) simulated 
Mycoplasma infection in rats. In order to achieve these aims, I had to acquire the techniques 
for administering pathogen-associated molecular patterns (PAMPs) and for measuring fever, 
anorexia and lethargy in rats (Chapter 2), which already were established in the laboratory 
in which I conducted my research (University of the Witwatersrand). However, no one in the 
laboratory previously had worked with the PAMP that I intended to administer to rats, namely 
FSL-1. I had to determine the most suitable drug concentrations, dosages and intervention 
periods for FSL-1 in order to establish a model suitable for recurrent acute infections without 
the development of pyrogenic tolerance (Chapter 5). Only one other study in the laboratory 
previously had attempted simulation of recurrent infection and had analysed the results from 
simulated recurrent infections (Chapter 5).  
 
Finally and most importantly, no one in the laboratory in which I conducted my research had 
implemented successfully a Morris Water Maze behavioural model, or indeed any other 
measure of learning and memory. The Morris Water Maze, which assesses spatial learning 
and memory in rodents, was a critical component for projects during my PhD (Chapter 2, 3 
and 5). I also applied skills and experience that I have gained during research for my 
Masters degree (North-West University, NWU), such as excising certain areas of the rat 
brain. For studies during my PhD I measured brain and plasma concentrations of the pro-
inflammatory cytokines, interleukin-1β (IL-1β) and interleukin-6 (IL-6) (Chapter 4) and also 
investigated histological pathology of certain regions of the brain (Chapter 5).  
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During infective illness the infected individual responds by implementing the “acute phase 
response” through activation of the innate immune system. The acute phase response 
comprises a series of physiological and behavioural changes hypothesized to accelerate 
recovery of the individual, to prevent ongoing damage from infecting pathogens (see 
Baumann and Gauldie, 1994; Johnson, 2002). Physiological changes include elevation of 
body temperature, including fever, and a suite of non-specific, non-thermal behavioural 
changes, collectively known as “sickness behaviour” (Hart, 1988). These changes are 
thought to be well organized, adaptive responses that are considered critical to host survival 
(Hart, 1988,  1991; Romanovsky and Szekely, 1998; Soszynski, 2003; Adelman and Martin, 
2009). However, scientists have challenged the idea that fever is always beneficial to the 
host (e.g. Kluger, 1986), and beneficial only to the host (e.g. Ewald, 1980).  
 
Sickness behaviours are not reflexive sickness-induced reactions or passive responses to 
illness, nor are they signs of debilitation; rather, sickness behaviours are thought to be 
active, defensive responses that reflect an evolved adaptive state of altered motivation that 
enables the sick individual to counteract the infection (Aubert et al., 1995; Maier and 
Watkins, 1998; Konsman et al., 2000; Dantzer, 2001a). Together with fever, sickness 
behaviours, including anorexia, lethargy, fatigue, malaise, hypersomnia, hyperalgesia and 
disturbed mood constitute the clinical manifestations of the acute phase response (Hart, 
1988; Konsman et al., 2002; Johnson, 2002). In recent years cognitive alterations, which 
include learning and memory disturbances, also have become recognised as members of 
the sickness behaviour syndrome, both clinically and experimentally (Capuron et al., 1999; 
Dantzer, 2001a; Reichenberg et al., 2001; Cunningham and Sanderson, 2008). But, is there 
really any adaptive value to being cognitively impaired during illness? It may well be that 
there is no adaptive purpose.  
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Clinical studies and animal models of infection have demonstrated that the physiological 
mechanisms underlying fever and sickness behaviours are similar, if not identical, in humans 
and laboratory animals. Therefore, investigations into sickness behaviour use animal models 
to mimic the human condition. To avoid ethical issues arising from administering live 
pathogenic organisms to humans and laboratory animals, pyrogenic moieties of the 
organisms, e.g., killed organisms or their cell wall components are used during simulated 
infection to stimulate the innate immune system in the same way as it would be in the actual 
infection. For example, the glycolipid pyrogenic moiety extracted from cell membranes of 
Gram-negative bacteria, lipopolysaccharide (LPS), is used widely to simulate Gram-negative 
infection. So too is polyinosinic:polycytidylic acid (poly I:C) used to mimic the double-
stranded RNA of viruses, and peptidoglycans (e.g. muramyl dipeptide; MDP) to mimic Gram-
positive bacteria. In experimental animals, fever and sickness behaviour, particularly 
learning and memory impairment have been studied extensively in infections relating to 
typical bacteria, i.e. Gram-positive and Gram-negative bacteria (Wellmer et al., 2000; 
Loeffler et al., 2001; Irazuzta et al., 2001; Bifrare et al., 2003; Hoffmann et al., 2007; 
Cunningham and Sanderson, 2008), and also in infections relating to viruses (Kent et al., 
2007; Self et al., 2009; Okun et al., 2010; Dilger and Johnson, 2010). Aside from these three 
well established animal models of infection, sickness behaviours must be characterized in 
various other pathogens. Comparatively little is known about fever and sickness behaviours 
resulting from ‘atypical’ bacteria, including the Mycoplasmas, despite the prevalence of these 
pathogens.  
 
The Mycoplasmas are causative agents for potentially serious respiratory diseases in 
humans and other animals and affect people of all ages, including otherwise healthy children 
between the ages of 5-15 years. Community acquired pneumonia, one of the conditions 
caused by the Mycoplasmas, occurs in a recurrent fashion. Pneumonia still is one of the 
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main causes of death among children, especially in developing countries (McIntosh, 2002; 
Waites and Talkington, 2004; Sinaniotis and Sinaniotis, 2005). In humans, pneumonia 
caused by the Mycoplasmas is characterized by headache, malaise, non-productive cough, 
a low-grade fever, and sometimes wheezing (Ruuskanen and Mertsola, 1999; McIntosh, 
2002), but some patients do develop severe life-threatening pneumonia (e.g. Miyashita et 
al., 2007). In animal models, intracerebroventricular (i.c.v.) administration of heat-inactivated 
Mycoplasma fermentans (M. fermentans) to rodents induced significant elevations in body 
temperature, decreased locomotor and exploratory activity, and suppressed the 
consumption of food intake (Yirmiya et al., 1997). Apart from the sickness behaviours of 
lethargy and anorexia, very little is known about another component of sickness behaviour, 
namely learning and memory impairment, following simulated Mycoplasma infection. 
 
This chapter reviews literature on animal models of sickness behaviours induced by 
simulated bacterial infections, other than Mycoplasma infection, and highlights the 
physiological consequences of such infections. This chapter also raises the questions 
relating to sickness behaviour in simulated Mycoplasma infection that will be addressed in 
my thesis. Because the febrile response to simulated, systemic bacterial infection is 
thoroughly characterised and because fever is an inevitable accompaniment of the acute 
phase response, the background of this thesis will focus mainly on sickness behaviours, and 
not necessarily on fever. 
 
1.1. INFECTION, PATHOGEN RECOGNITION AND INNATE IMMUNITY 
 
Stimulation of the host’s immune system in response to systemic infection, inflammation and 
injury, usually is initiated in the periphery. However, many of the sickness responses are 
mediated by the brain and not by peripheral organs. It is hypothesized that during illness the 
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brain and the immune system establish a bi-directional communication network: the immune 
system is responsible for providing the brain with information about processes occurring in 
the periphery, and the brain, in turn, influences and controls activity of peripheral organs and 
cells of the immune system (see Blalock et al., 1985; Maier and Watkins, 1998). Activation of 
the host’s innate immune system, i.e. detection of pathogens, relies upon recognition of 
conserved motifs unique to pathogens, known as pathogen-associated molecular patterns 
(PAMPs). PAMPs are essential for the metabolism and survival of pathogens and they are 
produced only by pathogens and not by host cells. In this way the host’s immune system can 
distinguish between self and non-self.  
 
PAMPs reflect intrinsic properties of pathogens of a given class (Medzhitov and Janeway, 
1997) and act as ligands for pattern recognition receptors (PPR) on immune cells in the host, 
including the Toll-like receptor family. To date, ten variants of human TLRs (TLR1-TLR10) 
have been identified (see Figure 1.1), which mediate recognition of a range of pathogens (for 
reviews see Janssens and Beyaert, 2003; Casanova et al., 2011). TLRs are believed to 
function as dimers and most TLRs appear to function as homodimers, except TLR1 and 
TLR6, which form heterodimers with TLR2 (Figure 1.1, Takeuchi et al., 1999; Ozinsky et al., 
2000; Takeda et al., 2002).  
 
In the host, interaction between Toll-like receptors (TLRs) and PAMPs initiates the innate 
immune response to the invading pathogen (Janeway and Medzhitov, 2002; Kapetanovic 
and Cavaillon, 2007), which leads to activation of intracellular signal transduction pathways 
and the formation of circulating pro-inflammatory cytokines (Akira et al., 2001; Imler and 
Hoffmann, 2001; Cartmell and Mitchell, 2005).  
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Figure 1.1. The human Toll-like receptor family with its specific PAMPs (adapted from 
Janssens and Beyaert, 2003). G+, Gram-positive bacteria; MDP, muramyl dipeptide; S. aureus, 
Staphylococcus aureus; MALP-2, macrophage-activating lipopeptide-2; FSL-1, fibroblast-stimulating lipopeptide-
1; G- bacteria, Gram-negative bacteria; LPS, lipopolysaccharide; E.coli, Escherichia coli; dsRNA, double-
stranded ribonucleic acid; poly I:C, polyinosinic:polycyidylic acid; CpG DNA, cystein-phosphodiester-guanine 
deoxyribonucleic acid; CD14, Cluster of Differentiation 14; MD-2, myeloid differentiation; TLR, toll-like receptor.   
 
Bacterial PAMPs include peptidoglycans and lipoteichoic acid from Gram-positive bacteria 
as well as endotoxin (a mixture of pure LPS and other proteins, Hitchcock et al., 1986) from 
the outer membrane of Gram-negative bacteria (see Akira et al., 2006). Unlike typical Gram-
negative and Gram-positive bacteria, the Mycoplasmas do not possess a cell wall and 
therefore are often referred to as ‘atypical’ bacteria. Thus, the Mycoplasmas do not possess 
bacterial modulins such as LPS, lipoteichoic acids or peptidoglycans. However, there is 
evidence to show that membrane-bound lipoproteins present in cell membranes of all 
Mycoplasma species are capable of activating monocytes, macrophages, lymphocytes or 
fibroblasts that are cytokine-producing cells (Razin et al., 1998; Shibata et al., 2000).  
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Figure 1.2. Signaling pathways employed by diacylated lipoproteins e.g. fibroblast-
stimulating lipopeptide-1 (FSL-1) (adapted from Mitchell et al., 2007). FSL-1, fibroblast-stimulating 
lipopeptide-1; CD36, Cluster of Differentiation 36; TLR 2/6, Toll-like receptor 2/6; MyD88, Myeloid differentiation 
factor 88; IRAK, interleukin one receptor-associated kinase; TRAF-6, tumour necrosis factor receptor-associated 
factor-6; NFκB, nuclear factor kappa-B. 
 
The diacylated lipoprotein, fibroblast-stimulating lipopeptide-1 (FSL-1), which represents the 
NH2-terminal sequence of the 44 kDa lipoprotein (LP44) of Mycoplasma salivarium (Shibata 
et al., 2000; Nakamura et al., 2002; Okusawa et al., 2004), has been identified as a potent  
immunostimulatory compound (Okusawa et al., 2004; Hübschle et al., 2006; Kiura et al., 
2006; Greis et al., 2007) signaling through the TLR2 and TLR6 (TLR2/6) heterodimer to 
CD3
6 
MyD88 
FSL-1 
IRAK 
TRAF-6 
NFĸB activation 
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stimulate cells implicated in innate immunity (Figure 1.2, Hübschle et al., 2006; Greis et al., 
2007). 
 
Similar to other TLRs, the TLR2/6 heterodimer also signals through the myeloid 
differentiation factor 88 (MyD88)-dependent pathway (Wesche et al., 1997; Takeuchi et al., 
2000). Upon activation with one of its agonists, namely FSL-1, TLR2/6 assembles with 
CD36, a class B pattern recognition/scavenger receptor involved in inflammation and 
immunity (Triantafilou et al., 2006; Silverstein et al., 2010). The resulting TLR2/6-CD36 
complex is essential for triggering the inflammatory response and leads to signal 
transduction via receptor associated proteins, including MyD88, IL-1 receptor-associated 
kinase (IRAK) and TNF receptor-associated factor-6 (TRAF-6) (Hoebe et al., 2005). 
Downstream signalling cascades ultimately lead to the activation of the transcription factor 
nuclear factor-κB (NF-ĸB) (for review see Aderem and Ulevitch, 2000) (see Figure 1.2). NF-
ĸB in turn, promotes transcription and expression of immune response genes, including 
genes for inflammatory mediators and pro-inflammatory cytokines such as interleukin-1β (IL-
1β), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) (for reviews see Miyamoto 
and Verma, 1995; Rasmussen et al., 2009). Apart from their critical role in innate immunity, 
TLRs have been implicated in mediating neural plasticity under physiological conditions in 
various brain regions, including the hippocampus (reviewed in Okun et al., 2011) and 
therefore may have a role in hippocampal-dependent learning and memory (see Okun et al., 
2010). 
 
1.2. FEVER AND SICKNESS BEHAVIOURS   
 
In human health care, surprisingly little attention has been given to the fact that, in addition 
to becoming febrile infected hosts develop sickness behaviours. It is the sickness behaviour, 
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rather than the fever, which compromises quality of life. Because sickness behaviours often 
outlast the fever (Pereira and Begum, 1987; Hübschle et al., 2006) it may well be that the 
non-thermal sickness behaviours, rather than the hyperpyrexia, are responsible for long-term 
consequences. The sickness behaviours relevant to my studies include anorexia and 
lethargy as well as impairment in learning and memory. These three phenomena, all of 
which incur considerable costs, may have deleterious long-term sequelae, especially in 
children: anorexia because of growth retardation, lethargy because of loss of motivation for 
life-sustaining processes or other fitness-enhancing activities, and impairment of learning 
and memory because of subsequent cognitive retardation. Because exposure to infectious 
agents during childhood is inevitable (Levy et al., 1999), those patients experiencing 
recurrent bouts of infections are more likely to suffer from long-term consequences. A high 
prevalence of recurrent childhood infections and recurrent fever accompanied by sickness 
behaviours can hamper seriously the overall development of children (Martorell et al., 1975; 
Rowland et al., 1988). Stunting has been reported in children (Cole and Parkin, 1977; 
Pereira and Begum, 1987; Black, 1991; Stephensen, 1999), but it is not the only long-term 
consequence of recurrent infection. Residual impairment in learning and memory was shown 
in animal models of acute (Wellmer et al., 2000), acute repeated or chronic simulated 
bacterial infection (Aubert et al., 1995; Hauss-Wegrzyniak et al., 1998; Hauss-Wegrzyniak et 
al., 1999; Sparkman et al., 2005c). To date, studies have not investigated the consequences 
after apparent recovery from recurrent acute infections, where the host recovers between 
infections.  
 
In addition, early immune activation, such as occurs during prenatal or neonatal infection, 
affects not only the febrile response, but also the neuroendocrine, neurochemical and 
behavioural responses later in life (Hornig et al., 1999; Boisse et al., 2004; Spencer et al., 
2005; Samuelsson et al., 2006). For example, neonatal rats exposed to 100 µg.kg-1 LPS 
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showed significant increases in anxiety and fear processes when they were tested eight 
weeks later (Spencer et al., 2005). Similarly, prenatal exposure of rats to intraperitoneal (i.p.) 
injections of IL-6, administered three times at two-day intervals, resulted in impairment of 
spatial learning when the rats where tested at 20 weeks of age (Samuelsson et al., 2006).  
 
During infection fever is initiated by specific pro-inflammatory cytokines, including TNF-α, IL-
1β and IL-6 (Luheshi and Rothwell, 1996). Interaction between cytokines plays a pivotal role 
in causing not only the febrile response, but also sickness behaviours (for reviews see 
Dantzer, 2001a, 2004). In the CNS, cytokines (and their receptors) are expressed 
constitutively under both normal and pathological states. However, CNS concentrations of 
pro-inflammatory and anti-inflammatory cytokines may increase greatly, when, after 
appropriate stimulation, these cytokines are induced peripherally, for instance during fever 
induction (for review see Szelényi, 2001). Although some cytokines are involved in the 
pathology accompanying infection and inflammation (i.e. pro-inflammatory cytokines), others 
also seem to have a crucial role in host’s defence against disease (i.e. anti-inflammatory 
cytokines) (see Oppenheim, 2001) and as therapeutic agents to suppress inflammatory 
processes (e.g. Henderson and Poole, 1994).   
 
In the brain, pro-inflammatory cytokines induce the production of prostaglandins (e.g. 
Feldberg and Saxena, 1975a, b), including prostaglandin E2 (PGE2), which then stimulates 
the neural pathways that raise body temperature (for reviews see Kluger, 1991; Saper and 
Breder, 1994; Roth et al., 2006; Hopkins, 2007). However, Gram-positive pathogens and 
their cell wall components can bypass the cytokine network and still activate the key 
intermediate, PGE2, which causes fever (see Mitchell and Laburn, 1997). Apart from its 
pyrogenic action, PGE2 also is critically involved in brain-mediated mechanisms underlying 
sickness behaviour (Johnson and von Borell, 1994; Teeling et al., 2007; Kent et al., 2007). It 
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is generally believed that sickness behaviours, which are confined to the period during and 
soon after infection, enable the host to conserve energy needed for the increased metabolic 
costs of fever and to direct the energy reserves to immune responses, in an effort to 
increase clearance of the invading pathogen and to fight infection. However, it has been 
hypothesized that host sickness behaviour, somehow, could benefit the invading pathogen 
(Poulin, 1994, 1995). It is therefore possible that the host’s cytokine network, which protects 
the host against the consequences of invading pathogens by inducing fever and sickness 
behaviours, can be manipulated by the pathogen so as to benefit itself (see Henderson et 
al., 1996).  
1.2.1. Pro-inflammatory cytokines as mediators of fever and sickness behaviours 
 
The role of pro-inflammatory cytokines in mediating sickness responses, including fever, 
lethargy and anorexia in humans, was confirmed when cytokines were administered to treat 
cancer patients and patients with chronic viral infections, who then developed typical clinical 
features of illness (e.g. fever, lethargy, anorexia) (Renault and Hoofnagle, 1989; Dinarello, 
1997). Experimental animal studies then followed and confirmed the role of pro-inflammatory 
cytokines, including IL-1β and IL-6, in mediating fever (Saper and Breder, 1992; Luheshi and 
Rothwell, 1996; Nilsberth et al., 2009) and a suite of sickness behaviours (for review see 
Dantzer and Kelley, 2007). 
  
Although IL-1 consists of two isoforms, IL-1α and IL-1β (Dinarello, 1991), there appears to 
be no difference between the biological actions of these two cytokines (Dinarello, 2005). 
While IL-1α mainly remains in the cell, IL-1β is secreted to play a role in host defense 
responses to infection or injury, including fever (for review see Dinarello, 1996) and sickness 
behaviours (e.g., Rothwell and Hopkins, 1995). IL-1β is considered the most potent 
endogenous pyrogen whether injected either systemically or into the brain (Dascombe et al., 
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1989; Rothwell et al., 1996; Dinarello, 1996; Miller et al., 1997a; Miller et al., 1997b). In the 
brain IL-1β is expressed at low concentrations, but IL-1β concentrations may increase 
massively during pathological conditions, such as during local, systemic of CNS insults (e.g., 
Szelényi, 2001). Brain IL-1β interacts with its receptor, IL-1R, which is expressed on cells 
(e.g., microglia and astrocytes) in the hypothalamus and the hippocampus (Loddick et al., 
1998; Conti et al., 2008). Because of its abundant expression in these two areas of the brain, 
IL-1β has a critical role in not only fever, but also brain-controlled sickness behaviours, 
including lethargy, anorexia and impairment in learning/memory. Numerous studies have 
confirmed the role of central IL-1β in mediating fever (for review see Leon, 2002), lethargy 
(e.g., Harden et al., 2008), anorexia (e.g., Kent et al., 1994; Layé et al., 2000) as well as 
cognitive impairment (for review see Goshen and Yirmiya, 2007).  
 
Similar to IL-1β, brain IL-6 also interacts with its receptor, IL-6R which is also is expressed 
on cells in the hypothalamus and the hippocampus (Loddick et al., 1998; Conti et al., 2008). 
It has been hypothesized that brain IL-6 acts synergistically with IL-1β in the brain to induce 
fever and sickness behaviour (Cartmell et al., 2000; Harden et al., 2008). The contribution of 
IL-6 (whether released peripherally or centrally) in mediating fever (e.g. LeMay et al., 1990; 
Cartmell et al., 2000; Harden et al., 2006), lethargy and anorexia (e.g.Hübschle et al., 2006; 
Harden et al., 2006; Greis et al., 2009) as well as impaired learning and memory (Goshen 
and Yirmiya, 2007; Dugan et al., 2009) also is well established. However, a recent study 
suggested that the role of IL-6 in mediating LPS-induced lethargy and anorexia appears to 
less important than its crucial role in mediating LPS-induced fever (Harden et al., 2011). 
Moreover, the role of IL-6 in mediating the sickness behaviour of impaired learning and 
memory also seems to be complex (for review see Goshen and Yirmiya, 2007). 
Nevertheless, because of their prominent and well established roles in fever and sickness 
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behaviours, measurement of IL-1β and IL-6 in the circulation as well as in the brain became 
part of my investigations (see Chapter 4). 
 
Pro-inflammatory cytokines are produced by peripheral immune cells, e.g. macrophages 
(e.g. see Maier and Watkins, 1998) and by cells in the central nervous system (CNS), e.g.  
microglia, astrocytes, neurones and endothelial cells (e.g. see Hopkins and Rothwell, 1995; 
Szelényi, 2001). Systemic exposure to exogenous pathogens induces the synthesis and 
release of pro-inflammatory cytokines, including IL-1β and IL-6, and other soluble mediators 
from activated immune cells at the site of infection/inflammation. Upon interaction with their 
specific receptors in the brain cytokines induce de novo synthesis of secondary pro-
inflammatory cytokines or other mediators, including PGE2. 
 
When an exogenous pathogen gains access to the brain (e.g. in encephalitis or meningitis) it 
is possible that the pathogen itself could induce the synthesis and release of brain-derived 
cytokines and so induce fever, in this way by-passing peripherally released cytokines. 
However, experimental studies that do not support this sequence of events have shown that 
the febrile response to intrathecal administration of LPS has a delayed onset compared with 
the febrile response to i.p. administration of LPS (reviewed in Coceani and Akarsu, 1998). 
Thus, in CNS infection communication across the blood-brain barrier (BBB) between 
peripheral and central mediators (e.g. cytokines) may not be critical for the development of 
fever, unless the long delay in the onset of the febrile response implies that there indeed is 
communication. Without the synthesis and release of cytokines either peripherally, centrally 
or both, communication between the immune system and the brain, and therefore the 
development of acute phase responses during infection, may not be possible.  
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Evidence that blood-borne cytokines could affect aspects of the CNS, including the induction 
of brain-mediated fever and sickness behaviours, originated from experimental studies in 
which cytokine neutralizing antibodies, administered peripherally, were found to inhibit fever 
and sickness behaviours (Kent et al., 1992; Roth et al., 1997b; Cartmell et al., 2000; Roth 
and De Souza, 2001; Harden et al., 2010). When peripheral cytokines are released into the 
circulation they may either act as humoral mediators between the periphery and the brain or 
interact with their specific receptors on glial cells in the circumventricular organs (CVOs) 
(see Schobitz et al., 1994). CVOs are regions in the brain where the BBB is ‘leaky’ (Blatteis 
et al., 1983; Blatteis, 1992). Based on the results of studies conducted over the last two 
decades, the following four specialized mechanisms that allow blood-borne cytokines access 
to the brain have been proposed (for reviews see Dantzer, 1994; Quan and Banks, 2007): 
(1) active and saturable (slow) transport into the brain via carrier-mediated transport 
mechanisms; (2) entering the brain via CVOs; (3) secretions of secondary mediators (e.g. 
nitric oxide and PGE2) from endothelial- and perivascular cells in the BBB; (4) rapid signaling 
via the neural route, e.g., via the vagus nerve, which may activate specific neural pathways 
in the brain and also stimulate microglia in the brain to produce cytokines (see Roth et al., 
2006). However, the role of the vagus in mediating fever and sickness behaviours is limited 
to a certain dose of LPS (Romanovsky et al., 1997) administered peripherally (Bluthé et al., 
1996; Goldbach et al., 1997). Thus, the BBB plays a dynamic role in the communication of 
peptides, including cytokines, between the periphery and the CNS (Banks et al., 1995). 
 
1.2.2. Lethargy, anorexia and impaired learning and memory as sickness behaviours 
 
The sickness behaviours typical of sick humans and other animals include lethargy, 
anorexia, social withdrawal, hyperalgesia, increased sleepiness and impaired cognitive 
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function (Kent et al., 1992; Dantzer, 2001a,  b). My study engages three of those behaviours, 
namely lethargy, anorexia and impaired learning and memory. 
 
 
 
1.2.2.1. Lethargy 
 
Infected humans often feel fatigued, listless and drowsy. Similarly, infected animals usually 
show signs of fatigue. These signs and feelings result in lethargy, a lack of motivation to 
engage in physical activity and exercise. The limited muscular activity may enable the body 
to save energy needed for the metabolic costs of fever. Conversely, the fatigue and limited 
physical activity also may result as a consequence of using the energy to generate fever. 
However, the energetic consequences of the lethargy of sickness behaviour, if there are any, 
remain unclear.   
 
Impairment of physical activity has been reported in hosts affected with PAMPs from 
different classes of pathogens, real or simulated. Experimentally, administration of moieties 
from Gram-negative bacteria, e.g. Escherichia coli or LPS, Gram-positive bacteria, e.g. 
Staphylococcus aureus or MDP, viruses, e.g. influenza virus (H3N2) or poly I:C, the yeast 
Saccharomyces cerevisiae, e.g. zymosan, and also from the Mycoplasmas, e.g. 
macrophage-activating lipopeptide-2 (MALP-2) or FSL-1, have all induced lethargy in 
rodents (Katafuchi et al., 2003; Campisi et al., 2003; du Plessis et al., 2005; Hübschle et al., 
2006, 2007; Jhaveri et al., 2007; Hopwood et al., 2009). 
 
Lethargy can be measured experimentally by measuring different types of activity during 
infection, real or simulated. For example, changes in spontaneous locomotor activity of 
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animals in their cages can be measured with activity-sensitive radiotransponders or 
radiotransmitters that are implanted intra-abdominally (e.g. Kozak et al., 1994; Hübschle et 
al., 2006; Hopwood et al., 2009), or with activity monitors in an automated open-field (e.g. 
Engeland et al., 2003). These two techniques are used as indices of day-to-day “house-
keeping” activity of animals. In addition, physical exercise measured as wheel running (e.g. 
in rats) is measured as an index of “voluntary” activity (e.g. Harden et al., 2006,  2008; 
2010). In LPS-induced lethargy in rats, suppression in voluntary exercise (measured as 
wheel-running) was a more prominent feature of illness than was depression in normal 
locomotor activity (measured as cage activity) (Hopwood et al., 2009). LPS-induced lethargy 
also appears to be a more sensitive predictor of illness than is LPS-induced anorexia or 
fever (Skinner et al., 2009).  
 
1.2.2.2. Anorexia 
 
Another sickness behaviour that forms part of the host’s acute phase response is loss of 
appetite, manifested as anorexia (for review see Asarian and Langhans, 2010). As with 
lethargy, a variety of pathogens or cell wall components of pathogens can cause anorexia. 
The well known anorexigenic agents include microbial moieties, such as LPS (Sachot et al., 
2004; Hopwood et al., 2009; Skinner et al., 2009) and MDP (Langhans et al., 1991; Plata-
Salamán and Borkoski, 1993). Hormones and cytokines, including the pro-inflammatory 
cytokine leptin (Grunfeld et al., 1996; Faggioni et al., 1997; Sachot et al., 2004) that regulate 
feeding behaviour (Friedman and Halaas, 1998), also cause anorexia. Therefore, anorexia 
of infection is not PAMP-specific and may be caused by a range of pathogens. 
 
During acute and chronic illness, anorexia occurs as a clinical manifestation that can be 
beneficial or detrimental depending on the time and duration of the illness (for review see 
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Plata-Salamán, 1996). For example, in an acute infection “anorexia of infection” (Cole and 
Parkin, 1977) or “infection-induced malnutrition” (Beisel, 1995) may occur in the absence of 
fever (McCarthy et al., 1985; O'Reilly et al., 1988) and may act as part of an active defence 
strategy with a positive survival value (Murray and Murray, 1979; Hart, 1988; Exton, 1997). 
However, if the disease occurs recurrently or becomes chronic, the long-term reduction in 
food intake may delay recovery and contribute to weight loss, muscle atrophy and fatigue 
(Plata-Salamán, 1996; Ravasco et al., 2004), resulting in a metabolic syndrome often 
referred to as “cachexia” (see Evans et al., 2008). Cachexia usually occurs in concert with 
anorexia (Bosaeus et al., 2001). 
 
Different magnitudes and durations of anorexia may be induced experimentally by using 
different PAMPs. Anorexia can easily be measured using well-established experimental 
techniques that analyze and quantify the animal’s feeding behaviour. In rodents, feeding 
behaviour can be measured as changes in food intake per day. For example, the amount of 
food consumed usually is quantified by subtracting the amount of food remaining in the cage 
from a weighed amount of food measured at the same time on the previous day (e.g. Harden 
et al., 2006,  2008; Harden et al., 2010). Others have used biotelemetry and specially-
equipped cages with food supply dishes placed on balances to continuously measure food 
intake in rats (Hübschle et al., 2006, 2007). 
 
1.2.2.3. Motivation vs. capacity in anorexia and lethargy 
 
In the sickness behaviour of lethargy there appears to be a clear distinction between 
motivation and capacity for activity (Maier and Watkins, 1998; Larson and Dunn, 2001; 
Rachal Pugh et al., 2001). In experimental animals the lethargy of sickness behaviours 
appears to be activity-specific. For example, the optional physical activity measured as 
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voluntary wheel running was abolished almost completely in rats after a low-dose bolus 
injection of LPS, while routine daily (“house-keeping”) activity measured as cage activity, 
continued (Hopwood et al., 2009; Skinner et al., 2009). Therefore, what appears to be 
impaired is the will or motivation to be active and not the capacity to be active (Hopwood et 
al., 2009; Skinner et al., 2009). Consonant with that theme, anorexic animals (i.e. animals 
with a loss of appetite) can eat; they just do not want to eat. In LPS-induced anorexia in rats, 
it was the will or motivation to eat that was impaired and not the capacity to eat (Hopwood et 
al., 2009; Skinner et al., 2009).  
 
However, motivation is not always impaired in sick animals. During illness, sickness 
behaviours observed in sick animals may reflect motivational changes rather than a result of 
depressed or impaired ability for ongoing activities. The phenomenon was demonstrated by 
Miller (1964) when he showed that the effects of endotoxin on the behaviour of rats were 
influenced by the outcome of a particular behaviour (Miller, 1964). After receiving an 
injection of endotoxin, rats increased bar pressing so as to terminate the rotation of a drum 
that is considered a mild aversive stimulus, whereas rats decreased bar pressing when this 
action would have resulted in termination of a more pleasant stimulus, e.g., food reward 
(Miller, 1964). However, based on Miller’s (1964) findings it is hypothesized that when the 
consequence of behavioural depression is harmful or unpleasant the behaviour is less likely 
to be disrupted by infection (Aubert et al., 1997a, b, 1999; Larson et al., 2001). Thus, 
sickness behaviour may occur differently on each exposure of the host to an infectious insult 
and also may depend on the context in which it occurs. For example, whether capacity or 
motivation or both are affected in sick animals that find themselves in life-threatening 
situations is still to be determined. One example of such a life-threatening situation is activity 
in a Morris Water Maze (Morris, 1984) in which a rat needs to swim and find a platform so as 
to escape from the water. A rat with cytokine-induced lethargy may still swim sufficiently, 
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because survival depends on it. The Morris Water Maze behavioural paradigm frequently is 
used to assess another aspect of sickness behaviour, namely learning and memory 
impairment.  
 
 
1.2.2.4. Impaired learning and memory 
 
Individuals who have suffered infections as infants appear to be at higher risk of developing 
cognitive disabilities (Dammann et al., 2002; Stoll et al., 2004). In addition, acute starvation 
in school children adversely affected cognitive processes, including attention and memory, 
especially in those children from low-income families who were nutritionally at risk (Pollitt et 
al., 1998). Emerging evidence shows that exposure to infectious agents during the perinatal 
period may alter immune responses, including the febrile response, in adulthood and also 
may increase disease susceptibility and vulnerability to cognitive disorders later in life 
(Boisse et al., 2004; Ellis et al., 2005,  2006; Bilbo and Schwarz, 2009; Bilbo et al., 2010). A 
recent study proposed that variation in the intensity of infectious diseases may determine 
worldwide distribution of cognitive ability (Eppig et al., 2010).  
 
Memory does not exist as a single entity (see Squire and Zola, 1996). Several kinds of 
memory, including declarative/explicit (cognitive) and non-declarative/implicit (non-cognitive) 
memory rely on different memory systems in the brain for normal memory functioning. 
Memory systems include, among others, the hippocampal formation in the medial temporal 
lobe (e.g. Morris et al., 1982), basal ganglia (e.g. Hikosaka et al., 1998) and neocortex (e.g. 
prefrontal cortex and temporal cortex) (see Wiltgen et al., 2004). In my studies I investigated 
declarative memory, particularly memory for spatial layouts that is dependent on the 
plasticity and integrity of the hippocampus (e.g. Morris et al., 1982).  
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To investigate the involvement of the hippocampus in processing spatial information and 
spatial memory, many experimental studies have been conducted in primates. However, the 
results remain contradictory when compared to the results of similar studies in humans (see 
Nadel, 1991). Rodents, on the other hand, are used frequently to study spatial learning and 
memory during infection (Cunningham and Sanderson, 2008) and the studies strongly 
support a role for the hippocampus in rodent memory for spatial layouts (Morris et al., 1982; 
Whishaw, 1998). I used rats as an animal model, not only to investigate the effects of 
simulated infection on aspects of hippocampal structure and function (Chapter 5), but also 
to study spatial learning and memory (i.e. declarative memory) in simulated infection 
(Chapters 3 and 5).   
 
The use and implementation of animal models greatly has improved investigations into 
cognitive ability, including learning and memory impairment, among those suffering from 
infection. Initial studies on spatial memory in rodents, as reviewed in a classic paper by 
Tolman (1948), laid the foundation for general research in the field of cognition (Tolman, 
1948). Since then, experimental investigations using various behavioural paradigms to 
assess spatial learning and memory have been conducted successfully in rodents. Animal 
models that specifically assess declarative, spatial memory, include the Morris Water Maze 
(D'Hooge and De Deyn, 2001; Cunningham and Sanderson, 2008), the Y-maze (Sanderson 
et al., 2009) and various radial arm mazes (Semmler et al., 2007; Chen et al., 2008; 
Sanderson et al., 2009; Dilger and Johnson, 2010). Whereas each of these behavioural 
models has contributed to our current understanding of spatial learning and memory during 
experimental infection, the Morris Water Maze (Morris, 1981) is most widely used (see 
Cunningham and Sanderson, 2008). Interestingly, Brynskikh and colleagues (2008) showed 
impairment in learning of SCID (severe combined immune deficient) mice that are depleted 
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from T-cells (i.e. cells of the adaptive immune system), when learning was assessed in four 
different learning tasks, including a Morris Water Maze. More detail about the Morris Water 
Maze will be discussed in Chapter 2. 
 
There are two types of declarative memory, namely episodic memory (i.e. to learn new 
events or skills) and semantic memory (i.e. to learn new facts). Because declarative memory 
comprises of conscious memories that are intentionally recollected (Cohen and Squire, 
1980), specific tests for declarative memory assess the recall or recognition of memories 
from prior places, lists, shapes etc. (see Squire and Zola, 1996; Gabrieli, 1998). That is what 
the Morris Water Maze (Morris, 1984) measures: it is a behavioural assay that requires 
‘visuo-spatial’ navigation of rodents swimming in a pool to learn and recall the spatial 
localization of visible cues in a room. In this way the Morris Water Maze measures ‘spatial’ 
learning and memory (see Chapter 3 and Chapter 5). My studies did not extend to the 
investigation of other learning and memory types, such as non-declarative memory. 
 
Thus far, most studies investigating impaired learning and memory as a component of 
sickness behaviour following simulated infections, have involved administering LPS to 
rodents (reviewed in Cunningham and Sanderson, 2008). Several other studies also have 
established the effects of simulated Gram-positive bacterial infections (Wellmer et al., 2000; 
Gerber et al., 2004; Barichello et al., 2009; Woodruff et al., 2010) as well as viral infections 
(Kent et al., 2007; Into et al., 2010; Okun et al., 2010; Dilger and Johnson, 2010) on learning 
and memory. As yet, very little is known about the effects of Mycoplasma infection on 
learning and memory. There has been one case report of pervasive changes in memory in a 
7-year-old girl suffering from possible M. pneumoniae encephalitis (Benjamin et al., 2007).  
Irrespective of the pathogen causing the cognitive alterations, it is likely that the disturbances 
of memory and learning observed in humans and other animals (e.g., Bohr et al., 1984; 
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Capuron et al., 1999; Wellmer et al., 2000) result from the actions of blood-borne and brain-
derived pro-inflammatory cytokines (Reichenberg et al., 2001; Goshen and Yirmiya, 2007) 
and the brain-derived prostaglandins induced by the cytokines (Hein et al., 2007; Kent et al., 
2007; Ishida et al., 2007). Administration of cytokines themselves, including IL-1β, IL-6, IL-2, 
TNF-α and interferon alpha (IFN-α) to patients (Denicoff et al., 1987; Valentine et al., 1998) 
and experimental animals (Goshen and Yirmiya, 2007; Dugan et al., 2009; Machado et al., 
2010) induce memory disturbances. It is therefore possible that cytokines may underlie the 
long-term changes in cognitive ability later in life as a consequence of infection early in life 
(see Bilbo and Schwarz, 2009). 
 
1.2.2.5. Spatial learning and memory following simulated systemic infection 
 
Even though PAMPs from many different classes of pathogens have been used in 
experiments to study the effect of systemic bacterial and viral infections on learning and 
memory processes, literature on the effect of systemic Mycoplasma pathogens or their 
PAMPs on learning and memory is scant. Table 1 reviews the research findings of 
investigations on spatial learning and memory, specifically using rodents in a Morris Water 
Maze after receiving an acute, systemic (i.p.) immune challenge.  
 
The Morris Water Maze may be applied in various ways that differ in duration and design 
requirements of the task. Although studies employing the Maze have found impairment in 
either learning or memory or both, several studies have not (see Table 1). For example, 
administration of the same PAMP (e.g. IL-1β) via the same route (i.p.) and in the same 
species (i.e. mice) shows different effects on learning and memory (Gibertini, 1996, 1998). 
Similarly, learning and memory of rodents may be affected differentially after administration 
of different strains of live Gram-negative bacteria, e.g., E.coli or L. pneumophila (Gibertini et 
Chapter 1    Introduction 
 
23 
 
al., 1995; Barrientos et al., 2006). Furthermore, administration of LPS seems to induce 
impairment in spatial learning without affecting spatial memory (Arai et al., 2001; Sparkman 
et al., 2005a, b). Some, but not all of the contradictory and inconsistent results (reviewed in 
Cunningham and Sanderson, 2008) may be related to Maze conditions (refer to section 2.5 
in Chapter 2).  
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Table 1.1. Studies investigating spatial learning and memory in a Morris Water Maze after an acute, i.p. immune challenge 
PAMP Dose Species 
Effect on 
learning 
Effect on 
memory 
Reference 
 
Gram-negative 
PAMP 
Legionella 
pneumophila 
(live bacterium) 
 
 
 
8 x 106 bacterial 
units per mouse 
 
 
 
Mouse 
 
 
 
Impairment 
(hidden platform) 
No impairment 
(visible platform) 
 
 
 
Impairment 
(hidden platform) 
No impairment  
(visible platform) 
 
 
 
 
Gibertini et al., 1995 
 
LPS  400-800 µg.kg-1 Mouse Impairment No impairment Arai et al., 2001 
LPS 
LPS  
100 µg.kg-1  
250 µg.kg-1 
Rat 
Mouse 
Impairment 
Impairment 
Impairment 
No impairment 
Shaw et al., 2001 
Sparkman et al., 2005a, b 
E.coli 
(live bacterium) 
1 x 1010 CFU.ml-1  Rats No impairment No impairment 
(Short-term 
memory) 
Impairment 
(Long-term 
memory) 
 
Barrientos et al., 2006  
LPS  250 µg.kg-1 Mouse  Impairment Lee et al., 2008 
LPS  10 µg.kg-1 Mouse  Impairment 
(working memory) 
 
Richwine et al., 2009 
LPS  100 µg.kg-1 Mouse  Impairment 
(working memory 
 
Zhang et al., 2009 
LPS  1.25 mg.kg-1 Mouse  No impairment Huang et al., 2010 
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PAMP Dose Species 
Effect on 
learning 
Effect on 
memory 
Reference 
      
Gram-positive 
PAMP      
SEA   5 µg per mouse Mouse No impairment No impairment Woodruff et al., 2010 
 
Viral PAMP 
 
Poly I:C 
 
 
 
20 mg.kg-1 
 
 
 
Mouse 
 
 
 
Impairment 
(platform position 
changed) 
No impairment 
(platform position 
fixed) 
 
 
 
Impairment 
(working memory) 
No impairment 
(reference memory)
 
Ito et al., 2010 
Pro-inflammatory 
cytokines 
     
IL-1β 100 ng per 
mouse 
Mouse  No impairment 
(reference memory)
 
Gibertini, 1996 
    Impairment 
(working memory) 
 
 
IL-1β 100 ng per 
mouse 
Mouse No impairment 
(spaced 
protocol) 
(cold water) 
 
  Gibertini, 1998 
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PAMP Dose Species 
Effect on 
learning 
Effect on 
memory 
Reference 
 
IL-1β 
 
100 ng per 
mouse 
 
Mouse 
 
Impairment 
(massed 
protocol) 
(warm water) 
 
  
 
 
Gibertini, 1998 
IL-1β 1 mg per mouse Mouse Facilitation  Gibertini, 1998 
 
IL-1β 2 µg.kg-1 Rat No impairment No impairment Thomson and Sutherland, 
2006 
 
  
        not tested in the study 
E.coli (Escherichia coli) 
SEA (Staphylococcus enterotoxin A) 
Poly I:C (polyinosinic:polycyidylic acid) 
CFU (colony forming units) 
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Although many studies have reported on the detrimental effects of infection on learning 
and/or memory, emerging evidence from investigations in rodents shows no impairment in 
learning and/or memory following i.p. injection of IL-1β (Thomson and Sutherland, 2006) and 
more recently, following i.p. injection of LPS (Huang et al., 2010) or i.p. injection of 
Staphylococcal enterotoxin A (Woodruff et al., 2010). Importantly, a recent clinical study 
showed that i.v. administration of LPS to human volunteers does not impair memory 
(Grigoleit et al., 2010). So, impairment in learning and memory does not seem to be an 
inevitable consequence of infection. 
 
1.2.3. Brain regions involved in fever, lethargy, anorexia and learning and memory  
 
Several parts of the brain are involved in temperature regulation, energy metabolism and 
food intake, but the hypothalamus is crucial for these functions (Lepkovsky, 1973; Plata-
Salamán, 1998; Morrison et al., 2008). The region in the hypothalamus critical for food intake 
and energy metabolism is the arcuate nucleus (Elmquist et al., 1999). However, the febrile 
response is induced by the action of PGE2 on its specific receptor, EP3, in the thermogenic 
region of the hypothalamus, the median pre-optic nucleus, an area crucially involved in 
raising the thermoregulatory set point (Ushikubi et al., 1998; Lazarus et al., 2007).  
 
The hypothalamus also is important in coordination of cardiovascular function and 
respiration (e.g. Yeh et al., 1997) without which physical activity is not possible. Together 
with the hypothalamus, several other parts of the brain are involved in the control of physical 
activity. The term ‘motor cortex’ is used to describe several cerebral cortical regions that are 
crucial for motor function. These regions include, among others, the prefrontal lobe that 
initiates activity in response to the environment and that is responsible for memory of motor 
activities, the parietal lobe that is responsible for goal-directed voluntary movements, the 
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primary motor cortex, the supplementary motor area and the premotor area. The cerebellum 
is responsible for executing and coordinating voluntary movements and muscle tone (for 
review see Cheney, 1985). Thus, if the functions of these brain regions are compromised 
during illness, the infected individual will feel fatigued and lethargic, and therefore will be 
reluctant to engage in physical activity.   
 
Although physical activity (i.e. swimming) is required in the Morris Water Maze, the ability to 
learn to navigate accurately in the Maze depends on the plasticity and integrity of the 
hippocampus (for review see Whishaw, 1998). The hippocampus is situated in the medial 
temporal lobe of the brain (for review see Sejnowski, 2007), and supports a “spatial map” 
function (O’Keefe and Nadel, 1978). Studies in hippocampal-lesioned animals have 
confirmed a role for the hippocampus in spatial learning, as well as in spatial reference- and 
working memory (Olton et al., 1978; Sutherland et al., 1982; Morris et al., 1982; Gage and 
Robertson, 1985). Similarly, humans with hippocampal damage displayed severe spatial 
memory impairment (Astur et al., 2002; Goodrich-Hunsaker et al., 2010).  
 
In the event of solving spatial navigational tasks the hippocampus may interact with the 
parietal cortex (for review see Nitz, 2009). Despite the crucial involvement of the 
hippocampus in declarative memory, including spatial learning / memory, the hippocampus 
also has a role in non-spatial types of memory (Brasted et al., 2003; Broadbent et al., 2010). 
Brain regions adjacent to the hippocampal formation are required for non-declarative 
learning and memory that are independent of the hippocampus. For example, the basal 
ganglia and the cerebellum seem to play a significant role in non-declarative, sensorimotor 
skill learning (Willingham et al., 1996). The basal ganglia also may have a role in visuo-
spatial abilities (e.g. Christensen et al., 1992). Thus, different types of memory processes 
depend on different memory systems in different brain regions. 
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1.3.  SIMULATING INFECTION EXPERIMENTALLY 
 
During infection, real or simulated, activated tissue macrophages and blood monocytes 
release a broad spectrum of pro-inflammatory cytokines that mediate the febrile response 
through the induction of PGE2 and also induce the release of acute phase plasma proteins 
by the liver. Although fever is an integral part of the host’s defense against invading 
pathogens, fever and sickness behaviours are characteristic of clinical infections. Therefore, 
fever and sickness behaviours would be expected acute phase responses in simulated, 
experimental infections. In the following sections of my thesis I will discuss mainly sickness 
behaviours as part of the acute phase response during simulated infections. I will deal, in 
part, with fevers, which is not the main focus of my thesis.         
 
1.3.1. Acute challenge 
 
Pathogenic moieties (or PAMPs) from various typical bacteria, e.g. LPS and MDP, atypical 
bacteria, e.g. FSL-1 or MALP-2 or viruses e.g. poly I:C have been used experimentally to 
simulate the acute phase response as it would be in the actual infection. A single, acute 
exposure to an infective pathogen does occur clinically, such as during an infected cut or a 
cat bite, and does activate the host’s acute phase response. However, such events generally 
are rare in the clinical context of infections. In spite of its clinical rarity, it is that kind of 
infection that is simulated most frequently in laboratory investigations of the acute phase 
response. “Acute” childhood infections, such as chicken pox or mumps (both viral infections) 
as well as diphtheria and ear infections (both bacterial infections), are not really acute 
infections because the pathogen usually is present in the host for many days. These 
infections are not simulated accurately by a bolus administration of a PAMP, although a 
bolus administration of a PAMP does stimulate the innate immune system. For example, a 
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bolus administration of particularly LPS, mimicking infection caused by Gram-negative 
bacteria, has been used extensively to study the acute phase responses, including fever, 
anorexia and lethargy (Hopwood et al., 2009; Skinner et al., 2009; Asarian and Langhans, 
2010; Harden et al., 2010).  
 
A bolus administration of LPS at doses ranging from 10 to 250 µg.kg-1 in rats, whether 
administered subcutaneously (s.c.) (Skinner et al., 2009) or i.p. (Hopwood et al., 2009) 
induced dose-dependent lethargy. Intraperitoneal administration in rats of LPS at the highest 
dose (250 µg.kg-1) depressed cage activity by almost 60 % and voluntary exercise by nearly 
100 % when measured within 24 h (Hopwood et al., 2009). Similarly, i.p. administration of 
the viral mimetic, poly I:C, at doses between 3 000 - 4 000 µg.kg-1 in rats, depressed cage 
activity by up to 50 % and voluntary exercise by almost 90 % (Hopwood et al., 2009). Thus, 
during a simulated infectious challenge voluntary exercise appeared to be affected more 
than cage activity, regardless of the pyrogen, i.e. LPS vs. poly I:C, or dose administered 
(Hopwood et al., 2009). Bolus administration of Gram-positive bacteria or their PAMPs also 
induces experimental lethargy. Night-time i.p. administration of heat-killed cell walls (2.5 x 
109) of S. aureus depressed cage activity in rats significantly over the first night after the 
injection (Luker et al., 2000). Even the non-bacterial agent, zymosan induced lethargy in rats 
over the first and third nights after injection when administered i.p. at a dose of 10 mg.kg-1 
(Hübschle et al., 2007). Zymosan often is used in animal models of human multiple organ 
dysfunction syndrome (MODS), in which systemic inflammation or septic shock is studied in 
relation to organ damage and failure (see Volman et al., 2005). 
 
Important for my study, bolus administration of moieties from Mycoplasma induced lethargy 
that lasted for longer than one day. Intraperitoneal administration of lipopeptides from 
Mycoplasma, including FSL-1 (from M. salivarium) or MALP-2 (from M. fermentans) at doses 
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of 100 - 1 000 µg.kg-1 in rats, induced lethargy (measured as cage activity) over the first night 
after the injection, while the lethargy induced by MALP-2 at a dose of 100 µg.kg-1 lasted into 
the third night (Hübschle et al., 2006). Intracerebroventricular (i.c.v.) administration of heat-
inactivated M. fermentans, at doses of 5.1 - 36.0 µg.kg-1 in rats, also induced lethargy 
(measured as cage activity and as social exploration in an open field) over the first 24 h 
following the injection (Yirmiya et al., 1997).  
 
PAMP-induced anorexia, like lethargy, seems to develop in a dose-dependent fashion. Bolus 
administration of moieties from infective organisms typically causes anorexia within 24 h 
following pyrogen administration, with the magnitude of LPS-induced anorexia in rats and 
mice depending on the dose of LPS administered (Langhans et al., 1989; Kozak et al., 
1994). Food intake in rats was reduced by almost 50 % over the first 24 h following bolus 
s.c. or i.p administration of LPS at a dose of 250 µg.kg-1 (Hopwood et al., 2009; Skinner et 
al., 2009). Similarly, bolus administration of LPS has reduced food intake in other animal 
species, including mice and sheep (Murray and Murray, 1979; Baile et al., 1981).The viral 
mimetic poly I:C, at a bolus dose of 4 000 µg.kg-1 but not 3 000 µg.kg-1, in rats, induced 
anorexia to a similar extent as that induced by LPS at a dose of 250 µg.kg-1 (Hopwood et al., 
2009). Anorexia induced by bolus administration of moieties from Gram-positive bacteria 
was observed in rats at 3 h after i.p. administration of 2 mg.kg-1 MDP (Porter et al., 1998) 
and at 6 h after i.p. administration of 0.8 mg.kg-1 MDP (Langhans et al., 1991). In guinea 
pigs, bolus intramuscular (i.m.) administration of 50 µg.kg-1 MDP resulted in significant 
anorexia within 24 h after injection (Madu et al., 2007). Furthermore, bolus i.p. administration 
of 50 mg.kg-1 zymosan in mice induced anorexia for up to 4 h after injection, but the food 
intake was restored after 24 h (Naoi et al., 2006).  
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Particularly relevant to my thesis is anorexia induced by Mycoplasma or its moieties. Bolus 
i.p. administration of 100 or 1 000 µg.kg-1 FSL-1 or MALP-2 induced anorexia over three 
nights after injections (Hübschle et al., 2006) and i.c.v. administration of heat-inactivated M. 
fermentans (at doses between 5.1 - 36.0 µg.kg-1) caused a significant suppression in food 
intake over the first 24 h following the simulated infection in rats (Yirmiya et al., 1997). 
 
While experimental anorexia and lethargy are well-described and consistent sickness 
behaviours in simulated acute infection, studies investigating another component of sickness 
behaviour, namely impaired learning and memory, thus far have rendered contradictory 
results. Lipopolysaccharide, which has been used extensively to investigate the effects of 
Gram-negative infection on learning and memory, has induced impairment in learning and/or 
memory in rats and mice when tested within 24 h after bolus i.p. administration at various 
doses (Aubert et al., 1995; Pugh et al., 1998; Thomson and Sutherland, 2005; Sanderson et 
al., 2009; Terrando et al., 2010; but also see Table 1). Adult rats infected as neonates with 
E. coli (1 x 106 colony forming units) had memory impairment after they received a bolus I.P 
injection of LPS (25 µg.kg-1), either 24 h before or immediately after context exposure in the 
context pre-exposure facilitation paradigm (Bilbo et al., 2005a, b,  2006). Studies in animal 
models of acute bacterial meningitis, induced by Streptococcus pneumoniae, have reported 
learning and memory impairments in mice and rats that had survived meningitis (Wellmer et 
al., 2000; Irazuzta et al., 2001). Bolus administration of the viral mimetic, poly I:C, induced 
learning and memory impairments in different animal species, including rats, mice, chickens 
and pigs (Ozawa et al., 2006; Kent et al., 2007; Ito et al., 2010; Dilger and Johnson, 2010). 
Together with reports of impairment in learning and/or memory following bolus administration 
of bacterial moieties, neuronal damage in the hippocampus (i.e., lesions or loss of neurons) 
also has been reported (Wellmer et al., 2000; Leib et al., 2003; Semmler et al., 2007; 
Hoffmann et al., 2007; Cunningham and Sanderson, 2008). 
Chapter 1    Introduction 
 
33 
 
Bolus injections of moieties from infective organisms are capable of inducing not only short-
term, but also long-term impairments in learning and/or memory. Semmler and colleagues 
(2007) reported long-term memory impairment when rats were tested in a radial maze and in 
the open field test, three months after a single i.p. injection of LPS at a dose of 10 mg.kg-1 
(Semmler et al., 2007). Neonatal rats that received an i.p. injection of LPS at a dose of 500 
µg.kg-1 had impaired memory when tested 70 days later in an object recognition task 
(Jenkins et al., 2009), while i.p. administration of E.coli induced both retrograde and 
anterograde amnesia in old, but not young rats, as measured in the Morris Water Maze and 
other behavioural tasks (Barrientos et al., 2006). In simulated acute bacterial meningitis in 
mice, induced by bolus administration of S. pneumoniae into the right forebrain, long-term 
spatial learning and memory impairments were evident 180 days later, as measured in a 
Morris Water Maze (Wellmer et al., 2000). Thus, even when fever and sickness behaviour 
has resolved following acute administration of a moiety from infective organisms, the 
challenged animal may harbour residual impairment to learning and memory. 
 
In spite of the body of evidence demonstrating impaired learning and memory, recent pre-
clinical and clinical studies have contradicted the findings of impairment in learning/memory 
in response to bolus administration of bacterial moieties (Cunningham and Sanderson, 2008; 
Huang et al., 2010; Woodruff et al., 2010; Grigoleit et al., 2010). In their review, Cunningham 
and colleagues (2008) concluded that, in the case of hippocampal-dependent spatial 
learning and memory, the effects of bolus administration of LPS are not obvious 
(Cunningham and Sanderson, 2008). Performance deficits, rather than true learning and/or 
memory deficits frequently have been reported in various behavioural models, including the 
Morris Water Maze (Sparkman et al., 2005a), the delayed matching-to-sample conditional 
discrimination task and a Y-maze (Gahtan and Overmier, 2001). A recent study in mice 
confirmed the lack of effect on memory of bolus i.p. administration of 1.25 mg.kg-1 LPS 
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(Huang et al., 2010), which is in contrast to results of other studies in mice, given LPS at 
much lower doses (10 - 250 µg.kg-1) (Sparkman et al., 2006; Lee et al., 2008; Zhang et al., 
2009; Richwine et al., 2009). Importantly, Huang and co-workers (2010) showed that in spite 
of other sickness behaviours and a significant increase in concentrations of the pro-
inflammatory cytokine, IL-1β, in the hippocampus of mice, bolus administration of LPS did 
not cause impairment in spatial memory retrieval when tested in a Morris Water Maze 4 h 
after injection (Huang et al., 2010). Additionally, acute i.p. administration of Gram-positive 
bacterial superantigen, Staphylococcal enterotoxin A (5 µg / animal) did not induce 
impairment in learning or memory in mice when tested in a Morris Water Maze 2 h after 
injections (Woodruff et al., 2010). In a human model of endotoxaemia, i.v. administration of 
LPS at a dose of 0.4 ng.kg-1 (a dose that is considered to induce low-grade inflammation in 
the host) did not impair memory functions or executive functions, as measured with various 
neuropsychological tests, despite causing fever and increases in concentrations of plasma 
cytokines and other hormones (Grigoleit et al., 2010), an observation that contradicted 
previous findings that showed impairments in declarative memory after subjects had 
received i.v. LPS at doses between 0.2 - 0.8 ng.kg-1 (Reichenberg et al., 2001; Krabbe et al., 
2005). The discrepancy might be explained by the different doses of LPS (0.2 vs. 0.4 vs. 0.8 
ng.kg-1), or by the different source of the LPS, i.e., E. coli vs. Salmonella abortus equi 
(Grigoleit et al., 2010). However, variation in bacterial species could not explain the 
discrepancies found in experimental animals, since most animal studies have used LPS from 
E. coli. 
 
Thus, the association between acute immune activation and deficits in learning and memory 
still is unclear both in humans and in other animals. In particular, the effect of acute, 
simulated systemic Mycoplasma infection on learning and memory still is unknown. 
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1.3.2. Chronic challenge 
 
Various experimental methods have been attempted to induce sustained fevers in an effort 
to mimic clinical fevers such as occur during a chronic infection. Ways of doing so include 
repetitive (e.g. daily) administration of a PAMP, with each new challenge being administered 
before the host recovers from the previous challenge, or continuous infusion (s.c. or i.v.) of a 
PAMP over days (e.g. O’Reilly et al., 1988; du Plessis et al., 2005). However, reproduction 
or simulation in laboratory animals of those long-lasting, sustained fevers, such as 
experienced clinically e.g. in typhoid fever (e.g. see Hook and Jones, 1966) has not yet been 
successful, because of fatalities or the development of pyrogenic tolerance. Greisman and 
colleagues (1961) showed that i.v. administration of 0.5 µg endotoxin from the Gram-
negative bacterium, Salmonella typhosa, successfully reproduced the clinical symptoms of 
typhoid fever in healthy volunteers (Greisman et al., 1961). However, subsequent 
experimental studies in humans conducted in the same laboratory confirmed the 
development of tolerance to the pyrogenic property of S. typhosa, Pseudomonas and E. coli 
endotoxin when administered (i.v.) at daily intervals (e.g. Greisman et al., 1968).  
 
Initially the phenomenon of ‘tolerance’ was described as a pathophysiological adaptation of 
the host to protect against uncontrolled inflammation, the latter occurring when cells of the 
immune system were unable to control the inflammatory reaction elicited by endotoxin or 
other immune stimuli (Zeisberger and Roth, 1998; Biswas and Lopez-Collazo, 2009). When 
a host is exposed to a certain PAMP, immune cells (e.g. monocytes and macrophages) may 
not respond to subsequent exposure to the PAMP and therefore may become ‘tolerant’. In 
the host, the result of the phenomenon of ‘tolerance’ is a diminished acute phase response 
to subsequent PAMP exposure.  
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Tolerance to PAMPs from Gram-negative bacteria, e.g. endotoxin or LPS, has been 
observed in various species of animals, including rats (He et al., 1992; Mekaouche et al., 
1996), guinea pigs, (Roth et al., 1994) and rabbits (Goelst and Laburn, 1991; Wakabayashi 
et al., 1994). Although tolerance to the febrile response was first described in animals after 
repetitive exposure to LPS, subsequent research has shown that tolerance to the febrile 
response is not specific to the actions of endotoxin or LPS (for reviews see West and Heagy, 
2002; Biswas and Lopez-Collazo, 2009). Tolerance has been reported with repeated 
administration, or continuous infusion, of moieties from Gram-positive bacteria, viruses, as 
well as for pro-inflammatory cytokines (Soszynski et al., 1991; Yamashiro et al., 1993; 
Goldbach et al., 1996; Roth et al., 1997b; Ferreira et al., 2001). For example, studies in 
guinea pigs have shown different febrile responses to repeated administration (at 3-day 
intervals) of PAMPs from various bacteria: five i.m. or i.p. injections of either LPS (5 µg.kg-1; 
Gram-negative PAMP), MDP (100 µg.kg-1; Gram-positive PAMP) or FSL-1 (100 µg.kg-1; 
Mycoplasma PAMP) resulted in tolerance to the febrile response (Roth et al.,1994, Roth and 
Zeisberger, 1995; Roth et al., 1997b; Greiss et al., 2009). However, whereas tolerance is 
well described for Gram-negative PAMP administration (e.g. Mathison et al., 1990; 
Zuckerman and Evans, 1992; Nakamori et al., 1995; Roth et al., 1997a), it is less understood 
for Gram-positive PAMPs. Tolerance does not occur consistently after administration of 
Gram-positive PAMPs (Goelst and Laburn, 1991; Roth et al., 1997b). Whereas five daily i.v. 
injections of LPS (0.1 µg.kg-1) in rabbits resulted in a significant attenuated febrile response 
on the second and subsequent days, administration of two doses of S. aureus cell walls (1 x 
107 or 5 x 107 cells) over the same time period induced unattenuated fevers over five days in 
other rabbits (Goelst and Laburn, 1991). Similarly, Mphahlele and co-workers produced 
sustained fevers in goats via continuous (6 days) i.v. infusion with S. aureus (2 x 1011 cell 
walls) and showed a possibility of febrile tolerance developing only at the final stage of 
infusion (Mphahlele et al., 2004). Thus, with repeated injections of LPS, but not S. aureus 
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cell walls, the magnitude and the duration (i.e. fever index) of the febrile response were 
reduced significantly over time, indicating the development of tolerance to fever in response 
to LPS, but not to S. aureus cell walls (Goelst and Laburn, 1991; Mphahlele et al., 2004). 
However, studies indeed have shown tolerance to PAMPs from Gram-positive bacteria, 
including MDP, when administered 5 times (spaced three days apart) at a dose of 100 
µg.kg-1 to guinea pigs, rather than injecting the pyrogen daily (e.g., Roth et al., 1997b).  
 
It is worth mentioning though that, in tolerant animals, the acute phase responses, including 
fever, anorexia, lethargy and impaired learning and memory, may each disappear separately 
(i.e. some disappear more quickly than others) (e.g. O’Reilly et al., 1988), or they all may 
disappear in parallel (du Plessis et al., 2005). For example, anorexia was observed in rats 
following the first i.p. injection of LPS (100 µg.kg-1), but tolerance developed to the anorexic 
effect of LPS after the second and third subsequent injections (Langhans et al., 1991; 
Riediger et al., 2010). However, when MDP was administered i.p. to rats at a dose of 1.6 
mg.kg-1 on four consecutive days, it induced a significant reduction in food intake on each of 
the four days of administration (Langhans et al., 1991). Therefore, compared with the 
tolerance that develops to the anorectic effect of LPS, tolerance does not seem to develop to 
the anorectic effect induced by MDP (Langhans et al., 1991). 
  
Not only repeated administration, but also long-term infusion of PAMPs, can result in 
tolerance to the acute phase response and therefore fails to simulate chronic fevers. Studies 
in rats, using implanted osmotic pumps that allow infusion (i.v. or s.c.) of LPS, reported 
fevers only at 6 h and 30 h over a 54 h infusion period (Lang and Spitzer, 1987) and only for 
two days over a 7-day infusion period (O’Reilly et al., 1988). The latter study also showed no 
tolerance to the anorexia induced by LPS, as evidenced by significant depressed food intake 
over the entire infusion period of 7-days (O’Reilly et al., 1988). A more recent study 
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confirmed tolerance in rats to fever and sickness behaviours induced by both Gram-negative 
and Gram-positive pyrogens, using continuous s.c. infusion of LPS or MDP, at a rate of 2 
µg.kg-1.min-1 over seven days: LPS infusion induced sustained fevers for only three of the 
seven days and on only one day during the MDP infusion (du Plessis et al., 2005). The 
authors reported tolerance to two of the sickness behaviours, namely lethargy and anorexia. 
The body mass of rats during infusion of either LPS or MDP was reduced significantly on the 
fourth day during the 7-day pyrogen infusion but the rate of weight gain was stabilized again 
one day after cessation of infusion (du Plessis et al., 2005). However, over the 7-day 
infusion period lethargy was evident for up to two of the seven days in response to LPS 
infusion, but only for one day of the infusion in response to MDP (du Plessis et al., 2005). 
The decline in lethargy occurred in parallel with the decline in fever (du Plessis et al., 2005).  
 
Despite the development of tolerance that might occur, continuous infusion of pyrogens in 
animals or humans is used to induce chronic inflammatory responses, e.g. sepsis 
(Vayssettes-Courchay et al., 2002; Lynn et al., 2003), septic shock (Herrera-Gutierrez et al., 
2011) and neuroinflammation (Min et al., 2009). Chronic central neuroinflammation induced 
by continuous LPS infusion into the brain often is used as an animal model to simulate the 
neurobiology underlying Alzheimer’s disease (e.g. Hauss-Wegrzyniak et al., 1998a). Animal 
studies also have employed the technique of i.c.v. infusion of LPS (and other pyrogens) to 
investigate impairment in learning and memory as a component of sickness behaviour. For 
example, i.c.v. infusion with LPS (0.25 µg.h-1) for 28 days in rats, induced spatial learning 
and memory impairment, as measured in a Morris Water Maze after 28 days (Cui et al., 
2008). The impairment in learning and memory possibly could be attributed to the extensive 
hippocampal inflammation that followed LPS infusion (Cui et al., 2008). Similarly, i.c.v. 
infusion in rats over a period of 37 days resulted in a significant increase in the activation of 
microglial cells in the hippocampus, which may have contributed to the impairment in spatial 
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learning and memory observed another 37 days later in a Morris Water Maze (Hauss-
Wegrzyniak et al., 2000). So, following repeated injections, or chronic infusion with LPS, 
tolerance does not seem to develop to the sickness behaviour of impaired learning and 
memory, which is contrary to the tolerance that develops to lethargy and anorexia. It could 
be hypothesized that individuals with chronic Gram-negative bacterial infection might be at 
risk for chronic impaired learning and memory, which could result in long-term cognitive 
retardation. However, there was no impairment in learning the hidden platform task of the 
Morris Water Maze over four days of training, following repeated (four consecutive days) i.p. 
administration in rats of the Gram-positive superantigen, Staphylococcus enterotoxin A 
(SEA) (Woodruff et al,. 2010). Interestingly, when the rats that had received four i.p. 
injections of SEA were retested one month later, and without further injections, the rats 
showed improved learning (Woodruff et al., 2010).  
 
1.3.3. Recurrent acute challenge 
 
In contrast to the way in which chronic infections have been simulated experimentally, 
recurrent, acute infections are simulated by administering a series of PAMPs as spaced 
injections, in such a way that each new challenge is administered after the host has 
recovered from the acute phase responses caused by the previous injection. Simulating 
recurrent acute infections is important because systemic infections, whether bacterial or 
viral, often occur in a recurrent, acute fashion, especially during childhood. Typical recurrent 
acute infections include recurrent gastroenteritis, recurrent malaria, recurrent viral or 
bacterial respiratory diseases (e.g. asthma, pneumonia), and others. These recurrent 
infections, including community-acquired pneumonia that commonly is caused by 
Mycoplasma may have a devastating impact on the developing nervous system of children, 
especially in developing countries where resources for detecting such infections are likely to 
Chapter 1    Introduction 
 
40 
 
be limited. In spite of their prevalence and importance, recurrent acute infections seldom are 
investigated in the laboratory as recurrent phenomena.  
 
Nevertheless, some models of recurrent fevers exist. When administered five times, i.m. at 
three day intervals, the viral mimetic poly I:C (500 µg.kg-1) induced recurrent fevers in guinea 
pigs that started three hours after each of the injections and continued for about 20 h (Voss 
et al., 2006). Although the magnitude of the febrile response was highest after the initial poly 
I:C injection, the shape and duration of the fevers in response to subsequent injections of 
poly I:C  were similar, without progressive reduction in the fever response to the second, 
third, fourth and fifth injections (Voss et al., 2006). Similarly, when MDP (50 µg.kg-1) was 
administered at 4-5 day intervals, there was no development of tolerance to the pyrogenic 
effect of MDP after eight recurrent injections in guinea pigs (Madu et al., 2007). More 
relevant to my study, five repeated administrations of a pyrogenic moiety from Mycoplasma, 
FSL-1, at a dose of 100 µg.kg-1 induced recurrent fevers in guinea pigs when administered 
i.a. at three-day intervals (Greiss et al., 2009).  
 
Although the fever response during simulated recurrent acute infections (i.e. spaced 
injections, not daily injections) seems to be better characterized, very little is known about 
the sickness behaviours during recurrent acute infections. However, growth failure has been 
reported in growing guinea pigs during simulated recurrent acute Gram-positive bacterial 
infection (Madu et al., 2007). When guinea pigs were injected i.m. with 50 µg.kg-1 MDP, eight 
times at 4-5-day intervals, each recurrent injection elicited decreased food intake as well as 
fever (Madu et al., 2007). Moreover, Langhans and colleagues (1991) showed that repeated 
i.p. administration at two-day intervals of 0.6 mg.kg-1 MDP, but not of 100 µg.kg-1 LPS, 
resulted in significantly reduced food intake of rats after each of the injections (Langhans et 
al., 1991). In a recent Alzheimer’s dementia mouse-model, transgenic Tg2576 mice were 
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infected four times (i.p.) with 2.5 x 105 colony forming units of S. pneumonia, spaced 30 days 
apart (i.e. recovery between injections) (Ebert et al., 2010). Surprisingly, when learning and 
memory were tested in the infected rats on a weekly basis in a Morris Water Maze there was 
no impairment in spatial learning or memory during the course of infections. Therefore, 
recurrent systemic infections did not aggravate the course of experimental Alzheimer’s 
dementia in rats (Ebert et al., 2010). Whether there also is a lack of impairment in learning 
and memory during recurrent acute infections in otherwise healthy adult rats (as opposed to 
rats with Alzheimer’s dementia), still is unknown.  
 
1.4. RATIONALE FOR CURRENT STUDY 
 
In the African context, pulmonary disease still is the leading cause of paediatric morbidity 
and mortality, and frequently is caused by ‘atypical’ bacteria such as the Mycoplasmas (e.g. 
Black, 2006,  2008). Mycoplasma pneumoniae (M. pneumoniae) is a cause of community-
acquired pneumonia, which in turn is a major cause of recurrent infection in school children 
and adolescents (Waites and Talkington, 2004; Black, 2008). Evidence also has implicated 
M. pneumoniae in chronic inflammatory conditions, such as asthma (e.g. Sutherland and 
Martin, 2007). Infections with M. pneumoniae may involve both the upper and the lower 
respiratory tract and occur both endemically and epidemically wordwide. For example, a 
recent study in HIV-infected hospitalized children in India showed a 32.2% prevalence of M. 
pneumoniae infection among children with respiratory tract infections (Nadagir et al., 2011). 
An epidemic of M. pneumoniae infections were reported in Denmark in 2010 and a similar 
increase in M. pneumoniae infections, with the identification of two novel strains of M. 
pneumoniae, was reported in England and Wales over the same period (Chalker et al., 
2011). In many other countries, including South Africa, the prevalence and burden of 
disease caused by the Mycoplasmas still are undefined and need to be explored (Black, 
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2006, 2008), particularly in high-risk populations such as those in schools, hospitals and in 
the military where a large number of people reside in close proximity.  
 
Moreover, M. pneumoniae has severe extra-pulmonary manifestations, including arthritis 
(e.g. Cedillo et al., 1992; Oen et al., 1995), meningitis, encephalitis and other life-threatening 
neurologic complications (for reviews see McIntosh, 2002; Narita, 2009). Very recently, 
another strain of mycoplasma, namely Mycoplasma salivarium, was isolated in cerebral 
abscesses from two adult patients (Ørsted et al., 2011). Thus, the general perception that 
infection, caused by Mycoplasma species, is self-limiting and confined to the respiratory 
system is incorrect. Although our understanding of mycoplasma organisms’ cell biology, host 
interactions, disease transmission and treatment strategies have improved, very little is 
known about the sickness responses experienced by the host during mycoplasma infection. 
 
1.4.1. Pyrogenic moieties of the Mycoplasmas 
 
The Mycoplasmas can be distinguished phenotypically from conventional bacteria, because 
they lack a peptidoglycan cell wall (for review see Dybvig and Voelker, 1996). Because of 
this, the Mycoplasmas often are referred to as ‘atypical’ bacteria. Although membrane-bound 
lipoproteins in the Mycoplasmas are capable of activating cytokine-producing cells of the 
innate immune system (for review see Razin et al., 1998), the lack of an experimental moiety 
for simulating Mycoplasma infections has restricted advances in studying Mycoplasma-
induced acute phase responses. More than two decades ago it was demonstrated that 
moieties of the Mycoplasmas that are devoid of LPS can modulate several components of 
the immune system (Rauth and Praz, 1989). When it was realised that some effects of the 
Mycoplasmas are mediated by the central nervous system (e.g. Brenner et al., 1994), and 
that i.c.v. administration of heat-inactivated M. fermentans in rats activated the 
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hypothalamus-pituitary adrenal axis (HPA) (Weidenfeld et al., 1995), further explorative 
studies were quick to follow.  
 
Shortly after M. fermentans was found in the brains of AIDS patients (Blanchard and 
Montagnier, 1994), the behavioural responses to Mycoplasma infection in rats were 
investigated (Yirmiya et al., 1997). The study showed that i.c.v. administration of heat-
inactivated M. fermentans in rats induced fever, suppressed the consumption of food intake, 
decreased locomotion and social exploration, and reduced body weight (Yirmiya et al., 
1997). After the discovery and identification of Mycoplasma-specific PAMPs, including 
macrophage-activating lipopetide-2 (MALP-2, Mühlradt and Frisch, 1994; Mühlradt et al., 
1997) and fibroblast-stimulating lipopeptide-1 (FSL-1, Shibata et al., 2000; Nakamura et al., 
2002; Okusawa et al., 2004), the question arose as to how the Mycoplasmas interact with 
host cells (Rottem, 2003). Later studies in rats and guinea pigs characterized the pyrogenic 
properties of synthetic diacylated lipopeptides from the Mycoplasmas, including FSL-1 from 
M. salivarium and MALP-2 from M. fermentans (Hübschle et al., 2006; Greis et al., 2007). 
Simulated, systemic infection induced by i.p. administration of either FSL-1 or MALP-2 
induced fever and sickness behaviours in rats via activation of the TLR2/6 heterodimer 
(Hübschle et al., 2006; Greis et al., 2007).   
 
Therefore, using otherwise healthy rats as a rodent model, and FSL-1 as a pyrogenic moiety 
of Mycoplasma to simulate infection, I set out to investigate the autonomic and behavioural 
consequences of simulated acute, and recurrent acute, Mycoplasma infection. My main 
focus was to assess the degree to which Mycoplasma infection affects growth and physical 
activity in rats and compromises the capacity to learn and to remember, which represents a 
completely novel study that to date has not been undertaken. 
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I have addressed the following questions: 
 
Does the sickness behaviour outlast the fever, as it does for other bacterial infections 
(Pereira and Begum, 1987; Hübschle et al., 2006)? Does the expected anorexia lead to 
temporary weight loss with catch-up, or permanent stunting (Madu et al., 2007)? Particularly 
relevant to my study, is there impairment of learning and memory during the infection, and, 
perhaps more perniciously, are there long-term cognitive deficits and/or residual histological 
damage to the hippocampus (required for learning and memory) after resolution of recurrent 
acute infections? What are the roles of the pro-inflammatory cytokines, IL-1β and IL-6, in 
simulated Mycoplasma infection? Is there differential production of these two cytokines in 
brain regions known to be important in mediating fever and sickness behaviour, namely the 
hypothalamus and the hippocampus?   
 
Understanding the consequences of FSL-1 injections and clarifying the roles of pro-
inflammatory cytokines in the plasma and in the brain would allow me to contribute to a 
better understanding of the pathways involved in Mycoplasma-induced fever and sickness 
behaviour, particularly with regard to learning and memory processes. Although previous 
studies already have characterized some aspects of the acute phase response to systemic 
administration of FSL-1 in rats, my aim was not only to confirm these earlier findings but to 
extend those findings by improving our understanding of the effects of FSL-1 on learning and 
memory processes. I also investigated other aspects of the acute phase response, including 
fever, lethargy and anorexia during simulated acute Mycoplasma infection, and for the first 
time, during simulated recurrent acute Mycoplasma infection.  
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1.5. THESIS AIMS 
   
The aim of my thesis was to study autonomic and behavioural consequences of acute, and 
recurrent acute activation of the immune system in rats, following systemic administration of 
FSL-1, an agent which simulates Mycoplasma infection. 
 
Chapter 1 reviews current literature on bacterial infections, other than Mycoplasma infection 
that thus far has contributed much to our understanding of sickness responses, including 
fever, lethargy, anorexia and particularly impaired learning and memory. Chapter 2 contains 
common methodologies used in my thesis. In Chapter 3 I have investigated fever and 
sickness behaviours, specifically anorexia, lethargy and learning and memory processes 
following simulated, acute Mycoplasma infection. In Chapter 4 I sought to examine the 
contribution of plasma and brain pro-inflammatory cytokines, IL-1β and IL-6, in mediating 
Mycoplasma-induced fever and sickness behaviours following simulated acute Mycoplasma 
infection. In Chapter 5 I have studied evidence for a lasting effect on learning and memory 
as well as changes in histology of the hippocampus following simulated recurrent acute 
Mycoplasma infection. Finally, Chapter 6 expresses the implications of my results and 
provides future prospects that could be considered to take this work further. 
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2.1. HOUSING AND HANDLING OF ANIMALS 
 
Male Sprague-Dawley rats were bred in the Central Animal Service (CAS) of the University 
of the Witwatersrand. During my studies, the rats were housed individually in cages in a 
specially-equipped, temperature-controlled room (22.5 ± 0.5 ºC), on a 12:12 hour light:dark 
cycle with lights on at 07:00 local time. The room also contained a Morris Water Maze (see 
section 2.5.1, Figure 2.1). In all experiments I used male rats to avoid the influence of cyclic 
changes in female steroid hormones (Owen, 1975) that may affect hippocampal-dependent 
task performance, hippocampal anatomy, and hippocampal cell function (Warren et al., 
1995; Warren and Juraska, 1997). All rats were handled daily and had access to food and 
water ad libitum. All cages were cleaned twice weekly and the clinical status of rats was 
monitored and recorded daily, either by myself or by staff of the CAS. 
  
2.2. GENERATING FEVER AND SICKNESS BEHAVIOUR 
 
The diacylated synthetic lipoprotein, fibroblast-stimulating lipopeptide-1 (FSL-1), which 
represents the NH2-terminal sequence of the 44 kDa lipoprotein LP44 of M. salivarium 
(Shibata et al., 2000; Nakamura et al., 2002; Okusawa et al., 2004) was used as a putative 
exogenous PAMP. FSL-1 was purchased as a lyophilized mixture of RR and RS stereo-
isomers (EMC microcollections, Tübingen, Germany; Product L7000) and the lyophilized 
powder was reconstituted with sterile, pyrogen-free phosphate-buffered saline (PBS) to a 
concentration of 1 mg.ml-1. All injections were administered intraperitoneally (i.p.) at 16:00, 
i.e. 3 h before lights-off. A dose-response curve for FSL-1, at doses of 10, 100 and 1 000 
µg.kg-1 has been established in rats (Hübschle et al., 2006). I therefore decided to use doses 
of 500 and 1 000 µg.kg-1 in my studies. 
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2.3. MEASURING FEVER AND LETHARGY 
 
Body core temperature and cage activity of rats were measured continuously by remote 
biotelemetry using radiotransponders that were pre-calibrated individually by the 
manufacturer (Mini Mitter, St. Paul, MN, USA) to a calibrated accuracy of 0.1 ºC.  
 
Rats had the radiotransponders (G2 E-Mitters, Mini Mitter, St. Paul, MN, USA) implanted 
intra-abdominally under general anaesthesia induced by intramuscular injection of a 
combination of 100 mg.kg-1 ketamine hydrochloride (Anaket-V, Bayer, South Africa) and 5 
mg.kg-1 xylazine (Chanazine, Bayer, South Africa). Once the rats were anaesthetised, the 
surgical area was shaved and cleaned with chlorhexidine gluconate. A 20 mm incision was 
made through the skin and muscle, into the peritoneal cavity. The transponder (size ~ 15.5 
mm x 6.5 mm; mass ~ 1.1 g) was inserted into the abdomen and sutured to the abdominal 
wall. The wound then was sutured and treated with a topical antiseptic (Necrospray®) and 
the animals were allowed seven days to recover from surgery in a warm recovery room. A 
receiver plate (ER-4000, Mini Mitter, Sunriver, OR, USA; size ~ 0.56 m x 0.29 m x 0.07 m) 
placed under each rat’s cage monitored the physical activity of rats in their cages based on 
detection of transponder movement. Transponder output frequency and transponder position 
were displayed on a computer screen at 5 min intervals as temperature and activity counts. 
E-mitters have been used previously for studying acute phase responses to various 
pathogens and in various species (Garami et al., 2011; Coon et al., 2011). 
 
2.4. MEASURING ANOREXIA AND GROWTH 
 
Food containers were filled daily with 200 g of the pelleted rat chow (Epol, Johannesburg, 
South Africa). Food intake was measured at 16:00 by weighing the remaining pellets in the 
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food container as well as food fragments on the cage floor. However, food powder on the 
cage floor was ignored. Food powder generally weighs less than a gram and has been 
reported to be similar amongst rats (Mueller et al., 1997). Body mass of the rats was 
weighed with a bench top-loading scale (Diamond®) to an accuracy of 1 g and recorded daily 
at 16:00.  
 
2.5. MEASURING LEARNING AND MEMORY 
 
2.5.1. The Morris Water Maze 
 
The Morris Water Maze was described and developed 30 years ago by Richard Morris 
(Morris, 1981, 1982, 1984), and has been employed as a research tool for studying mainly 
learning and memory (Brandeis et al., 1989). Today the Morris Water Maze still is a popular 
test for studying the neurobiology and neuropharmacology of spatial learning and memory in 
rodents (see D’Hooge and De Deyn, 2001; Terry, 2009). Since its development the Water 
Maze also has been used for evaluating the effects of aging, experimental brain lesions and 
drug effects in rodents (Barnes, 1988; D’Hooge and De Deyn, 2001) as well as in stroke 
research (for review see DeVries et al., 2001). Several animal studies have confirmed the 
successful use of the Maze in investigations of neurodegenerative and neuropsychiatric 
illnesses where cognition is impaired, including animal models of Alzheimers disease (e.g. 
Nitta et al., 1994; Deshmukh et al., 2009) and posttraumatic stress disorder (Harvey et al., 
2003). Because of the reliability and robustness of the Water Maze, it has been adapted for 
use in humans by employing life-size mazes (Wertlieb and Rose, 1979; Bohbot et al., 1998; 
2002) and virtual water mazes (three-dimentional pool) (e.g. Astur et al., 1998).  
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The Morris Water Maze is based upon a reward principle: although rats can swim, they do 
not like water and they want to escape from it. Escaping from water as a technique to 
motivate learning was used long before the development of the Morris Water Maze (Glaser, 
1910; Wever, 1932; Waller et al., 1960). Indeed, some stress paradigms are designed 
closely around the typical swimming-learning protocol used in the Morris Water Maze in 
which the stressor (swimming in the pool) promotes resilience due to adaptive learning 
(learning to escape the water) (e.g., Brown et al., 2001; Wegener et al., 2010). Using the 
escape technique in a Water Maze allows motivation for escape behaviour without the 
animals being exposed to electric shock, extensive pre-training, or food deprivation. The 
Maze measures the ability of rodents to learn and remember the spatial location of visual 
cues in a room in order to find and escape onto a submerged platform located in a pool of 
water (Figure 2.1). Having to swim provides the motivation for optimal learning as well as for 
remembering the task.  
 
Learning is assessed mainly by the degree to which the rats show a decrease in swimming 
latency as a function of repeated trials. This approach is based on the idea that animals will 
attempt to develop an optimal strategy to explore their environment and escape from the 
water. The “Cued test” (see Morris, 1984), where the platform is visible and raised above the 
water, can help to determine if any differences in a particular rat’s performance are due to 
motivational/emotional or sensorimotor abnormalities as opposed to learning and memory 
impairment. The Cued test therefore assesses learning and memory processes that are 
independent of the hippocampus (Cunningham and Sanderson, 2008; Sanderson et al., 
2009). Further confirmation that the location of the platform has been learned is that, if the 
platform is removed, i.e. the “Probe trial” (see Morris, 1982), rats will spend more time 
searching the area near the former location of the platform. Thus rats will show a spatial bias 
for that area. Measures for spatial bias during a Probe trial include, for example, the percent 
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time spent in the correct (i.e. target) quadrant or zone in which the platform was located, 
percent time spent in the target quadrant/zone vs. the other three quadrant/zones, platform 
crossings as well as the time, distance and speed travelled to the former platform location 
(see Maei et al., 2009). Successful navigation to the submerged platform in order to escape 
the water requires acquisition, processing, consolidation, retaining and retrieval of the spatial 
localization of visual cues (see Poucet et al., 2000), and depends on the integrity of the 
hippocampus (Sutherland et al., 1982; Sutherland and Rudy, 1987; Jarrard, 1993). 
 
My Morris Water Maze was developed based on the method of Hamlyn and colleagues 
(2009) with minor amendments (Hamlyn et al., 2009). The Maze consisted of a circular 
black-walled pool (0.5 m high and 1.75 m in diameter), divided into four virtual quadrants and 
filled with water (25-26 ºC) to a depth of 350 mm. An adjustable black platform (100 mm in 
diameter) was placed within the pool, either 10 mm below the water surface, rendering it 
accessible but invisible, or 15 mm above the surface (for the Cued test), so visible to the rats 
when swimming (see Figure 2.1). The water was rendered opaque with potassium 
permanganate (which I also used as a disinfectant) and stirred between trials to eliminate 
possible olfactory cues. A white noise generator (ANY-maze; Stoelting, IL, USA) excluded 
search strategies based on auditory cues. Four stationary poster boards, supporting different 
geometrical black shapes against a white background, surrounded the pool and served as 
extra-maze visual spatial cues. I concealed myself behind the poster boards while the rats 
were swimming. The length of time that a rat remained in the water in each swim was limited 
to 60s. 
 
The pool was illuminated by indirect light to reduce light reflections from the water surface. A 
camera (Canon Digital Video Camcorder, Model DM-MV550i E) situated above the pool, and 
a video tracking system (ANY-maze; Stoelting, IL, USA) recorded swimming activities.                     
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Figure 2.1 Illustration of the experimental set-up of a water maze task (drawn by Roy Hollowday, University of the Witwatersrand). 
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2.5.2. Advantages and limitations of a Morris Water Maze 
 
The Morris Water Maze has many advantages over other available behavioural models that 
assess cognitive processes.  An important advantage is that the Maze tests a high level of 
cognitive function: behavioural responses in the Maze are not merely reflex responses, 
which could be the case in, e.g. electric shock paradigms. Immersion into water, though 
unpleasant, also may not be as aversive as food deprivation or electric shock paradigms, 
which apply negative reinforcement. Other advantages of the Maze include a short training 
period (without pre-training) with a modest number of animals as well as operation of video 
tracking systems, reducing distraction of animals by the experimenter and identifying 
confounding factors such as motor, visual and motivational deficits. The Morris Water Maze 
also is a very versatile paradigm in which spatial and non-spatial learning, re-learning as well 
as reference and working memory processes can be assessed (see Terry, 2000).     
   
However, as with all other animal behavioural models the Morris Water Maze also has 
limitations, especially when used to assess sick animals (see Cunningham & Sanderson, 
2008). Hypothermia and hyperthermia as well as sickness behaviours, such as lethargy, 
affect performance in the Maze, thus potentially confounding assessment of cognition 
(Ahlers and Riccio, 1987; Sparkman et al., 2005a, b; Cunningham and Sanderson, 2008; 
Sanderson et al., 2009). Because the Maze procedure has to be run by hand, it could be 
more tedious than other paradigms that use fully automated equipment. Technical and 
procedural variables, e,g., dimensions of the pool, immersion into water and water 
temperature may cause endocrine responses to stress, such as the release of glucocorticoid 
(e.g. Sandi, 1998), which could skew the results. Other confounding factors, such as visual 
acuity, motivation, stress and anxiety also need thorough consideration when using the 
Morris Water Maze as a cognitive tool (see Sharma, 2009). Moreover, whereas the Maze 
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measures declarative, spatial learning and memory it does not measure non-declarative, 
non-spatial types of memory. Thus, measures of Maze performance in experimental animals 
(e.g. rodents) are not direct measures of human cognitive function. Although the underlying 
functional mechanisms of the brain are shared across most mammalian species, one has to 
acknowledge the differences in complexity between human and rodent behaviour. Direct 
extrapolation of results in rodent studies to humans is therefore ill advised (see Lindner, 
1997). 
 
2.5.3. Validation of my use of a Morris Water Maze 
 
Animal models of human conditions should be reliable and well validated in terms of 
predictive, construct and face validity (see van der Staay, 2006). Predictive validity refers to 
the ability of the animal model to accurately predict the behaviour and events it is supposed 
to model as well as the response of the animal to treatment as used in the human condition. 
Construct validity requires that the animal model be based on the same physiological and 
neurobiological mechanisms as the human condition, and refers to the accuracy with which 
a test measures what it is supposed to measure. Face validity implies that an animal model, 
at least, should be similar to the human condition that it is mimicking with respect to 
aetiology, symptomatology and treatment (van der Staay, 2006). The Morris Water Maze 
indeed has predictive, construct and face validity (see Terry, 2009): pharmacological studies 
in the Maze have shown that neurotransmitter systems, including glutamate, dopamine and 
GABA that are involved in mediating spatial learning and memory are most critical for 
adequate performance in the Maze (McNamara and Skelton, 1993). Importantly, the Maze 
has been used in humans, albeit as a “Virtual Morris Water Maze” (e.g. Astur et al., 1998, 
2002, 2004; Newhouse et al., 2007), and has proven highly sensitive for assessing various 
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human conditions, including cognitive decline in children and adults (Overman et al., 1996; 
Lindner, 1997). 
  
I validated my use of the Morris Water Maze technique by means of a pharmacological 
challenge with scopolamine, a known amnesic drug. Scopolamine, a centrally acting anti-
cholinergic (anti-muscarinic) agent routinely is used to induce amnesia in laboratory animals 
(Diez-Ariza et al., 2003; Janas et al., 2005; Choi et al., 2006) and humans (Antonova et al., 
2010). Previous studies also have used scopolamine to induce memory impairment in rats 
before testing them in a Morris Water Maze (Ormerod and Beninger, 2002; Takahata et al., 
2005; Hirst et al., 2006). None of the studies has reported long-term debilitating effects 
(motivation, motor activity, sensory processing) on the rats’ performance following 
administration of scopolamine at various doses. Consequently, I used scopolamine as a 
positive control in an experimental model for assessing spatial learning and memory deficits 
in a Morris Water Maze. On the basis of pilot studies, I injected rats i.p. with 0.8 mg.kg-1 
scopolamine (Sigma-Aldrich, St. Louis, MO, USA), a dose sufficient to induce amnesia. To 
prove validity of my use of the Maze, I would expect scopolamine to impair performance in 
the Maze, i.e. induce impairment in learning and memory.   
 
2.5.4. Maze protocol 
 
Before the start of each of the experiments, the rats were exposed to an initial habituation 
trial in the Morris Water Maze from which the platform had been removed (see Morris, 1981), 
during which they were allowed to swim freely for 120 s to explore the pool and its 
surroundings. The rats then were subjected to a single 60 s Cued test with the platform 
visible and placed in the centre of the pool to confirm motivation, vision and physical ability 
of rats. Thereafter the rats underwent a set of training sessions (one per day) over four days 
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(i.e. acquisition phase) intended for them to learn the position of a submerged platform in the 
Water Maze. One training session consisted of four learning trials per day (e.g. four attempts 
to search and swim to the submerged platform), with 90 s inter-trial intervals. Each rat was 
placed on the submerged platform for 10 s to orientate before the start of the initial trial on 
each day. Data recording started when the rat was placed into the water, tail first and with its 
head facing the wall of the pool. The quadrant in which the rats were released was changed 
between trials; using different starting points prevents the animal from using unintended 
response strategies such as swimming in the same direction. The rat was allowed 60 s to 
find the submerged platform. If the rat did not find the platform, it was guided gently to the 
platform. Once on the platform, rats were allowed to remain there for an additional 10 s. The 
rat then was removed from the platform and the next rat started its training trial.  
 
The day after the last training trial on day 4, rats were assessed on their ability to remember 
the Maze task in a single 30 s Probe trial (platform removed), as described in section 2.5.1. 
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CHAPTER 3 
 
 
 
SICKNESS BEHAVIOURS DURING SIMULATED, ACUTE 
MYCOPLASMA INFECTION 
 
 
 
 
 
 
 
 
Data presented in this chapter have been published:  
 
Swanepoel T., Harvey BH., Harden LM., Laburn HP. and Mitchell D. 2011. 
Dissociation between learning and memory impairment and other sickness behaviours              
during simulated Mycoplasma infection in rats. 
Brain, Behavior, and Immunity 25: 1607-1616. 
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3.1 ABSTRACT 
 
To investigate fever and sickness behaviours, specifically, lethargy and anorexia, as well as 
potential consequences for learning and memory following simulated, acute Mycoplasma 
infection, I have simulated the effects of Mycoplasma infection, in rats, by administering 
fibroblast-stimulating lipopepide-1 (FSL-1), a pyrogenic moiety of Mycoplasma salivarium. I 
measured the effects on body temperature, cage activity, food intake, and on spatial learning 
and memory in a Morris Water Maze. Male Sprague-Dawley rats had radiotransponders 
implanted to measure abdominal temperature and cage activity. After recovery, rats were 
assigned randomly to receive intraperitoneal (i.p.) injections of FSL-1 (500 or 1000 µg.kg-1 in 
1 ml.kg-1 phosphate-buffered saline; PBS) or vehicle (PBS, 1 ml.kg-1). Body mass and food 
intake were measured daily. Training in the Maze commenced eighteen hours after 
injections and continued daily for four days. Spatial memory was assessed on the fifth day. 
FSL-1 administration induced a dose-dependent fever (~ 1 ºC) for two days, lethargy (~ 78 
%) for four days, anorexia (~ 65 %) for three days and body mass stunting (~ 6 %) for at 
least four days. Eighteen hours after FSL-1 administration, when rats were febrile, lethargic 
and anorexic, learning in the Maze was unaffected. There also was no memory impairment. 
My results support emerging evidence that impaired learning and memory is not inevitable 
during simulated infection. 
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3.2 INTRODUCTION 
 
Impaired learning and memory has become entrenched as a member of the sickness 
behaviours, the suite of behaviours associated with the acute phase response. Its 
membership is supported by observations of sickness-induced cognitive dysfunction in acute 
experimental bacterial infections (as reviewed by, but also for contradictory evidence see, 
Cunningham and Sanderson, 2008) and, to a lesser extent, viral infections (Kent et al., 2007; 
Dilger and Johnson, 2010). However, there is emerging evidence that learning and memory 
is not always impaired when sickness behaviour is induced (Thomson and Sutherland, 2006; 
Cunningham and Sanderson, 2008; Huang et al., 2010; Woodruff et al., 2010; Grigoleit et 
al., 2010). Knowing whether or not impaired learning and memory is inevitable during the 
response to infection is crucial for assessing the cognitive consequences of infection in 
patients, especially in children in their phase of rapid learning. If cognition is impaired by 
acute infection, then the patients most likely to be compromised are those who are victims of 
recurrent acute infection.  
 
Community-acquired pneumonia occurs in a recurrent fashion, commonly in children and 
adolescents (for review see McIntosh, 2002). One causative agent of this illness, 
Mycoplasma pneumoniae, has severe extra-pulmonary manifestations, including life-
threatening neurologic complications (for review see Narita, 2009). A case study of a 7-year-
old girl suffering from possible M. pneumoniae encephalitis reported evidence of pervasive 
changes in memory (Benjamin et al., 2007). Investigations into learning and memory 
impairment as a sickness behaviour have been undertaken for the behaviour following acute 
bacterial infections. However, despite the prevalence of the illness, there have been no 
systematic investigations of learning and memory following Mycoplasma infections. This is in 
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spite of intracerebroventricular (i.c.v.) administration of heat-inactivated Mycoplasma 
fermentans to rodents, inducing other sickness behaviours (Yirmiya et al., 1997, 1999).  
 
Although killed pathogens are used experimentally to generate sickness behaviours, 
pyrogenic moieties of pathogens, extracted from the cell walls of bacteria (e.g. 
lipopolysaccharide; LPS from Gram-negative bacteria) or mimicking the double-stranded 
RNA of viruses (polyinosinic:polycytidylic acid; poly I:C), are used more frequently to 
stimulate the innate immune system, as it would be in the actual infection. Although the 
Mycoplasmas can be distinguished phenotypically from conventional bacteria by the lack of 
a cell wall (for review see Dybvig and Voelker, 1996), membrane-bound lipoproteins in the 
Mycoplasmas are capable of activating cytokine-producing cells of the innate immune 
system (for review see Razin et al., 1998). The Mycoplasmas, though, activate different Toll-
like receptors than do other pathogens (Takeuchi and Akira, 2001). One of the lipoproteins, 
fibroblast-stimulating lipopeptide-1 (FSL-1), the diacylated lipopeptide from M. salivarium, 
induces sickness behaviour when administered to rats (Hübschle et al., 2006). Whether 
FSL-1 administration induces learning and memory impairment has not been investigated. 
 
I therefore investigated the effects of FSL-1 administration in rats on changes in spatial 
learning and memory performance, as well as on fever, lethargy and anorexia. I used the 
Morris Water Maze (see Morris, 1984), a standard tool for investigating spatial learning and 
memory performance in animals (for review see D'Hooge and De Deyn, 2001) and humans 
(virtual Morris Water Maze) (Aguirre et al., 1996; Astur et al., 2004; Goodrich-Hunsaker et 
al., 2010).  
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3.3 MATERIALS AND METHODS 
(Also refer to Chapter 2, i.e. ‘Common methodology’)  
 
3.3.1. Animals 
 
Fifty seven male Sprague-Dawley rats with an average body mass of 381 ± 29 g (mean ± 
SD) on injection day were used, with no significant differences in the average body mass of 
the treatment groups. 
 
Experiments were carried out in accordance with the regulations of the Animal Ethics and 
Control Committee of the University of the Witwatersrand and were approved by its Animal 
Ethics Screening Committee (clearance certificates AESC 2009/43/04. and AESC 
2010/34/04). 
 
3.3.2. Pyrogen administration 
 
The lyophilized powder of FSL-1 was reconstituted with sterile, pyrogen-free phosphate-
buffered saline (PBS) and injected i.p. at a dose of 500 or 1000 µg.kg-1, at 1 ml.kg-1 volume. 
The dosage of FSL-1 was established after pilot studies showed that doses of 500 µg.kg-1 
and 1000 µg.kg-1 induced pronounced dose-dependent fever and sickness behaviours within 
6 h of administration. In these pilot studies, I administered an even higher dose of FSL-1 
(2000 µg.kg-1) but the ensuing fever and sickness behaviours did not appear to differ from 
that following administration of 1000 µg.kg-1 (data not shown). To reduce the risk of toxic 
responses, and to reduce cost, I did not follow up the 2000 µg.kg-1 dose systematically. I 
injected the rats at 16:00 so that the peak in fever would coincide with the dark phase of the 
24 h day, when rats are most active.  
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3.3.3. Body temperature and cage activity 
 
I recorded body core temperature and cage activity of rats continuously by remote 
biotelemetry as discussed in detail in section 2.2 of Chapter 2. Although I measured 24 h 
activity, which includes day time and night time activity, for the purpose of this study I chose 
to analyze only night time cage activity when rats are most active.   
 
3.3.4. Food intake and body mass 
 
Food intake and body mass of the rats, before and after intervention, were recorded daily at 
16:00 (refer to section 2.4 of Chapter 2). 
 
3.3.5. Learning and memory: Morris Water Maze 
 
The Morris Water Maze apparatus and the protocol I used are discussed in detail in section 
2.5 of Chapter 2.  
 
Spatial learning and memory in the Morris Water Maze were measured as described 
previously (Hamlyn et al., 2009), with minor modifications. Technical and procedural 
variables need thorough consideration when one uses the Morris Water Maze as a cognitive 
tool (see Sharma, 2009), especially when studying learning and memory in immune-
challenged animals (reviewed in Cunningham and Sanderson, 2008). Therefore, I paid 
particular attention to exclude or reduce potential confounders which I could manage, such 
as water temperature, room temperature, dimensions of the pool, gender, housing and 
hormonal status of the rats. I also handled the rats regularly in an attempt to reduce stress 
levels. Furthermore, because I did not want to confound measurement of fever and activity, 
Chapter 3        Sickness behaviour during acute infection 
 
63 
 
which are most pronounced during the nocturnal period or rats, I did not immerse the rats 
over that time and chose to start the training in the Water Maze 18 h after FSL-1 
administration. 
 
I measured the rats’ swim speed, latency to platform, distance travelled and the time spent in 
the target zone of the maze. I validated the use of the Morris Water Maze by injecting rats 
i.p. with 0.8 mg.kg-1 scopolamine (Sigma-Aldrich, St. Louis, MO, USA), an agent which 
induces amnesia in laboratory animals (Diez-Ariza et al., 2003; Janas et al., 2005; Choi et 
al., 2006) and humans (Antonova et al., 2010). 
 
3.3.6. Experimental procedure 
 
The rats were assigned randomly to four experimental groups. The rats in two groups 
received either 500 µg.kg-1 FSL-1 (n = 8) in PBS or 1000 µg.kg-1 FSL-1 (n = 10) in PBS. The 
rats of the other two groups received phosphate-buffered saline (PBS, 1 ml.kg-1; n = 
10/group), and served as controls; PBS and FSL-1, at one of the two doses, were 
administered randomly.  
 
As described in Chapter 2 (section 2.5.4) the rats were first exposed to an initial habituation 
trial followed by a Cued test in the Morris Water Maze. The rats then received their injection 
of FSL-1 (at one of the two doses) or PBS on the same day that the Cued test was 
performed, but at 16:00.  
 
The next day (about 16 h after the injections), the rats were tested again in a Cued test (60 
s) to determine the effect, if any, of FSL-1 on motivation, vision and motor function. Training 
in the Morris Water Maze (i.e. acquisition phase) then commenced about 2 h later (i.e. 18 h 
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after the injections). I chose to wait 18 h before training the rats based on data from prior 
pilot studies, which showed that the acute fever have resolved by then; hyperthermia itself 
induces anterograde amnesia in rats (Ahlers and Riccio, 1987). For four consecutive days, 
rats were given four 60 s trials per day, in which they attempted to find the submerged 
platform from different randomly-chosen starting quadrants.  
 
A single 30 s Probe trial, in which the platform was removed from the water, was conducted 
on the fifth day, to assess recall of spatial reference memory (recalling phase). Over the 5 d 
Morris Water Maze procedure, body core temperature and cage activity were measured 
continuously with biotelemetry and food intake and body mass were measure daily.  
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1 x Habituation trial (120 s) 
 
 
1 x Cued test (60 s) 
Single injection of FSL-1 or PBS 
 
 
1 x Cued test (60 s) 
Day 1:  4 x training trials (60 s each) 
Day 2:  4 x training trials (60 s each) 
Day 3:  4 x training trials (60 s each) 
Day 4:  4 x training trials (60 s each) 
 
 
1 x Probe trail (30 s) 
 
Same day 
Same day 
Acquisition phase 
over 4 days 
Recalling phase 
 
Figure 3.1. Schematic representation of the experimental procedure of training and 
testing rats in a Morris Water Maze, after receiving a single injection of 500 or 1000 µg.kg-1 
FSL-1 or 1ml.kg-1 PBS. 
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3.3.7. Data analyses 
 
There were no differences between the two groups of rats receiving PBS, so I subsequently 
combined data from rats given PBS to form one control group (n = 20). For statistical 
purposes I used the thermal response index (TRI, ˚C.h) as an integrated measure of fever 
duration and magnitude; TRIs were calculated separately over four successive 12 h periods 
on the day of injection starting at 19:00. To take account of circadian rhythms in body 
temperature, TRIs were calculated as the time integrals of the differences between the 
abdominal temperature of each rat and the abdominal temperature of that rat at the same 
time, averaged for the three days before the day of injection, when the rats were undisturbed 
in their home cages. TRIs were analyzed by one-way analysis of variance (ANOVA) with 
post hoc tests when ANOVA showed significance.  
 
Night-time cage activity (19:00-07:00) was expressed as percent change from the mean 
activity measured for the same time period over the four days before injection. Food intake 
was expressed as grams of food consumed in 24 h per 100 g of body mass. Twenty-four 
hour change in body mass was determined by subtracting the body mass measured on each 
day after the injection from the average body mass measured for three days before injection, 
and expressed as change in body mass (g) per 100 g of rat body mass. Changes in activity, 
body mass and food intake were compared by means of two-way repeated measures 
ANOVA (intervention, time, interaction) with post hoc tests when ANOVA showed 
significance.  
 
For each of the training days in the Morris Water Maze the mean speed, latency and 
distance to reaching the submerged platform over all four trials on that day, were determined 
for each rat, and then averaged across the group of rats. Changes in speed, latency and 
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distance measured during the four-day acquisition phase in the Morris Water Maze were 
compared by means of two-way repeated measures ANOVA (intervention, time, interaction) 
with post hoc tests when ANOVA showed significance. A one-way ANOVA was performed 
for indices measured during the Cued tests and during the Probe trial in the Morris Water 
Maze.  
 
Data are expressed as mean ± SD and a statistical significance was accepted for P < 0.05. 
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3.4 RESULTS 
 
3.4.1. Body temperature and cage activity 
 
Abdominal temperatures of rats receiving FSL-1 started to exceed significantly those of rats 
receiving PBS about 4 h after injection (Fig. 3.2). On average the body temperature of rats 
receiving FSL-1 peaked approximately 6 h after the injections at 39 ºC, a degree higher than 
that of rats receiving PBS. On the night immediately after the injections the mean 12 h 
thermal response indices (TRI) (Fig. 3.3) for rats receiving 500 or 1 000 µg.kg-1 FSL-1 were 
not significantly different from each other (P > 0.05), but were significantly greater than the 
mean 12 h TRI for rats receiving PBS (P < 0.05), (F (2,37) = 54.78, P < 0.0001). On the 
following day the mean 12 h TRI (Fig. 3.3) for rats receiving 500 or 1 000 µg.kg-1 FSL-1 were 
significantly different from each other (P < 0.05), and both significantly greater than the 
mean 12 h TRI for rats receiving PBS (P < 0.05), (F (2,37) = 62.84, P < 0.0001) . On the 
second night the mean 12 h TRI for rats receiving 1 000 µg.kg-1 FSL-1 was significantly 
greater than the mean 12 h TRI for rats receiving 500 µg.kg-1 FSL-1 (P < 0.05) and for rats 
receiving PBS (P < 0.05), (F (2,37) = 5.14, P = 0.01). Similarly, on the second day  the mean 
12 h TRI for rats receiving 1 000 µg.kg-1 FSL-1 was significantly greater than the mean 12 h 
TRI for rats receiving 500 µg.kg-1 FSL-1 (P < 0.05) and for rats receiving PBS (P < 0.05), (F 
(2,37) = 31.67, P < 0.0001), (Fig. 3.3). By the third night and day after injection, the 
temperatures of rats that had received FSL-1 were not different to those of rats that had 
received PBS. 
 
Chapter 3        Sickness behaviour during acute infection 
 
69 
 
36
37
38
39
-4 8 20 32 44 56 68
Time (h)
* #
* # $
#
#
$
$
B
o
d
y
 t
e
m
p
e
ra
tu
re
 (
 °
C
)
Night 1 Day 1 Night 2 Day 2
 
 
Figure 3.2. Abdominal temperatures (mean ± SD) of rats over 72 h after receiving a 
single i.p. injection of 1 ml.kg-1 PBS (○; n = 20) or FSL-1 at doses of 500 µg.kg-1 in 1 ml.kg-1 
PBS (●; n = 8) or 1 000 µg.kg-1 in 1 ml.kg-1 PBS (▲; n = 10). Five-minute recordings of each 
rat’s temperature were averaged over 2 h intervals and then averaged for the group. The 
arrow indicates time of injection (16:00) and the black bars indicate lights off (19:00-07:00). 
The hatched bars indicate when rats were swimming in the Morris Water Maze. Significant 
differences: * PBS vs. 500 µg.kg-1;  # PBS vs. 1 000 µg.kg-1;  $ 500 µg.kg-1 FSL-1 vs. 1 000 
µg.kg-1 FSL-1, during 12 h periods as shown. 
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Figure 3.3. Twelve hour night-time and day-time thermal response indices (TRIs) (mean 
± SD) of rats over 48 h after receiving a single i.p. injection of 1 ml.kg-1 PBS (n = 20) or FSL-
1 at doses of 500 µg.kg-1 in 1 ml.kg-1 PBS (n = 8) or 1 000 µg.kg-1 in 1 ml.kg-1 PBS (n = 10). 
Significant differences: * PBS vs. 500 µg.kg-1;  # PBS vs. 1 000 µg.kg-1;  $ 500 µg.kg-1 FSL-1 
vs. 1 000 µg.kg-1 FSL-1. 
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Figure 3.4 shows the change in nocturnal cage activity of rats after receiving an i.p. injection 
of 500 or 1 000 µg.kg-1 FSL-1, or PBS. There was a significant statistical interaction between 
intervention and time (F (6,105) = 97.62, P < 0.0001). Cage activity was depressed 
significantly over the first night, by nearly 80 %, following an injection of FSL-1 at doses of 
both 500 µg.kg-1 (P < 0.0002) and 1 000 µg.kg-1 (P < 0.0002), compared to activity after PBS 
injection. From the second night, the magnitude of the decrease in cage activity of rats 
receiving FSL-1 was dependent on the dose of FSL-1 injected, although still significant for 
both doses, compared to PBS (P < 0.0002). Rats treated with 1 000 µg.kg-1 FSL-1, but not 
500 µg.kg-1 FSL-1, still had a significant decrease in the cage activity on the third (P < 
0.0002) and fourth (P < 0.04) days after the injection, compared to rats treated with PBS.   
  
3.4.2. Food intake and body mass 
 
On average, rats consumed 9.7 ± 0.8 g of food, per 100 g of body mass per day, for the four 
days before receiving injections (Fig. 3.5A). Two-way repeated measures ANOVA of food 
intake following injections showed a significant interaction between intervention and time (F 
(6,105) = 32.50, P < 0.0001). Over the first day after injections, rats receiving FSL-1 at both 
doses consumed significantly less food than did rats receiving PBS (P < 0.0002). How long 
food intake was suppressed depended on the dose of FSL-1 injected. FSL-1 at a dose of 
500 µg.kg-1 suppressed food intake significantly for two days (P < 0.0004) whereas a dose of 
1 000 µg.kg-1 FSL-1 suppressed food intake significantly for three days (P < 0.0002).  Food 
intake returned to pre-injection value by the fourth day after injection of FSL-1 at 1 000 
µg.kg-1. 
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Figure 3.4. Night-time (19:00-07:00) cage activity (mean ± SD) of rats after receiving one 
i.p. injection of 500 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (●; n = 8), 1 000 µg.kg-1 FSL-1 in 1 ml.kg-1 
PBS (▲; n = 10), or 1 ml.kg-1 PBS (○; n = 20). Activity was expressed as percent change 
from the mean activity measured over the same time period for the four previous days, with -
100 % representing a complete cessation of cage activity. Significant differences: * PBS vs. 
500 µg.kg-1; # PBS vs. 1 000 µg.kg-1;  $ 500 µg.kg-1 FSL-1 vs. 1 000 µg.kg-1 FSL-1.  
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Figure 3.5B shows the daily change in body mass of rats receiving i.p. injections of PBS or 
FSL-1. Two-way repeated measures ANOVA of change in body mass following injections 
showed a significant interaction between intervention and time (F (6,105) = 12.24, P < 
0.0001). The body mass of rats receiving 500 or 1 000 µg.kg-1 FSL-1 decreased equally on 
the first day after the injections, compared to the body mass change of rats receiving PBS (P 
< 0.0002). From the second day, the magnitude of the decrease in body mass was 
dependent on the dose of FSL-1 administered. Although the decreases following injections 
of both doses of FSL-1 were significantly different from the decrease following injection of 
PBS (P < 0.0002), injection of the 1 000 µg.kg-1 dose resulted in a significantly greater 
decrease than did injection of the 500 µg.kg-1 dose (P < 0.0002). The body mass of rats 
receiving 500 µg.kg-1 FSL-1 stabilized a day after injection, while that of the rats receiving 
1000 µg.kg-1 FSL-1 stabilized only two days after injection. However, injection of both doses 
of FSL-1 resulted in stunting, at least for the four-day period of observation, because body 
mass remained significantly below pre-injection mass, and below the body mass of the rats 
that had received PBS.  
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Figure 3.5. Food intake (mean ± SD) (A) and change in body mass (mean ± SD) (B) of 
rats after one i.p. injection of 500 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (●; n = 8), 1 000 µg.kg-1 
FSL-1 in 1 ml.kg-1 PBS (▲; n = 10), or 1 ml.kg-1 PBS (○; n = 20). Food intake was expressed 
as grams of food consumed in 24 h per 100 g of body mass (BM) on that day. Change in 
body mass was measured over successive 24 h intervals starting at 16:00 and was 
expressed as grams of BM per 100 g of BM on that day. Significant differences:  * PBS vs. 
500 µg.kg-1; # PBS vs. 1 000 µg.kg-1;  $ 500 µg.kg-1 FSL-1 vs. 1000 µg.kg-1 FSL-1.  
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3.4.3. Learning and memory:  Morris Water Maze   
 
Figures 3.6B and 3.6F validate my use of the Morris Water Maze, and confirm the retarding 
effect of scopolamine on learning in rats (Fig. 3.6F). In the Cued test (visible platform) there 
were no significant differences between the rats receiving scopolamine and those receiving 
PBS with respect to their latency to locate the platform (t (28) = 0.78,  P = 0.44; unpaired t-
test; Fig. 3.4B). This result was confirmed using swim speed (t (28) = 0,69, p = 0.49; 
unpaired t-test; data not shown) and distance to platform (t (28) = 0.02, P = 0.99; unpaired t-
test; data not shown). Over the four training days after i.p. injection of 0.8 mg.kg-1 
scopolamine or 1 ml.kg-1 PBS (Fig. 3.6F), the latency to reaching the submerged platform 
decreased significantly for both groups of rats (time effect: F (3,84) = 41.11, P < 0.0001). 
However, the latency was significantly longer in the rats that had received scopolamine 
(intervention effect: (F (1,28) = 89.85, P < 0.0001), but there was no significant interaction 
between intervention and time (F (3,84) = 1.79, p = 0.15).  
 
Figure 3.6 also shows the effect of an i.p. injection of FSL-1 or PBS on learning and memory 
in rats, as measured by performance in the Morris Water Maze. When rats were given a 
Cued test (visible platform) before interventions and training in the maze, there were no 
significant differences between those receiving FSL-1 and those receiving PBS, in any of the 
indices measured, including latency to platform, speed and distance to platform (data not 
shown). However, when rats were given the Cued test 16 h after injections and before they 
began training in the maze, the swim speed (Fig. 3.6C) of rats receiving 1 000 µg.kg-1 FSL-1 
was significantly slower than was the swim speed of rats receiving 500 µg.kg-1 FSL-1 and 
PBS (F (2,34) = 9.62, P = 0.0005). Despite the decrease in swim speed, neither the latency 
to the visible platform (Fig. 3.6A, F (2,34) = 1.71, P = 0.19), nor the distance to the visible 
platform (Fig. 3.6D, F (2,34) = 2.48, P = 0.09) was significantly different between the groups.  
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Figure 3.6. Performance (means ± SD) of rats as measured in a Morris Water Maze. 
Rats receiving one i.p. injection on Day 0 of 500 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (n = 8), 1000 
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µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (n = 9), or 1 ml.kg-1 PBS (n = 20) were given a single attempt 
to find the visible platform in the Cued test during which latency (A), swimming speed (C) 
and distance (D) to the visible platform were measured. During the acquisition phase 18 h 
post injection, rats were given four trials per day over four days where latency (E), swimming 
speed (G) and distance (H) to the submerged platform were measured; mean values for the 
four trials are presented. Reference memory was tested on the fifth day post injection with a 
single Probe trial (no platform), during which percentage time in the target zone (I) and 
latency to locate the original position of the platform (J) were measured. Rats receiving i.p. 
injections of 0.8 mg.kg-1 scopolamine (n = 10) showed retarded learning over four days with 
a submerged platform (F), but unaffected performance with a visible platform in the Cued 
test  (B), compared with rats receiving 1 ml.kg-1 PBS (n = 20). Significant differences:  # PBS 
vs. 1000 µg.kg-1 FSL-1;  $ 500 µg.kg-1 FSL-1 vs. 1 000 µg.kg-1 FSL-1;   
^ Scopolamine vs. PBS;  ** PBS, 500 µg.kg-1 FSL-1, 1 000 µg.kg-1 FSL-1 vs. 30 s.   
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Over the four training days the latency to reaching the submerged platform (Fig. 3.6E) 
decreased significantly for all three groups of rats (time effect: F (3,102) = 78.35, P < 
0.0001), but there was no significant intervention effect (F (2,34) = 2.34, P = 0.11) or 
interaction (F (6,102) = 1.74, P = 0.12). Similarly, over the four training days the distance to 
the submerged platform (Fig. 3.6H) decreased significantly for all three groups of rats (time 
effect: F (3,102) = 47.57, P < 0.0001), but there was no significant intervention effect (F 
(2,34) = 0.20, P = 0.82) or interaction (F (6,102) = 0.38, P = 0.89). For swim speed there was 
a significant time effect (F (3,102) = 3.27, P = 0.02) over the four training days (Fig 3.6G), 
but there was no significant intervention effect (F (2,34) = 3.18, P = 0.054) or interaction (F 
(6,102) = 1.13, P = 0.35). When the rats were tested in the Probe trial (platform removed) on 
the fifth day, neither the percentage time spent in the target zone of the water maze (Fig. 
3.6I, F (2,34) = 0.43, P = 0.65) nor the latency to reach the platform position (Fig. 3.6 J, F 
(2,36) = 0.0632, P = 0.94) differed between the groups of rats. There also were no significant 
differences in the swim speed, distance to the former platform position, or virtual platform 
crossings between the groups of rats that had received PBS and FSL-1 (data not shown). 
Moreover, for all groups, the mean latency to the former platform position was significantly 
shorter than 30s (see section 3.4) (PBS, t (19) = 7.23, p < 0.0001; 500 µg.kg-1 FSL-1, t (7) = 
5.0, P = 0.0016; 1 000 µg.kg-1 FSL-1, t (8) = 5.17, P = 0.0009; one-sample t-test). 
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3.5 DISCUSSION  
 
To my knowledge, I am the first to assess potential deficits in spatial learning and memory, 
as a component of sickness behaviour, following simulated Mycoplasma infection in rats. I 
showed that parenteral administration of a single bolus of FSL-1, the pyrogenic moiety of M. 
salivarium, generated fever for up to 48 h, and profound sickness behaviour, in a dose-
dependent manner. It caused anorexia for three days and lethargy for four days, as well as 
body mass stunting for at least four days. The lethargy was sufficiently intense so as almost 
to abolish cage activity on the night after FSL-1 administration. However, FSL-1 
administration did not cause impairment of spatial learning in rats, as measured in the Morris 
Water Maze 18 h after the initial FSL-1 injection, a time at which they still were febrile, 
lethargic and anorexic. Thus, FSL-1 induced profound sickness behaviour but spared spatial 
learning and memory. 
 
Although the rats were febrile, lethargic and anorexic during most of the training days in the 
Morris Water Maze (see Fig. 3.2), their spatial learning appeared not to be impaired as they 
did learn: the time taken for the rats to learn the location of the submerged platform reduced 
progressively over the four-day training period with the rate of reduction (Fig. 3.6E) 
unaffected by earlier FSL-1 administration. The absence of an effect of FSL-1 in the Morris 
Water Maze was not the result of failure of the test procedure, because scopolamine 
administration, a challenge used to validate the procedure, induced the expected 
impairments in spatial learning (Fig. 3.6F). Moreover, the rats did remember (as assessed in 
the Probe trial on the fifth day) despite being stunted as a consequence of sickness: earlier 
FSL-1 administration did not increase the latency exhibited by trained rats to find the former 
location of the platform after the platform had been removed (Fig. 3.6J). Thus hippocampal-
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dependent learning and memory functions, as tested at the time points I used, appear to be 
spared during the acute phase response induced by simulated Mycoplasma infection.  
 
A test procedure that studies a behavioural endpoint that is dependent on locomotion, such 
as the Morris Water Maze, may deliver spurious results if the rats are locomotor impaired. I 
therefore measured cage activity not only as an index of the sickness behaviour of lethargy, 
but, equally importantly, to assess whether any diminished performance in the Morris Water 
Maze could be attributed to lethargy rather than a decline in cognitive function. After FSL-1 
administration, the rats were lethargic, at least for voluntary activity; they virtually had 
abandoned their typical nocturnal cage activity on the night immediately after the FSL-1 
administration and reduced activity for a few nights thereafter (Fig. 3.4). However, lethargy 
did not affect their swimming performance during the four-day acquisition phase in the maze 
(Fig. 3.6 E,G,H). At the time at which I tested spatial memory rather than learning, cage 
activity had returned to normal, so lethargy was not a potential confounding factor then. The 
Cued test component of the Morris Water Maze procedure, in which the escape platform is 
visible to the rats, distinguishes impairments in motivation and sensorimotor functions from 
impairments in learning and memory. Following administration of my highest dose of FSL-1, 
the rats initially swam more slowly in the Cued test (Fig. 3.6C), but not sufficiently to affect 
the latency (Fig. 3.6A) or the distance (Fig. 3.6D) required to reach the visible platform, 
which were not altered significantly. Thus, even though they had abandoned much of their 
spontaneous cage activity, the rats swam competently in the Morris Water Maze during their 
simulated Mycoplasma infection, so no deconvolution of the effects of FSL-1 on locomotor 
performance and learning was necessary. 
 
My results relate to the consequences of parenteral administration of a single bolus of FSL-1 
in rats, at doses up to 1 000 µg.kg-1. It is possible that repeated i.p. injections of FSL-1 
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(Greis et al., 2007), or intracerebroventricular (i.c.v.) injections of FSL-1 (Abe et al., 2010), 
as is the case with LPS, could induce a more profound inflammatory response in the brain 
with accompanying hippocampal malfunction and cognitive impairment. Also, my conclusion 
that learning and memory was spared during the fever and sickness behaviour, which 
followed FSL-1 administration, has to be confined to the components of the process of 
spatial learning and memory that are tested by the Morris Water Maze, as I implemented it. 
For example, while I assessed spatial reference memory in the Maze, I did not assess 
spatial working memory (see Lacosta et al., 1999; Sparkman et al., 2006; Richwine et al., 
2009). Furthermore, the Probe trial was conducted on the fifth day after FSL-1 
administration, a time at which the rats were stunted but no longer febrile, lethargic or 
anorexic. Therefore, if I had detected impairment in spatial reference memory, that 
impairment would have been a residual effect of the simulated acute infection, rather than 
dependent on concurrent fever, lethargy and anorexia. Finally, it is possible that FSL-1, like 
LPS, could adversely affect cognition in a hippocampus-independent task, e.g. the Y-maze 
task (see Sanderson et al., 2009), or in a task that is not physically demanding (e.g. Barnes-
maze) and not as stressful as the Morris Water Maze (Harrison et al., 2009).  
 
Though I believe that I am the first to assess potential deficits in learning and memory during 
simulated Mycoplasma infection, I am not the first to explore fever and sickness behaviour 
during such simulated infection. Hübschle and colleagues (2006) showed that FSL-1, 
administered intraperitoneally at doses of 100 and 1 000 µg.kg-1, dose-dependently induced 
fever, lethargy, anorexia and adipsia in rats; that team also confirmed the pyrogenic 
properties of the FSL-1 in guinea pigs (Greis et al., 2007, 2009). My data, derived from a 
different strain of rat (Sprague-Dawley vs. Wistar) generally are in line with the findings of 
Hübschle et al. (2006), although I did not observe consistent hypothermia preceding fever 
(see Fig. 3.2) which Hübschle et al. (2006) observed when administering FSL-1 at a dose of 
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1 000 µg.kg-1. In my hands, administration of both doses of FSL-1 resulted in significant 
body mass stunting for at least four days, a phenomenon not reported previously for FSL-1 
challenge, though mass of rats may recover later. I also did not find learning impairment 
despite the prevailing fever; hyperthermia itself induced anterograde amnesia in rats (Ahlers 
and Riccio, 1987).  
 
The dissociation between impairment of learning and memory and other sickness 
behaviours, which I have shown parallels emerging evidence in rodents that shows no 
impairment in learning and/or memory following i.p. injection of IL-1β (Thomson and 
Sutherland, 2006) and, more recently, i.p. injection of LPS (Huang et al., 2010) or i.p. 
injection of Staphylococcal enterotoxin A (Woodruff et al., 2010). Acute administration of 
LPS at a dose of 1 mg.kg-1 in mice also did not induce hippocampal neuronal damage 
(Chung et al., 2010), and a sub-pyrogenic dose of LPS failed to impair spatial working and 
reference memory in hippocampal-dependent spatial tasks (Sanderson et al., 2009).  
Importantly, a recent clinical study also has shown that i.v. administration of LPS to human 
volunteers does not impair memory (Grigoleit et al., 2010).  
 
However, the dissociation that I and others have observed is not a consistent finding of all 
investigations of sickness behaviour. In experimental animals, learning and memory 
impairment indeed has been reported during Gram-positive bacterial infections (live 
Streptococcus pneumoniae) (Wellmer et al., 2000; Gerber et al., 2004; Barichello et al., 
2009), and viral infections (poly I:C) (Kent et al., 2007; Dilger and Johnson, 2010; Okun et 
al., 2010). However, the majority of studies reporting that learning and memory is impaired 
have employed Gram-negative bacterial infections (LPS or live Escherichia coli) and various 
behavioural tasks including the Morris Water Maze (as reviewed in Cunningham and 
Sanderson, 2008), the Y-maze and the T-maze (Sanderson et al., 2009), contextual fear 
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conditioning (Pugh et al., 1998; Bilbo et al., 2006, 2008; Barrientos et al., 2006, 2009), 
context pre-exposure (Bilbo et al., 2005a, b, 2007) radial mazes (Semmler et al., 2007; Chen 
et al., 2008; Sanderson et al., 2009) and autoshaping (Aubert et al., 1995). In the Maze 
though, results obtained with LPS, at various doses, seem to be inconsistent for reasons 
unrelated to Maze technicalities. So, the effects of LPS on hippocampal-dependent spatial 
learning and memory still are inconclusive (Cunningham and Sanderson, 2008). It remains 
to be investigated why experimental infection, real or simulated, results in impaired learning 
and memory in some animal studies, but not in other animal studies, my study included, and 
not in human volunteers. 
 
In the case of my study, it could be that there is something different about simulated 
Mycoplasma infection. Different bacterial and viral pathogens may activate the innate 
immune system in different ways via recognition by pathogen-specific members of the Toll-
like receptor (TLR) family (Janssens and Beyaert, 2003). For example, membrane 
components from Mycoplasma are recognized by heterodimers formed from both TLR-2 and 
TLR-6 (Takeuchi et al., 2001). In the host, activation of a specific TLR, or combination of 
TLRs (e.g. TLR2/6) initiates a cascade of intracellular events that results in synthesis and 
release of a variety of pro- and anti-inflammatory cytokines which can be specific for those 
TLRs (for review see Takeuchi and Akira, 2010). In vitro studies have shown that FSL-1, 
acting presumably via the TLR 2/6 heterodimer, can induce IL-1β and IL-6 production 
(Shibata et al., 2000; Nakamura et al., 2002; Into et al., 2002; Okusawa et al., 2004; Senn, 
2006; Rose et al., 2009), as do the pyrogenic moieties of other pathogens (Cartmell and 
Mitchell, 2005). So if the acute phase responses to FSL-1 administration depend on it being 
a TLR2/6 agonist, those responses are likely to involve cytokines including IL-1β and IL-6. 
This latter association is considered in Chapter 4. However, the situation is complicated by 
ambiguities about how pro-inflammatory cytokines affect learning and memory (reviewed in 
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Goshen and Yirmiya, 2007) and more specifically, how IL-1β affects learning and memory 
processes (Goshen et al., 2007; Huang and Sheng, 2010). 
 
Apart from any consequences that my study might have for my understanding of the role of 
impaired learning and memory in sickness behaviour, I believe I have made an important 
contribution to understanding sickness behaviour responses during an acute infectious 
episode. Although the rats had abandoned almost all of their spontaneous cage activity 
following administration of the higher dose of FSL-1, they swam competently, albeit slower, 
during the Cued test. Thus, the lethargy of sickness behaviour appears to be activity-
specific: what appeared to be impaired was the will or motivation to be active (i.e. in their 
cages), not the capacity to be active (i.e. in the Morris Water Maze). Consonant with that 
theme, in LPS-induced anorexia in rats, it is the will to eat that is impaired and not the 
capacity to eat (Hopwood et al., 2009; Skinner et al., 2009). Similarly, the optional activity of 
voluntary wheel running was abolished almost completely in rats after a low-dose bolus 
injection of LPS, while routine daily (“house-keeping”) activity measured as cage activity, 
continued (Hopwood et al., 2009; Skinner et al., 2009). Because activity in the Morris Water 
Maze is not optional, and survival of the rats depends on escaping from the water, I 
hypothesize that the rats invoked their capacity for activity, unimpaired by concurrent 
sickness behaviour. I believe that in sickness behaviour, the distinction between motivation 
and capacity (a distinction also reported in reviews by Maier and Watkins, 1998; Rachal-
Pugh et al., 2001; Larson and Dunn, 2001), has important clinical implications, and deserves 
more research. 
 
Returning to the primary goal of my study, which was to assess learning and memory in the 
full context of the acute phase response, I found no impairment in spatial learning and 
memory, as assessed by a Morris Water Maze during simulated, acute Mycoplasma 
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infection in rats. My results show, for the first time, a dissociation of spatial learning and 
memory processes from other sickness behaviours following systemic administration of FSL-
1, a pyrogenic moiety of Mycoplasma and support an emerging body of evidence that, 
contrary to the usual view, impaired learning and memory is not an inevitable consequence 
of exposure to pyrogenic pathogens. 
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CHAPTER 4 
 
 
 
CYTOKINES AS MEDIATORS OF SIMULATED, 
MYCOPLASMA-INDUCED SICKNESS BEHAVIOUR 
 
 
 
 
 
 
 
 
Part of the data presented in this chapter has been published:  
 
Swanepoel T., Harvey BH., Harden LM., Laburn HP. and Mitchell D. 2011. 
Dissociation between learning and memory impairment and other sickness behaviours 
during simulated Mycoplasma infection in rats.  
Brain, Behavior, and Immunity 25: 1607-1616. 
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4.1. ABSTRACT 
 
Pro-inflammatory cytokines, including interleukin (IL)-6, are key mediators of fever and 
sickness behaviours induced by fibroblast-stimulating lipopeptide-1 (FSL-1), a pyrogenic 
moiety of Mycoplasma. Whether the pro-inflammatory cytokine, IL-1β, in the plasma, or both 
IL-1β and IL-6 in the brain, is involved in mediating sickness responses in rats after 
administration of FSL-1, is unknown. Moreover, the potential role for IL-1β and IL-6 in 
learning and memory processes, following FSL-1 administration in rats, also is not known. 
Male Sprague-Dawley rats had radiotransponders implanted to measure body core 
temperature. After recovery, rats randomly received a single I.P administration of FSL-1 at a 
dose of 1 000 µg.kg-1, or 1 ml.kg-1 vehicle (phosphate-buffered saline, PBS). Plasma and 
brain concentrations of IL-1β and IL-6 were measured at 3 h and 18 h after injections. 
Concentrations of IL-1β were elevated significantly in the plasma and brain at 3 h, and to a 
similar extent in both the hippocampus and hypothalamus at 18 h, after FSL-1 
administration. However, concentrations of IL-6 were markedly increased in the plasma at 3 
h after FSL-1 administration, but not at 3 h or 18 h in either of the brain regions. During 
simulated Mycoplasma infection in rats plasma and brain IL-1β, but not IL-6, may mediate 
fever, lethargy and anorexia, but not learning and memory impairment. However, if IL-6 and 
IL-1β act synergistically the presence of IL-6 in the brain potentially may have facilitated the 
action of brain IL-1β. 
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4.2. INTRODUCTION  
 
That cytokines play a pivotal role in communication between the periphery and the brain 
during bacterial or viral infection is well established (Maier and Watkins, 1998; Larsun and 
Dunn, 2001; Kelley et al., 2003; Dantzer, 2004). Cytokines act as messengers for 
communication between immune cells, the endocrine system and the central nervous 
system (e.g. see Maier and Watkins, 1998) and help orchestrate the physiological and 
behavioural adjustments that occur in the host during sickness. During inflammation and 
infection cytokines are synthesized both peripherally and centrally, and can affect the 
synthesis and secretion of each other (Cartmell and Mitchell, 2005). The pro-inflammatory 
cytokines IL-1β and IL-6 have significant roles in sickness responses, including fever, 
anorexia, lethargy and impaired learning and memory, induced by a Gram-negative 
pyrogenic moiety, namely lipopolysaccharide (LPS) (Luheshi and Rothwell, 1996; Dantzer et 
al., 2004; Harden et al., 2008, 2010; Goshen and Yirmiya, 2007). Moreover, serum 
concentrations of IL-1β and IL-6 were elevated significantly in patients with community-
acquired pneumonia that was caused by Mycoplasma pneumoniae (Lieberman et al., 1997; 
Hsieh et al., 2001). 
 
Membrane components of the Mycoplasmas, including fibroblast-stimulating lipopeptide-1 
(FSL-1), are capable of inducing in vitro and in vivo production of the pro-inflammatory 
cytokines IL-1β, IL-6 and tumor-necrosis factor alpha (TNF-α) (Mühlradt and Schade, 1991; 
Yirmiya et al., 1999; Shibata et al., 2000; Nakamura et al., 2002; Into et al., 2002; Okusawa 
et al., 2004; Hübschle et al., 2006). For example, systemic (intraperitoneal, i.p.) 
administration in rats of FSL-1, extracted from Mycoplasma salivarium, induced acute phase 
responses including fever, lethargy, anorexia and adipsia, accompanied by elevated 
concentrations of pro-inflammatory cytokines IL-6 and TNF-α in the plasma (Hübschle et al., 
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2006). Whether plasma IL-1β also has a role to play in FSL-1 induced sickness responses in 
rats, including fever, lethargy and anorexia, is unknown. Moreover, i.c.v. administration of 
heat-inactivated Mycoplasma fermentans in rats induced the expression of TNF-α and IL-1β 
in various brain regions, including the hippocampus and the hypothalamus, which was 
associated with anorexia and suppressed social behaviour (Yirmiya et al., 1999). However, 
Yirmiya’s team did not measure brain concentrations of IL-6. Contributions of IL-1β and IL-6, 
in the brain, in mediating FSL-1 induced sickness responses in rats, are unknown.  
 
I have shown that administration of FSL-1, which simulates the acute phase responses to 
Mycoplasma infection, dose-dependently induced fever, lethargy and anorexia (see Chapter 
3), and therefore confirm the findings of Hübschle and colleagues (2006). In addition, I also 
found body mass stunting in rats, following i.p. administration of FSL-1, but did not find 
impairment in spatial learning and memory (see Chapter 3). The dissociation of learning and 
memory impairment, from fever, lethargy, anorexia and stunting following acute 
administration of FSL-1 that I have shown, could be explained by differential production of, 
or sensitivity to, pro-inflammatory cytokines in those brain areas required for learning and 
memory, including the hippocampus. Spatial learning and memory, in humans and other 
animals, depend on the integrity and plasticity of the hippocampus (e.g. Morris, 1982; 
Squire, 1992). However, the hypothalamus mediates fever and anorexia (Lepkovsky, 1973; 
Morrison et al., 2008) and also is important in mediating lethargy, indirectly. The 
hypothalamus has a crucial role in controlling cardiovascular and respiratory processes (Yeh 
et al., 1997), without which physical activity is not possible.   
 
To investigate the possible role for IL-1β and brain IL-6 in mediating FSL-1 induced fever, 
lethargy and anorexia, and to investigate any link between effects on learning and memory 
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and the presence of IL-1β and IL-6 in the brain, I measured concentrations of these two pro-
inflammatory cytokines in the plasma and brain following acute FSL-1 administration in rat.  
 
4.3. MATERIALS AND METHODS 
(Also refer to Chapter 2, i.e. ‘Common methodology’) 
  
4.3.1. Animals 
 
Twenty four male Sprague-Dawley rats with an average body mass of 335 ± 18 g (mean ± 
SD) on injection day were used, with no significant differences in the average body mass of 
the treatment groups. 
 
Experiments were carried out in accordance with the regulations of the Animal Ethics and 
Control Committee of the University of the Witwatersrand and were approved by its Animal 
Ethics Screening Committee (clearance certificate AESC 2010/34/04). 
 
4.3.2. Pyrogen administration 
 
The lyophilized powder of fibroblast-stimulating lipopeptide-1 (FSL-1) was reconstituted with 
sterile, pyrogen-free phosphate-buffered saline (PBS) (refer to section 2.2 in Chapter 2). 
Rats received a single i.p. injection of FSL-1 (n = 15) at a dose of 1 000 µg.kg-1, at 1 ml.kg-1 
volume, or 1 ml.kg-1 vehicle (PBS, n = 9).  I injected the rats at 16:00 so that the peak in 
fever would coincide with the dark phase of the 24 h day, when rats are most active.  
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4.3.3. Body temperature 
 
I recorded body core temperature of rats continuously by remote biotelemetry as discussed 
in detail in section 2.3 of Chapter 2. 
  
4.3.4. Food intake and body mass 
 
Food intake and body mass of rats, before and after intervention, were recorded daily at 
16:00 (refer to section 2.4 in Chapter 2). 
 
4.3.5. Cytokine concentrations 
 
I measured concentrations of IL-1β and IL-6 in the plasma, as well as in the hypothalamus 
and hippocampus of rats after administration of FSL-1 or PBS. Brain tissue of rats destined 
for cytokine analysis was collected in different rats, 3 h and 18 h after administration of FSL-
1 or PBS. I chose the 3 h time point because the only previous study of FSL-1 administration 
to rats had shown that plasma cytokine concentrations were increased 3 h after acute FSL-1 
administration (Hübschle et al., 2006). I chose the 18 h time point because that coincided 
with the time after FSL-1 administration at which performance was assessed in a Morris 
Water Maze (refer to Chapter 3).  
 
At the designated time after FSL-1 administration, rats were anaesthetized deeply with an 
i.p. injection of 1 ml sodium pentobarbital (Euthapent, 200 mg.ml-1; Kyron Laboratories (Pty) 
Ltd., South Africa). Blood was collected via cardiac puncture into sterile tubes containing 
EDTA, and centrifuged at 5 300 g at 4 ºC for 10 min. Anaesthetized rats then were perfused 
transcardially for 2 min with about 250 ml of ice-cold sterile saline (0.9 % NaCl) via the left 
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ventricle. Tissue from the hypothalamus and from the hippocampus was dissected out 
rapidly on an ice-chilled plate, placed separately in micro-centrifuge tubes, snap-frozen in 
liquid nitrogen and stored in a – 80 ºC freezer until enzyme-linked immunosorbent assay 
(ELISA) was performed. 
 
For these assays, tissue was dissociated mechanically with an ultrasonic cell disrupter 
(Microson XL 2000, Newton, CT, USA), in cold Iscove’s culture medium (0.25 ml) containing 
5% fetal calf serum and a cocktail enzyme inhibitor (100 mM amino-n-caproic acid, 10 mM 
EDTA, 5-benzamidine-HCL, and 0.2 mM phenylmethyl sulfonyl fluoride). Sonicated samples 
were centrifuged at 10 000 g at 4 °C for 10 min. Supernatants were removed and kept at 4 
°C. Bradford protein assays (Bradford, 1976) were performed to determine total protein 
concentrations in sonicated samples. Concentrations of IL-1β and IL-6 protein were 
determined with commercially-available rat IL-1β and IL-6 ELISA kits (R&D Systems, 
Minneapolis, MN, USA), in duplicate, according to the manufacturer’s instructions, and 
normalized to total protein (pg.mg total protein-1). The detection limit for the IL-1β assay was 
5 pg.ml-1 and 21 pg.ml-1 for the IL-6 assay. 
 
4.3.6. Data analysis 
 
The cytokine concentrations were not normally distributed so I log-transformed them for 
statistical analysis. I then compared plasma IL-1β and IL-6 concentrations separately, over 
the two time points (3 h vs. 18 h) in response to intervention with two-way ANOVA and post 
hoc tests when ANOVA showed significance, for rats given FSL-1 or PBS. Brain 
concentrations of IL-1β and IL-6 were compared separately, over the two brain sites 
(hypothalamus and hippocampus) in response to intervention with two-way ANOVA and post 
hoc tests when ANOVA showed significance. 
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4.4. RESULTS 
 
Mean abdominal temperatures (data not shown) before rats were euthanized did not differ 
from those shown in Fig. 3.2 in Chapter 3. For plasma IL-1β concentrations (Fig. 4.1) a two-
way ANOVA showed a significant intervention (FSL-1 vs. PBS) effect (F (1,20) = 27.30, P < 
0.0001), a significant time effect (F (1,20) = 11.87, P = 0.003) and a significant interaction (F 
(1,20) = 9.44, P = 0.006). IL-1β concentrations were elevated significantly at 3 h in rats that 
had received FSL-1 compared to 18 h after injection (significant interaction) and compared 
to rats that had received PBS (P < 0.001). Regrettably, the plasma concentrations of IL-6 
(Fig. 4.2) exceeded the ceiling of the assay of 2 000 pg.ml-1 at 3 h, so I could not validly 
analyze 3 h plasma IL-6 concentrations statistically. However, there was no doubt that 
plasma IL-6 was raised markedly 3 h after FSL-1 injection.  
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Figure 4.1. Plasma IL-1β concentrations (means ± SD) in rats at 3 h and 18 h after 
receiving a single i.p. injection of 1 000 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (n = 6 at 3 h; n = 9 at 
18 h), or 1 ml.kg-1 PBS (n = 4 at 3 h; n = 5 at 18 h). Significant differences based on log-
transformed data: * 3 h [IL-1β]:  FSL-1 vs. PBS; : ** 3 h [IL-1β] FSL-1 vs. 18 h [IL-1β] FSL-1.  
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Figure 4.2. Plasma IL-6 concentrations (means ± SD) in rats at 3 h and 18 h after 
receiving a single i.p. injection of 1 000 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (n = 6 at 3 h; n = 9 at 
18 h), or 1 ml.kg-1 PBS (n = 4 at 3 h; n = 5 at 18 h).  
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Figure 4.3 shows brain IL-1β concentrations three hours and eighteen hours after injections 
of FSL-1 or PBS. Three hours after injections there was a significant intervention effect (F 
(1,16) = 7.31, P = 0.02), but there were no significant differences between brain sites (F 
(1,16) = 1.48, P = 0.24) and no interaction (F (1,16) = 1.09, P = 0.31). At this time point (3 h), 
the concentration of IL-1β in rats that had received FSL-1 was elevated significantly in the 
hypothalamus (P < 0.05). Eighteen hours after injections there was a significant intervention 
effect (F (1,24) = 18.73, P = 0.0002), but there were no significant differences between brain 
sites (F (1,24) = 1.79, P = 0.19) and no interaction (F (1,24) = 0.73, P = 0.40). At this time 
point (18 h), when other rats were learning in a Maze (see Chapter 3), rats that had received 
FSL-1 had significantly elevated IL-1β concentrations in the hippocampus (P < 0.05) and in 
the hypothalamus (P < 0.01), compared to those rats that had received PBS. However, 
concentrations of IL-1β in the hippocampus and hypothalamus were not significantly 
different. 
 
For brain IL-6 concentrations (Fig. 4.4) at three hours after injections there was no significant 
intervention effect (F (1,16) = 2.67, P = 0.12), or brain site effect (F (1,16) = 1.28, P = 0.27) 
or interaction (F (1,16) = 0.62, P = 0.44). At three hours, the concentrations of IL-6 were not 
significantly different in the hippocampus (P = 0.56) nor in the hypothalamus (P = 0.11) for 
rats that had received either FSL-1 or PBS. Similarly, at eighteen hours after injections, there 
was no significant intervention effect (F (1,24) = 1.78, P = 0.19), or brain site effect (F (1,24) 
= 0.30, P = 0.59) or interaction (F (1,24) = 0.40, P = 0.53). At eighteen hours, the 
concentrations of IL-6 were not significantly different in the hippocampus (P = 0.18) nor in 
the hypothalamus (P = 0.63) for rats that had received either FSL-1 or PBS. 
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Figure 4.3. Brain IL-1β concentrations (means ± SD) in rats at 3 h and 18 h after 
receiving a single i.p. injection of 1 000 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS (n = 6/brain site at 3 
h; n = 9/brain site at 18 h), or 1 ml.kg-1 PBS (n = 4/brain site at 3 h; n = 5/ brain site at 18 h). 
Significant differences based on log-transformed data: + 3 h [Hypothalamic IL-1β]: FSL-1 vs. 
PBS;  ++ 18 h [Hippocampal IL-1β]: FSL-1 vs. PBS;  +++ 18 h [Hypothalamic IL-1β]: FSL-1 vs. 
PBS. 
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Figure 4.4. Brain IL-6 concentrations (means ± SD) in rats at 3 h and 18 h after receiving 
a single i.p. injection of 1 000 µg.kg-1 FSL-1 (n = 6/brain site at 3 h; n = 9/brain site at 18 h) 
in 1 ml.kg-1 PBS, or 1 ml.kg-1 PBS (n = 4/brain site at 3 h; n = 5/ brain site at 18 h). There 
were no significant differences in either of the brain sites at either time point, after 
administration of either FSL-1 or PBS. 
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4.5. DISCUSSION 
 
Pro-inflammatory cytokines, in particular IL-1β and IL-6, appear to be key mediators of fever 
and sickness behaviours, including lethargy, anorexia and impaired learning and memory 
(Kelley et al., 2003; Dantzer, 2001; Goshen and Yirmiya, 2007). Therefore, I measured 
concentrations of both IL-1β and IL-6 in the plasma as well as in brain regions known to be 
important in mediating fever and sickness behaviour, namely the hypothalamus and the 
hippocampus. My study is the first, I believe, to have measured cytokine concentrations in 
the brains of rats following administration of FSL-1, which simulates Mycoplasma infection.  
Concentrations of IL-1β and IL-6 in plasma and brain tissue were measured in a sub-sample 
of rats 3 h after FSL-1 administration, an established time of release of plasma pro-
inflammatory cytokines (Hübschle et al., 2006), and in another sub-sample of rats 18 h after 
FSL-1 administration, a time at which I tested other rats for spatial learning and memory in a 
Morris Water Maze (see Chapter 3).  
 
I found that at 3 h, but not at 18 h, after FSL-1 administration, the concentration of IL-1β was 
elevated significantly in the plasma (Fig. 4.1). IL-6 concentrations in the plasma were 
elevated massively, 3 h following administration of FSL-1 (Fig. 4.2), but unfortunately, the 
data could not be analysed statistically. Thus, 3 h after administration of FSL-1, plasma 
concentrations of both IL-1β and IL-6 may have a role in the initiation of the febrile response 
induced by FSL-1 (see section 3.4.1 and Fig. 3.2, Chapter 3). In addition, at the same time 
point (i.e. 3 h) the concentrations of IL-1β, but not IL-6, were elevated significantly in the 
hypothalamus (Fig. 4.3; Fig. 4.4), thereby allowing a possible involvement for brain 
concentrations of IL-1β in the initiation of the febrile response induced by FSL-1. In the brain, 
IL-6 was present, but not up-regulated at either brain site, 3 h after FSL-1 administration, 
compared to after PBS administration (Fig. 4.4). That IL-6 was not elevated in either the 
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hippocampus or the hypothalamus indicates that there was neither significant transport of 
circulating IL-6 into those brain sites, nor de novo synthesis of IL-6 in the brain. Three hours 
after FSL-1 administration may be too early for brain IL-6 concentration to be affected.  
 
Eighteen hours after FSL-1 administration neither the concentration of IL-1β nor that of IL-6 
was elevated significantly in the plasma, but the rats still had fever, lethargy and anorexia. 
Therefore, at 18 h peripheral concentrations of neither IL-1β nor IL-6 could play a role in 
maintaining FSL-1 induced fever and sickness behaviours. If IL-1β or IL-6 has any role at 18 
h after FSL-1 administration it may be a role in the brain. Eighteen hours after FSL-1 
administration the concentration of IL-1β (although no longer at its peak), but not IL-6, was 
elevated significantly to a similar extent in both the hippocampus and the hypothalamus (Fig. 
4.3; Fig. 4.4). In my investigations of sickness behavior, 18 h after FSL-1 administration rats 
actively were learning in a Morris Water Maze (see section 3.4.3 and Fig. 3.6, Chapter 3), 
while at the same time being febrile, lethargic and anorexic. Thus, the concentration of IL-1β 
in the hypothalamus that was sufficient to accompany sickness responses mediated by the 
hypothalamus, in this case fever, lethargy and anorexia, did not impair hippocampal function 
underlying spatial learning. The absence of elevated concentrations of IL-6 in the brain at 18 
h after FSL-1 administration (Fig. 4.4) does not prove that IL-6 had no role in mediating the 
fever, lethargy and anorexia that was evident in the rats at that time. At 18 h, IL-6 was 
present in the brain (Fig. 4.4) and it is possible that brain IL-6 concentrations may have risen 
temporarily between 3 h and 18 h after administration of FSL-1. There also is the possibility 
that IL-1β and IL-6 act synergistically in the brain and that the action of IL-1β may depend on 
IL-6 being present. 
 
I did not measure concentrations of the pro-inflammatory cytokine, TNF-α, following 
administration of FSL-1 as others have (Hübschle et al., 2006). It is possible that 
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concentrations of TNF-α in the brain may have a role in mediating fever, lethargy and 
anorexia induced by FSL-1. Other pro-inflammatory cytokines, namely leptin and cytokine-
induced neutrophil chemoattractant-1 (CINC-1) that are known to be involved in fever 
(Harden et al., 2006; Soares et al., 2008; Kamerman et al., 2011) also may be involved in 
fever induced by FSL-1 administration. Moreover, there may be a role for anti-inflammatory 
cytokines, such as interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1ra), in modulating 
the febrile response (e.g. Cartmell et al., 2001 Ledeboer et al., 2002) to FSL-1 
administration. It also may be the case that one or more of the above-mentioned cytokines 
has a different concentration in the hippocampus and hypothalamus. 
 
For cytokines to be able to modulate fever and sickness behaviours, they have to be able to 
interact with the brain via humoral or neural pathways (e.g. see Dantzer et al., 2000; Roth et 
al., 2006). Cytokines in the brain, including IL-1β and IL-6, may interact with their receptors 
(IL-1R and IL-6R) which are expressed abundantly on cells (e.g. astrocytes and microglia) in 
brain regions including the hippocampus (e.g. granule cells) and the hypothalamus (Loddick 
et al., 1998; Conti et al., 2008). The hypothalamus controls body temperature and eating 
behaviour (Lepkovsky, 1973; Morrison et al., 2008), but also is important in coordination of 
cardiovascular function and respiration (e.g. Yeh et al., 1997) without which physical ability is 
not possible. Parenteral administration in rats of FSL-1 increased concentration of IL-1β in 
the hypothalamus (~ 13 pg.mg protein-1, Fig. 4.3), a concentration which is characteristic of 
hypothalamic IL-1β concentrations in other simulated infections (Rachal Pugh et al., 2001; 
Richwine et al., 2008; Richwine et al., 2009; Barrientos et al., 2009; Terrando et al., 2010; 
Dilger and Johnson, 2010; Harden et al., 2010; Huang et al., 2010). My finding also parallels 
a previous study in rats that showed increased concentrations of IL-1β in several brain 
regions, including the hypothalamus, following i.c.v. administration of heat-inactivated M. 
fermentans (Yirmiya et al., 1999). However, my study is the first to show that in simulated 
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systemic Mycoplasma infection, induced by i.p. administration of FSL-1, IL-1β in the 
hypothalamus may have a role in mediating fever, lethargy and anorexia (see Chapter 3).  
 
Like some using LPS (Richwine et al., 2008), I did not find an increase in brain IL-6 
concentrations (Fig. 4.4). However, increased brain IL-6 concentrations have been 
associated with fever and sickness behaviour during simulated Gram-negative bacterial 
infection (Nilsberth et al., 2009; Richwine et al., 2009; Terrando et al., 2010; Frank et al., 
2010; Teeling et al., 2010). The actions of IL-6 to causing an increase in body temperature, 
perhaps also to cause sickness behaviour may depend on IL-6 being present in the brain 
concurrently, if IL-6 acts synergistically with IL-1β within the brain to induce fever and 
sickness behaviour in rats (Cartmell et al., 2000; Harden et al., 2008). Central, or peripheral, 
co-administration of non-pyrogenic doses of IL-1β and IL-6 induced fever in rats, but when 
injected alone, neither cytokine had any effect on body temperature (Cartmell et al., 2000; 
Harden et al., 2008). So, because IL-6 in the brain seems to act in concert with IL-1β, I 
hypothesize that the presence of IL-6 in the brain may have facilitated the action of IL-1β, 
even though brain IL-6 concentration itself did not change.  
 
It is also possible that IL-6 may affect some, but not all brain functions: administration (i.p.) in 
mice of biologically active IL-6, at doses between 0.031-2.0 µg per animal, reduced the 
scopolamine-induced amnesia without affecting scopolamine-induced hyperactivity (Bianchi 
et al., 1997). That IL-6 may have a role in central modifications that occur following 
peripheral immune activation was confirmed in a study that reported peripheral endogenous 
IL-6 to be a primary mediator of fever and sickness behaviour induced by s.c. administration 
of LPS (Harden et al., 2006). Similar to the increased plasma concentrations of IL-6 I have 
observed following i.p. administration of FSL-1, Hübschle and colleagues (2006) previously 
have reported elevated plasma concentrations of IL-6 in rats, which was associated with the 
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fever induced by i.p. administration of 100 µg.kg-1 FSL-1 (Hübschle et al., 2006). 
Intraperitoneal or i.a. administration of FSL-1 (100 or 1000 µg.kg-1) in guinea pigs also 
induced a marked increase in plasma concentrations of IL-6, which coincided with the 
observed fever (Greis et al., 2007). Anomalously, after intratracheal inoculation of M. 
hyopneumoniae (strain P5722–3, 1 x 1010 units.L-1) in growing pigs IL-6 was undetectable in 
the plasma of infected pigs (Escobar et al., 2004). In spite of this anomalous result, systemic 
administration of most PAMPs generally induces a substantial rise in plasma concentrations 
of IL-6, which may be associated with the fever and sickness behaviours following 
administration of that PAMP, even though brain concentrations of IL-6 may not be elevated 
concurrently. Circulating concentrations of IL-1β were undetectable in pigs infected with M. 
hyopneumoniae (strain P5722–3, 1 x 1010 units.L-1), so my finding of significant elevations in 
concentrations of IL-1β in the plasma 3 h after administration of FSL-1, which simulates 
Mycoplasma infection, is novel.  
 
The role of IL-1β, but also IL-6, has been investigated extensively in another aspect of 
sickness behaviour, namely impaired learning and memory (see Goshen and Yirmiya, 2007), 
but the results remain controversial. However, most of the studies have shown that elevated 
concentrations of either IL-6, or IL-1β, are detrimental for spatial learning and memory 
(reviewed in Goshen and Yirmiya, 2007). The hippocampus is crucial for spatial learning and 
memory processes (Morris et al., 1982; Squire, 1992). Interestingly, i.c.v. administration of 
IL-1β, but not IL-6, into the hippocampus of experimental animals induced impairment in 
spatial learning and memory (Oitzl et al., 1993; Pugh et al., 1999; Barrientos et al., 2002). 
The lack of impairment in learning and memory after administration of IL-6 was confirmed in 
IL-6 knockout mice in which an improvement in learning and memory was observed 
(Balschun et al., 2004). Improved learning and memory in knockout mice may imply that 
endogenous IL-6 indeed does impair learning and memory, even if additional IL-6 does not 
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worsen the impairment. So, the role of IL-6 in learning and memory seems to be complex. 
That I found IL-6 to be present in the brain, including the hippocampus, without having an 
effect (detrimental or beneficial) on spatial learning and memory (Chapter 3), is in line with 
studies that also reported no effects after i.p. administration of IL-6 (Bianchi et al., 1997, 
1998; Brennan et al., 2004). Moreover, I did not find impairment in spatial learning of rats 
despite concentrations of IL-1β being elevated significantly in the hippocampus (~ 9 pg.mg 
protein-1) at 18 h after FSL-1 administration. My finding is consistent with a recent study that 
showed no impairment in spatial memory of rats despite significant elevations of IL-1β in the 
hippocampus (~ 7 pg.mg protein-1 ), 4 h after i.p. administration of 1.25 mg.kg-1 LPS (Huang 
et al., 2010). IL-1β seems to be the cytokine induced most consistently in the brain following 
immune activation (Abraham and Williams, 2003). Therefore, numerous studies have 
investigated the effect of administration of IL-1β itself on cognition and have shown elevated 
concentrations of this cytokine to be detrimental for learning and memory, whether 
administered i.c.v., i.p. or intra-hippocampal (reviewed in Goshen and Yirmiya, 2007). 
Despite these reports, there remains uncertainty concerning the specific involvement of IL-
1β, produced endogenously in the hippocampus during simulated infection, on spatial 
learning and memory. An inverted U-shaped dose-response relationship has been proposed 
for IL-1β and memory functioning (Goshen et al., 2007). According to this model, basal or 
slight elevations in IL-1β concentrations, specifically in the hippocampus, improve and 
promote aspects of spatial memory whereas any deviation from the physiological range, 
either by excessive elevation in IL-1β concentrations or by blocking IL-1β signalling, impair 
hippocampal-dependent memory and neural plasticity (see Goshen and Yirmiya, 2007). 
Thus, the role of both IL-1β and IL-6 in hippocampal-dependent learning and memory 
processes, during simulated infection, still is inconclusive. Further research is needed not 
only to elaborate why simulated infection sometimes affects learning and memory and 
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sometimes not, but also to elucidate the role of pro-inflammatory cytokines when learning 
and memory are impaired. 
 
In conclusion, I have confirmed that in experimental animals the acute phase responses to 
i.p. administration of FSL-1, including fever, lethargy and anorexia are associated with 
elevated plasma and brain concentrations of the cytokines IL-1β and IL-6. Because 
concentrations of IL-1β were elevated to a similar extend in both the hippocampus and the 
hypothalamus 18 h following administration of FSL-1, the lack of impairment in spatial 
learning and memory that I have found at a similar time when rats actively were learning in a 
Maze (see Chapter 3) cannot be explained by differential production of pro-inflammatory 
cytokines in the brain. I support the emerging evidence that learning and memory not always 
are impaired when there is, at the same time, a significant increase in concentration of IL-1β, 
specifically in the hippocampus. A fundamental relationship between elevated 
concentrations of pro-inflammatory cytokines in the hippocampus and impairment in learning 
and memory has not been established yet. 
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CHAPTER 5 
 
 
SICKNESS BEHAVIOURS DURING SIMULATED 
RECURRENT ACUTE MYCOPLASMA INFECTION 
 
 
 
 
 
 
 
 
 
Data presented in this chapter have been published 
  
Swanepoel T., Harvey BH., Harden LM., Laburn HP. and Mitchell D. 
Simulated systemic recurrent Mycoplasma infection in rats induces recurrent sickness 
responses without residual impairment in spatial learning and memory.  
Physiology and Behavior 105: 800-808. 
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5.1 ABSTRACT 
 
In spite of their prevalence and importance clinically, recurrent acute infections seldom have 
been investigated in the laboratory. I set out to measure fever and sickness behaviour in 
simulated recurrent Mycoplasma infection; Mycoplasma is a common cause of recurrent 
acute infection in humans. Specifically, the aim was to investigate residual detrimental 
cognitive effects, such as impaired learning and memory, after apparent recovery from a 
series of simulated recurrent infections. Male Sprague-Dawley rats had radiotransponders 
implanted to measure abdominal temperature and cage activity. After recovery, rats received 
three intraperitoneal (i.p.) injections, 10 days apart, of either fibroblast-stimulating 
lipopeptide-1 (FLS-1), a pyrogenic moiety of Mycoplasma salivarium at a dose of 500 µg.kg-1 
in 1 ml.kg-1 phosphate-buffered saline (PBS), or vehicle (PBS, 1ml.kg-1). Body mass and 
food intake were measured daily. For measurement of learning and memory, training in a 
Morris Water Maze commenced 10 days after the last of the three successive injections and 
continued daily for four days. Spatial memory was assessed on the following day. 
Hippocampal tissue of rats was collected on the day of the last exposure to the Maze. 
Recurrent FSL-1 administration induced recurrent fevers (~ 1 ºC) for about 9 hours, 
recurrent lethargy (~ 40-60 %) for one day, recurrent anorexia (~ 16-30 %) for one day and 
recurrent reductions in the rate of mass gain (~ 112 %) for one day, but the stunting resolved 
by the subsequent injection. Recurrent FSL-1 administration did not result in tolerance to 
fever, lethargy or anorexia. There was no residual histological damage to the hippocampus 
and no residual detrimental effect in learning or memory in rats. Though we cannot 
extrapolate our results directly to humans, our results imply that children who have 
recovered from recurrent acute Mycoplasma infection may not be at high risk of stunting or 
impaired spatial learning and memory. 
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5.2 INTRODUCTION 
 
Particularly in resource-poor countries, exposure to infectious agents during childhood is 
inevitable. Recurrent childhood infections and recurrent fever, accompanied by a suite of 
brain-controlled behavioural changes (sickness behaviours), can hamper seriously the 
growth and overall development of children (Martorell et al., 1975; Rowland et al., 1988). 
Mycoplasma is a common causative agent for recurrent community-acquired pneumonia and 
affects children, adolescents and adults (see McIntosh, 2002). Whereas many adults with 
Mycoplasma pneumoniae present as asymptomatic (giving the infection the nickname of 
“walking pneumonia”), the same is not true for infected children (for reviews see Waites and 
Talkington, 2004; Vervloet et al., 2007). For example, a follow-up case report of an 
adolescent patient with M. pneumoniae showed impaired executive functioning and memory 
deficits, as long-term sequelae (Termine et al., 2005). Thus, a potential problem for 
developing countries, which needs to be addressed, is whether growth and capacity to learn 
in children is compromised by a recurrent acute infection, such as M. pneumoniae, even 
when the children appear well after such an infection. 
 
Studying the effects of recurrent, Mycoplasma-induced, acute activation of the innate 
immune system, especially on cognition and growth in children, has been hampered by a 
lack of an adequate animal model that does not involve a live pathogen. The opportunity for 
such a study has been realised by the recent availability of a synthetic lipopeptide, fibroblast 
stimulating lipopeptide-1 (FSL-1), an analogue of a pyrogenic moiety of Mycoplasma 
salivarium. After it was discovered that FLS-1 is capable of stimulating cells implicated in 
innate immunity (Shibata et al., 2000; Nakamura et al., 2002; Okusawa et al., 2004), 
subsequent in vivo studies showed that acute intraperitoneal administration of FLS-1 
induced fever and sickness behaviours in rats and guinea pigs, which was accompanied by 
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elevations in plasma and brain concentrations of the pro-inflammatory cytokines interleukin-
1β (IL-1β), interleukin-6 (IL-6) and tumour-necrosis factor alpha (TNF-α) (Hübschle et al., 
2006; Greis et al., 2007; Chapter 4). The duration of the sickness behaviours induced by 
FSL-1 outlasted the febrile response (Hübschle et al., 2006; Chapter 4). 
 
Because sickness behaviours may outlast the fever after stimulation of the innate immune 
system, it is possible that the sickness behaviours, rather than the hyperpyrexia, are better 
biomarkers of long-term sequelae. For example, “anorexia of infection” (Cole and Parkin, 
1977) may act as part of an active defence strategy (Exton, 1997) to conserve energy during 
acute infections, but, when an infection occurs frequently or becomes chronic, the reduced 
food intake may contribute to mass loss, muscle atrophy and fatigue (Ravasco et al., 2004; 
Ravasco et al., 2007). Although the suite of sickness behaviours is complex, those relevant 
to my study are anorexia, lethargy and impairment in learning and memory. These three 
sickness behaviours may have deleterious long-term sequelae in children: anorexia because 
of growth retardation or permanent stunting, lethargy because of loss of motivation for life-
sustaining physical activity, and impairment of learning and memory because of subsequent 
cognitive retardation, the latter likely to have the most impact on the child’s welfare. 
 
To discern whether there is any impairment in growth or physical activity, or residual 
impairment in learning and memory, following recurrent acute activation of the innate 
immune system, I investigated the effects of recurrent acute FSL-1 administration in growing 
rats between the ages of 36 and 56 days, which represents the adolescent age group in 
humans (see Quinn, 2005). The rats received three intraperitoneal injections of the same 
dose of FSL-1, 10 days apart, which I showed to be long enough apart for the acute effects 
on innate immunity to have resolved, and for each subsequent response to have the same 
magnitude. I then tested for residual effects on learning and memory after the rats had 
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recovered from the effects of the third injection. To do so I used the Morris Water Maze, 
which is a preferred instrument to assess spatial learning and memory deficits in 
experimental animals (for review see D’Hooge and De Deyn, 2001) and in humans (i.e. the 
virtual Morris Water Maze) (Aquirre et al., 1996; Astur et al., 2004; Kallai et al., 2005; 
Goodrich-Hunsaker et al., 2010). In addition, I measured body core temperature, cage 
activity, food intake and rate of growth throughout the acute stimulations of innate immunity, 
and in the subsequent period of recovery. Necrotic and apoptotic neuronal cell death of the 
hippocampal formation has been reported after experimental infusion of lipopolysaccharide 
(LPS, the pyrogenic moiety of Gram-negative bacteria) (Hauss-Wegrzyniak et al., 1998; Lee 
et al., 2008; Cui et al., 2008), but also in autopsy and animal models of bacterial meningitis 
(Leib et al., 1996; Zysk et al., 1996; Nau et al., 1999). Therefore, I also examined the 
histology of tissue from the hippocampus, a brain area crucial for spatial learning and 
memory (Morris et al., 1982; Squire, 1992), after rats had received three spaced injections of 
FSL-1 and once the Morris Water Maze procedures were completed. 
 
My aim was not to simulate chronic infections. Rather, I simulated recurrent acute infections 
(i.e. with recovery between infections) that are typical of Mycoplasma infections (e.g. 
pneumonia). Thus, although residual impairment in learning and memory has been detected 
in rats following acute, repeated (i.e. consecutive days) or chronic (i.e. infusion) 
administration of LPS (Aubert et al., 1995; Hauss-Wegrzyniak et al., 1998, 1999; Sparkman 
et al., 2005b), my study is to the best of my knowledge the first to assess residual deficits in 
learning and memory in otherwise healthy rats, following recurrent acute stimulation of the 
innate immune system.  
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5.3 MATERIALS AND METHODS 
(Also refer to Chapter 2, i.e. ‘Common methodology’)  
 
5.3.1. Animals 
 
Thirty three male Sprague-Dawley rats with a body mass of 130 ± 27 g on the day of the first 
injection were used, with no statistically significant differences in the mean body mass of the 
treatment groups. On the day of the first injection the rats were about 5 weeks old. When the 
procedures ended about a month later, the rats weighed 362 ± 26 g. The rats had access to 
pelleted rat chow and water ad libitum and were housed individually in cages in a 
temperature-controlled room on a 12:12 hour light: dark cycle, with lights on at 07:00 local 
time (see section 2.1 in Chapter 2).  
 
Experiments were carried out in accordance with the regulations of the Animal Ethics and 
Control Committee of the University of the Witwatersrand and were approved by its Animal 
Ethics Screening Committee (clearance certificate AESC 2007/72/4). 
 
5.3.2. Pyrogen administration 
 
The lyophilized powder of fibroblast-stimulating lipopeptide-1 (FSL-1) was reconstituted with 
sterile, pyrogen-free phosphate-buffered saline (PBS) to a concentration of 1ml.kg-1. Based 
on pilot studies, I gave the rats three intraperitoneal (i.p.) injections of FSL-1 at a dose of 500 
µg.kg-1, 10 days apart, to simulate recurrent acute infection with Mycoplasma. I have shown 
in Chapter 3 that a dose of 500 µg.kg-1 FSL-1 induced pronounced fever and sickness 
behaviours in rats within 6 h of administration, while pilot studies showed that tolerance to 
the pyrogenic effect of FSL-1 did not develop when it was injected at 10 day intervals. I 
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injected the rats at 16:00 so that the peak in response to FSL-1 would occur during the dark 
phase of the 24 h day, when rats are most active. 
 
5.3.3. Body temperature and cage activity 
 
I recorded body core temperature and cage activity of rats continuously by remote 
biotelemetry as discussed in detail in section 2.2 of Chapter 2. I analysed nocturnal activity 
(19:00 - 07:00), which accounts for virtually all of a rat’s voluntary locomotor activity and is 
not confounded by activities such as food replenishment.  
 
5.3.4. Food intake and body mass 
 
Food intake and body mass of the rats, before and after intervention, were recorded daily at 
16:00 (refer to section 2.4 of Chapter 2). 
 
5.3.5. Learning and memory: Morris Water Maze 
 
The Morris Water Maze apparatus and the protocol I used are discussed in detail in section 
2.5 of Chapter 2.  
 
Spatial learning and memory in the Morris Water Maze were measured as described 
previously (see section 2.5 in Chapter 2, but also see Fig. 5.1). Because tests in a Morris 
Water Maze are sensitive to technical and procedural variables, I paid particular attention to 
exclude or reduce potential confounders that I could manage, such as water temperature, 
room temperature, dimensions of the pool, gender, housing and hormonal status of the rats. 
I also handled the rats regularly in an attempt to reduce stress levels.  
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Day 0   Day 10  Day 20  Day 31-37  Day 37 
 
 
 
FSL-1 
(500 µg.kg-1) 
or 
PBS 
(1 ml.kg
-1
) 
FSL-1 
(500 µg.kg-1) 
or 
PBS 
(1 ml.kg
-1
) 
FSL-1 
(500 µg.kg-1) 
or 
PBS 
(1 ml.kg
-1
) 
Morris Water Maze 
(7 days) 
Hippocampal 
tissue collection 
10 d 10 d 10 d 7 d 
17 d 
 
Figure 5.1. Sequence of injections and investigations. Rats received three single 
injections, at 10 d intervals, of either FSL-1, or PBS, before they were tested in a Morris Water 
Maze. 
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I measured the rats’ swim speed, latency and distance travelled to the platform, and the time 
spent in the target zone of the maze. I previously have validated the protocol for use of the 
Morris Water Maze (see section 2.5.3 in Chapter 2, but also Chapter 3), by testing rats 
given scopolamine (Sigma-Aldrich, St. Louis, MO, USA), a drug known to induce amnesia in 
laboratory animals (Diez-Ariza et al., 2003; Janas et al., 2005; Choi et al., 2006). 
 
5.3.6. Experimental procedures 
 
The rats were assigned randomly to two groups, one group receiving three successive i.p. 
injections of 1ml.kg-1 PBS (n = 16), and the other receiving three successive i.p. injections of 
500 µg.kg-1 FSL-1 in PBS (n = 17), at 1 ml.kg-1 volume. The injections were given at 10 d 
intervals (Fig. 5.1).  
 
On the eleventh day after the last of the three injections, rats started their training in the 
Morris Water Maze (see Fig 5.1; procedure described in detail in Chapter 2). They were 
given an initial habituation trial in the Maze (see Morris, 1981), a single 60 s “Cued” test (see 
Morris, 1984), four days of training (i.e. phase of acquisition of memory) and a single 30 s  
“Probe” trial. One hour after the “Probe” trial, the rats again were tested in a “Cued” test. 
Rats then were returned to their home cages, until euthanasia the next day when 
hippocampal tissue was excised (see section 5.3.7 below). Over the seven days of the 
Morris Water Maze procedure, I continued to measure body core temperature and cage 
activity with biotelemetry as well as food intake and body mass (see sections 5.3.3 and 5.3.4 
above). 
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5.3.7. Histopathology 
 
I examined hippocampal tissue in a sub-sample of rats (n = 19) for possible histopathological 
changes induced by recurrent i.p. injections of either 500 µg.kg-1 FSL-1 (n = 10) or 1 ml.kg-1 
PBS (n = 9). Brain tissue of rats destined for histology was collected 17 days after 
administration of the last of the three injections, i.e. the day of the last exposure to the Morris 
Water Maze (see Fig. 5.1). Rats were anaesthetized deeply with an i.p. injection of 1 ml 
sodium pentobarbital (Euthapent, 200 mg.ml-1; Kyron Laboratories (Pty) Ltd., South Africa) 
and were perfused transcardially for 2 min with about 250 ml of ice-cold sterile saline (0.9 % 
NaCl) via the left ventricle. Hippocampal tissue was dissected out rapidly on an ice-chilled 
plate and placed in microcentrifuge tubes, to which 0.5 ml RNAlater Solution (AEC 
Amersham, (Pty) Ltd., South Africa) was added to preserve the tissue. Post-fixed 
hippocampal tissue, in the micro-centrifuge tubes, then was snap-frozen in liquid nitrogen 
and stored at – 80 ºC. For histopathological examination, specimens were cut at 50 µm 
intervals and stained in cresyl violet. The sections were inspected for necrosis, and cells in 
the dentate gyrus with morphological changes compatible with apoptosis were counted with 
a microscope (Olympus BX41) in three visual fields (per rat) at 400x magnification. 
Apoptosis was scored as follows: 0-5 apoptotic cells = 0; 6-30 apoptotic cells = 1; more than 
30 apoptotic cells = 2 (see Pfister et al., 2000). The histopathology was performed by a 
qualified histopathologist, Bridget Mitchell, who was blind to the experimental interventions. 
 
5.3.8. Data analysis 
 
I used the thermal response index (TRI, ºC.h) as an integrated measure of fever duration 
and magnitude. To take account of circadian rhythms in body temperature, TRIs were 
calculated as the time integrals of the differences between the abdominal temperature of 
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each rat after injection and the abdominal temperature of that rat at the same time of day, 
averaged for the three days before the day of injection, when the rats were undisturbed in 
their home cages. TRIs were calculated separately for day 0, day 10 and day 20, over a 12 h 
period starting at 19:00, i.e. three hours after injections. For statistical analyses, TRIs were 
compared between groups separately on days 0, 10 and 20 by t-tests. Nocturnal cage 
activity counts detected over 5 min were summed for the same twelve hours following 
injections. Cage activity was expressed as a percent change from the mean activity 
measured for the same time period over three nights before the injection.  For statistical 
analyses, percent change in cage activity was compared between the groups over the first 
five days following each of the injections, separately, by two-way repeated-measures 
ANOVA.  
 
Food intake was expressed as grams of food consumed in 24 h per 100 g of rat body mass. 
Twenty-four hour change in body mass (g) of each rat was determined by subtracting the 
body mass measured at 16:00 from the body mass measured at the same time on the 
previous day. The rate of mass gain was expressed as change in body mass per 24 h (g.d-1). 
For statistical analyses, changes in food intake as well as changes in body mass were 
compared between the groups over the first two days following each of the injections, 
separately, by two-way repeated-measures ANOVA.   
 
For each of the training days in the Morris Water Maze the mean speed, mean distance and 
latency to reaching the submerged platform over all four trials on that day was determined 
for each rat and then averaged across the group of rats. Changes in the indices measured 
during the four-day acquisition phase in the Morris Water Maze were compared between 
groups and over time, by two-way repeated-measures ANOVA. Indices measured during the 
Cued tests were analyzed by means of unpaired t-tests. The percentage time spent in the 
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zones of the Morris Water Maze during the Probe trial was analyzed with one-way ANOVA, 
separately, for rats that had received PBS and for rats that had received FSL-1. Appropriate 
corrections were applied for multiple comparisons and post hoc tests were performed when 
ANOVA showed significance.  
 
Data are expressed as mean ± SD and a statistical significance was accepted for P < 0.05. 
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5.4 RESULTS 
 
5.4.1. Body temperature and cage activity 
 
Five minute recordings of abdominal temperature responses were averaged over 15 min 
intervals and plotted as temperature-time curves (Fig. 5.2). Handling and injection caused an 
immediate, but temporary, hyperthermia of similar magnitude and duration for rats receiving 
both FSL-1 and PBS injections. Then, about 3 h after each of the three successive 
injections, on day 0, day 10 or day 20, abdominal temperatures of rats that had received 
FSL-1 started to exceed those of rats that had received PBS. On average the body 
temperature of rats that had received FSL-1 peaked approximately 6 h after the injections, at 
about 38.8 ºC, a degree higher than that of rats that had received PBS. Twelve hour TRIs 
(19:00-07:00) calculated for rats that had received FSL-1 injections showed significant 
differences to the TRIs calculated for rats that received PBS (Fig. 5.3) on day 0 (t (31) = 
6.79, P < 0.0001), day 10 (t (31) = 4.96, P < 0.0001), and day 20 (t (31) = 5.95, P < 0.0001). 
The mean 12 h TRIs on day 0, day 10 and day 20 of rats that had received FSL-1 were not 
significantly different from each other (F (2,32) = 1.30, P = 0.29, one-way repeated 
measures ANOVA) (Fig. 5.3). 
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Figure 5.1. Abdominal temperature (mean ± SD) of rats from 2 h before to 15 h after they 
received three single i.p. injections, spaced 10 days apart, of either 500 µg.kg-1 FSL-1 in 1 
ml.kg-1 PBS (●; n = 17), or 1 ml.kg-1 PBS (○; n = 16). The arrow indicates time of injection 
(16:00) and the black bar indicates lights off (19:00-07:00). See Fig. 5.3 for statistical 
analyses. 
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Figure 5.2. Twelve hour night-time (19:00 - 07:00) thermal response indices (TRIs) 
(mean ± SD) of rats after receiving three i.p. injections, 10d apart, of 1 ml.kg-1 PBS (n = 17) 
or FSL-1 at a dose of 500 µg.kg-1 in 1 ml.kg-1 PBS (n = 16). Significant differences: * PBS vs. 
FSL-1. 
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Figure 5.4 shows the change in nocturnal cage activity of rats after receiving an i.p. injection 
of either FSL-1 or PBS. On average over the first nights after injection, the activity of rats 
was depressed by 59 ± 21% after the first injection, by 40 ± 31% after the second injection 
and by 47 ± 29% after the third injection and those depressions were not significantly 
different from each other (F (2,32) = 1.63, P = 0.21, one-way repeated measures ANOVA). 
The main effects of intervention (F (1,31) = 58.99, P < 0.0001), time (F (4,124) = 49.16, P < 
0.0001) and interaction (F (4,124) = 41.57, P = 0.27) after the first injection were significant 
such that the activity of rats was depressed significantly over the first (P < 0.003) and 
second (P < 0.003) nights after the FSL-1 injection compared to the activity of rats that 
received PBS. The main effects of intervention (F (1,31) = 13.09, P = 0.001), time (F (4,124) 
= 18.11, P < 0.0001) and interaction (F (4,124) = 17.51, P < 0.0001) after the second 
injection were significant such that the activity of rats was depressed significantly only over 
the first night after the FSL-1 injection compared to activity of rats that received PBS (P < 
0.003). Similarly, the main effects of intervention (F (1,31) = 6.24, P = 0.02), time (F (4,124) 
= 30.61, P < 0.0001) and interaction (F (4,124) = 30.52, P < 0.0001) after the third injection 
of FSL-1 were significant such that the activity of rats was depressed significantly only over 
the first night after the injection of FSL-1 compared to activity of rats that received PBS (P < 
0.003).  
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Figure 5.4. Nocturnal (19:00-07:00) cage activity (mean ± SD) of rats after receiving 
three, spaced, i.p. injections of either 500 µg.kg-1 FSL-1 in 1 ml.kg-1 PBS  (●; n = 17), or 
ml.kg-1 PBS (○; n = 16). Cage activity was expressed as a percent change from the mean 
activity measured over the same time period for the four days before the first injection. 
Negative changes represent a reduction in cage activity below pre-injection levels. The 
arrows indicate the days on which each of the three injections was administered. Significant 
differences: * FSL-1 vs. PBS; see sections 5.3.3 and 5.3.8 in text for details. 
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5.4.2. Food intake and body mass 
 
On average, rats consumed 19.7 ± 2.1 g of food per 100 g of body mass over the three days 
before receiving FSL-1 or PBS injections (Fig. 5.5A). The main effect of intervention (F 
(1,31) = 12.62, P = 0.001), time (F (1,31) = 18.43, P = 0.0002) and interaction (F (1,31) = 
9.36, P = 0.005) after the first injection of FSL-1 were significant such that rats consumed 
significantly less food over the first day  compared to rats that received PBS (P < 0.003). 
After the second injection, the main effect of intervention (F (1,31) = 3.45, P = 0.07), time (F 
(1,31) = 0.98, P = 0.33) and interaction (F (1,31) = 6.75, P = 0.01) indicated that there were 
no significant differences in the amount of food consumed by rats that received either FSL-1 
or PBS. After the third injection the main effect of intervention (F (1,31) = 24.86, P < 0.0001), 
time  (F (1,31) = 6.71, P = 0.01) and interaction (F (1,31) = 24.11, P < 0.0001) were 
significant such that rats consumed significantly less food over the first day immediately after 
the FSL-1 injection compared to rats that received PBS (P < 0.003). Furthermore, after each 
of the three FSL-1 injections, the 24 h change in food consumption (per 100 g of BM) of rats 
was significantly different (F (2,32) = 12.10, P = 0.0001, one-way repeated measures 
ANOVA): the decrease in food consumption after the first FSL-1 injection was significantly 
greater than that after the second (P < 0.05) and third (P < 0.05) FSL-1 injections. From the 
third day after each of the three injections, rats that had received FSL-1 consumed similar 
amounts of food to the rats that had received PBS. 
  
Figure 5.5B shows the rate of mass gain of rats before and after they had received three i.p. 
injections of either FSL-1 or PBS, spaced 10 d apart. Before injections, rats grew at similar 
constant growth rates. However, after the first injection of either FSL-1 or PBS, the main 
effect of intervention (F (1,31) = 15.91, P = 0.0004), time (F (1,31) = 87.26, P < 0.0001) and 
interaction (F (1,31) = 44.13, P < 0.0001) were significant such that the rate of mass gain of  
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Figure 5.5. Daily (24 h) food intake (mean ± SD) and rate of mass gain (mean ± SD) of 
rats measured for 10 d after receiving three, spaced, i.p. injections of either 500 µg.kg-1 FSL-
1 in 1 ml.kg-1 PBS (●; n = 17), or 1 ml.kg-1 PBS (○; n = 16). Food intake (A) was calculated 
as grams of food consumed in 24 h per 100 g of body mass on that day. The rate of mass 
gain (B) was calculated over successive 24 h intervals starting at 16:00, and was expressed 
as grams of body mass gain, per day. The arrows indicate the days on which each of the 
three injections was administered. Significant differences: * FSL-1 vs. PBS; see sections 
5.3.4 and 5.3.8 in text for details.   
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rats that had received FSL-1 was reduced over the first day after the injection compared to 
that of rats that had received PBS (P < 003). Similarly, after the second injection of either 
FSL-1 or PBS, there was no significant intervention effect (F (1,31) = 3.84, P = 0.06), but the 
main effect of time (F (1,31) = 23.18, P < 0.0001) and interaction (F (1,31) = 14.86, P < 
0.0005) were significant such that the rate of mass gain of rats that had received FSL-1 was 
reduced significantly over the first day compared to that of rats that had received PBS (P < 
0.003). After the third injection of either FSL-1 or PBS the main effect of intervention (F 
(1,31) = 7.29, P = 0.01), time (F (1,31) = 40.33, P < 0.0001) and interaction (F (1,31) = 
17.01, P = 0.0003) were significant such that the rate of mass gain of rats that had received 
FSL-1 was reduced over the first day compared to that of rats that had received PBS (P < 
0.003). Furthermore, after each of the three FSL-1 injections the rate of reductions was not 
statistically significantly different from each other (F (2,32) = 40.33, P < 0.0001, one way 
repeated measures ANOVA). From the third day after each of the three injections, rats that 
had received FSL-1 grew at rates not significantly different to those of the rats that had 
received PBS. 
 
5.4.3. Learning and memory: Morris Water Maze 
 
Figure 5.6 shows the performance of rats as measured in a Morris Water Maze after 
completing three i.p. injections at 10 day intervals of either FSL-1 or PBS (see Fig. 5.1). 
During the Cued test (visible platform), a day before the rats started their 4-day acquisition 
training, there were no significant differences between the two groups of rats in any of the 
indices measured, namely latency to finding the platform (Fig. 5.6A; t (31) = 1.72, P = 0.09), 
distance swum to the platform (Fig. 5.6B; t (31) = 0.75, P = 0.46) and speed of swimming 
(Fig 5.6C; t (31) = 1.84, P = 0.08).  
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Figure 5.6. Performance of rats during the Cued test, the phase of acquisition of memory 
and the phase of memory recall, as measured in a Morris Water Maze from 12 d after the 
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last of the three successive i.p. injections of either 500 µg.kg-1 FSL-1  in 1ml.kg-1 PBS (●; n = 
17), or 1ml.kg-1 PBS (○; n = 16). Data are means ± SD. During the Cued test (A-C), which 
was performed on Day 32, the rats were given one attempt at finding the visible platform 
during which latency (A), distance swum (B) and swim speed (C) were measured. During the 
phase of acquisition of memory (E-G), the rats were given four trials per day over four days 
to find the submerged platform; mean values for the four trials are presented, and latency 
(E), distance swum (F) and swim speed (G) were measured. The phase of memory recall 
was performed on Day 37, in which reference memory was tested with a single Probe trial, 
and the % time spent in each zone of the Maze (D, H) was measured. # indicates significant 
differences to the other three zones. 
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When the Cued test was repeated at the end of the “Probe” trial, there again were no 
significant differences between the two groups of rats in any of those indices (data not 
shown).  
 
Over the four-day training in the Maze (i.e. the phase of acquisition of memory), there was a 
significant main effect of time (F (3,93) = 35.15, P < 0.0001) with the latency to reach the 
submerged platform (Fig. 5.6E) decreasing for both groups of rats, but there was no 
significant intervention effect (F (1,31) = 0.07, P = 0.79) and no significant interaction (F 
(3,93) = 0.91, P = 0.44). Similarly, the distance to reach the submerged platform (Fig. 5.6F) 
decreased significantly for both groups of rats (time effect: F (3,93) = 35.70, P < 0.0001), but 
there was no significant intervention effect (F (1,31) = 0.91, P = 0.35) and no significant 
interaction (F (3,93) = 0.05, P = 0.98). Furthermore, for swim speed (Fig. 5.6G) there was a 
significant time effect over the four days (F (3,93) = 4.04, P = 0.01), but there was no 
significant intervention effect (F (1,31) = 0.61, P = 0.44) and no significant interaction (F 
(3,93) = 2.25, P = 0.09).  
 
When the rats were tested in the Probe trial (platform removed) 24 h after the last acquisition 
trial, there was a significant difference in the percentage time spent in each of the four zones 
(i.e. NW, NE, SE, SW) for rats that had received PBS (Fig. 5.6D; F (3,60) = 19.52, P < 
0.0001) and for rats that had received FSL-1 (Fig. 5.6H, F (3,64) = 22.81, P < 0.0001). Rats 
in both groups spent significantly more time searching for the platform in the SE target zone 
(where the platform was originally located) compared to the other three zones (i.e. NW, NE, 
SW), so both groups of rats successfully could recall the former location of the platform. The 
mean latency to the platform position (data not shown) was significantly shorter than the cut-
off value of 30 s for both rats that had received PBS (t (15) = 5.04, P = 0.0001) and rats that 
had received FSL-1 (t (15) = 5.04, P < 0.0001). Furthermore, there were no significant 
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differences in the swim speed, distance swum and latency to finding the former platform 
position, or platform crossings, between rats that had received PBS or FSL-1 (data not 
shown).  
 
5.4.4. Histopathology 
 
There was no significant evidence of apoptosis or neurodegeneration (necrosis) in any of the 
treatment groups. Specifically, histology of the granular cell layer of the dentate gyri (Fig. 
5.7) showed no evidence of histopathological changes in cresyl violet brain sections of the 
hippocampi of rats receiving either PBS (Fig. 5.7A) or FSL-1 (Fig. 5.7B).  
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Figure 5.7. Cresyl violet stained sections (400 x magnification; bar = 25 µm) of the 
granular cell layer of the hippocampal dentate gyrus of rats 17 days after receiving the last of 
the three successive i.p. injections of either 1 ml.kg-1 PBS (n = 9) (A) or 500 µg.kg-1 FSL-1 in 
1 ml.kg-1 PBS (n = 10) (B). 
 
B 
A 
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5.5 DISCUSSION 
 
There have been many experimental studies of simulated acute fever, and some of chronic 
fevers, but my study is one of few to investigate the consequences of recurrent, acute 
simulated infections. I have shown in growing rats that repetitive parenteral administration, at 
10 day intervals, of FSL-1, the pyrogenic moiety of Mycoplasma salivarium, generated 
recurrent fevers without the development of tolerance to the pyrogen, and caused recurrent 
lethargy and anorexia without the development of tolerance to those two sickness 
behaviours. Importantly, repetitive administration of FSL-1, at the dosage we used, did not 
leave residual impairment in spatial learning or memory when rats were tested in a Morris 
Water Maze. In accordance with the lack of effect on spatial learning and memory, histology 
of the dentate gyri of rats also showed no evidence of apoptotic cell death after the 
simulated, recurrent acute Mycoplasma infection.  
 
In seeking to model a recurrent infection, I set out to simulate repetitive infections at intervals 
long enough for the acute phase effect of the first injection to have resolved, and achieved 
this goal. Repetitive administration of FSL-1 generated recurrent fevers of statistically similar 
magnitude, which started about 3 h after each of the three injections and lasted for about 9 h 
(Fig. 5.2, 5.3). However, two of the sickness behaviours that I measured, namely lethargy 
and anorexia, were affected differentially, somewhat, after each of the three injections of 
FSL-1. The initial magnitudes of the lethargy were the same after each of the three 
injections, but the lethargy resolved more rapidly after the second and third injections, then 
being confined to one day (Fig. 5.4). Contrary to what was seen with lethargy, the initial 
magnitude of anorexia induced by the first injection was significantly different from that after 
the second and third injection (Fig. 5.5A), perhaps because the rats were younger at the first 
injection.  
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Together with the recurrent fever and anorexia, the rats exhibited reduced rate of mass gain 
after each of the three FSL-1 injections (Fig. 5.5B). Again, the initial reduction in rate of mass 
gain was statistically similar after the three injections. The recurrent acute reduction in food 
intake and mass gain following repetitive administration of FSL-1, were superimposed on a 
progressive reduction in food intake per 100 g of body mass in both groups of rats, as they 
grew (Fig. 5.5). Their average body mass almost tripled over the duration of the procedure, 
so absolute food intake increased appreciably. Interestingly, on the second day following 
each of the three injections of FSL-1 there was a small, albeit insignificant, increase in rate 
of mass gain relative to that of rats that had received PBS, despite no difference in food 
intake (Fig. 5.5B), ruling out a rebound hyperphagia. Rather, I speculate that, following the 
simulated infection, the rats digested and absorbed the food more slowly than did rats 
receiving PBS, resulting in a slower transit time and delayed gastric emptying and hence, 
increased residual food or faecal material in the gastrointestinal tract. A reduction in transit 
time and delayed gastric emptying as well as inhibition of gastric acid and pepsin secretion 
(e.g. Uehara et al., 1990), has been shown previously with i.p. LPS (Langhans et al., 1990; 
Takakura et al., 1997; Liang et al., 2005; Chen et al., 2010). However, the dominant effect of 
recurrent FSL-1 administration on rate of mass gain remained as a recurrent transient 
reduction in that rate (Fig. 5.5B). 
 
Having demonstrated that repeated administration of FSL-1, at 10-day intervals, induced 
recurrent acute fever and sickness behaviour, I then could address my primary questions, 
namely whether the accumulated effects of these transient insults left any residual 
impairment in spatial learning and memory; and whether any observed impairments may be 
associated with apoptosis in the hippocampus, the principle brain region involved in spatial 
learning and memory. Rats started their training in the maze 10 days after the last injection 
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of PBS or FSL-1, a time at which the acute effects of the last injection of FSL-1 had 
resolved. If I had detected impaired learning and memory, such impairments could not have 
arisen because the agents that induce fever and sickness behaviour (i.e. pro-inflammatory 
cytokines) still were active. In fact, in the Cued test (Fig. 5.6A-C) motivation and 
sensorimotor functions of rats were not affected adversely after they had received FSL-1 
repetitively, given that the latency and distance travelled to the visible platform, as well as 
the swim speed of rats were not altered significantly, compared to those that followed PBS 
administration. Similarly, during task acquisition over four days with a submerged platform 
(Fig. 5.6E-G), the progressive reduction in the latency and distance to finding the submerged 
platform was the same for both groups of rats, confirming that earlier recurrent acute 
administration of FSL-1 had no residual effects on learning. Finally, when the platform was 
removed during the Probe trial (Fig. 5.6D, H) the rats showed the same, significant, spatial 
bias for the former location of the platform in the target zone relative to the other zones, 
regardless of whether they had received prior FSL-1 or PBS administration. Thus, recurrent 
FSL-1 administration also had no residual effects on spatial memory. Furthermore, histology 
of sections of the granular layer of the hippocampal dentate gyri (Fig. 5.7A, B) showed no 
significant evidence of apoptosis in the rats that had received recurrent FSL-1 injections (Fig. 
5.7B). Since an intact hippocampus is essential for successful spatial learning and memory 
(Aguirre et al., 1996; D’Hooge and De Deyn, 2001), these findings are congruent with data 
obtained in the Morris Water Maze. Taken together, the evidence presented here 
demonstrates that recurrent bouts of immune stimulation by FSL-1, at the dosage I used and 
allowing for adequate recovery between challenges did not leave residual deleterious effects 
on spatial learning and memory as assessed in a Morris Water Maze. 
  
The dose of FSL-1 that I employed was effective in inducing unequivocal fever and sickness 
behaviours, though I cannot exclude the possibility that higher doses of FSL-1, when 
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administered repetitively, could have induced residual effects on spatial learning and 
memory. It also is possible that a longer series of recurrent injections of FSL-1, or a different 
route of administration, e.g. intracerebroventricular (i.c.v.), could induce a more profound 
brain inflammatory response with accompanying hippocampal cell damage and/or 
impairment in spatial learning and memory. My results are confined to effects of simulated 
Mycoplasma infection; administration of live organisms (e.g. M. hyopneumoniae, see 
Escobar et al., 2004, 2007), mimicking more closely what happens in Mycoplasma-induced 
pneumonia, may have other deleterious effects on cognition that I did not detect. Moreover, 
the Morris Water Maze, measures only hippocampal-dependent spatial learning and 
memory. It is possible that I could have detected residual impairment in working rather than 
reference memory, or in other behavioural tasks such as the T-Maze or the Y-maze (see 
Sanderson et al., 2009), the Barnes-maze (Harrison et al., 2009), the radial arm maze 
(Semmler et al., 2007; Chen et al., 2008; Sanderson et al., 2009), contextual fear 
conditioning (e.g. Pugh et al., 1998; Bilbo et al., 2008) or context pre-exposure (Bilbo et al., 
2005a, b, 2007), some of which measures components of hippocampal-independent 
learning. 
  
That I found no residual effects on spatial learning and memory was not the consequence of 
test insensitivity, as I previously have shown impaired learning ability of rats in a Morris 
Water Maze (Chapter 3) after administration of scopolamine, a substance often used to 
induce amnesia in laboratory animals (e.g. Choi et al., 2008). Other animal studies have 
shown that administration of drugs can lead to “state-dependent” effects on learning 
(Overton, 1964). For example, when one assesses learning and memory during immune 
stimulation, the context in which subsequent retrieval of memories is tested should be similar 
to the context in which learning occurred, to control for contextual differences in training (i.e. 
learning) and testing (i.e. memory) (for review see Cunningham and Sanderson, 2008). My 
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study was not compromised by issues of context, because I had ceased all other 
interventions before testing learning and memory in the Morris Water Maze.  
 
Previous studies, however, have reported residual effects on learning and memory following 
acute, or chronic, simulated infection. For example, mice that had received an i.p. injection of 
LPS (250 µg.kg-1) four hours before being tested had acquisition decrements that persisted 
up to 10 days, as assessed in a non-spatial, hippocampal-dependent,   avoidance 
conditioning task  (Sparkman et al., 2005b). When rats were injected with a single i.p. 
injection of LPS (250 µg.kg-1) on day two of acquisition training in a non-spatial, 
hippocampal-independent autoshaping task, the observed learning impairment persisted 
across 12 days of testing  (Aubert et al., 1995). Chronic neuro-inflammation, induced by 28 
days of LPS infusion into the fourth ventricle of rats, impaired spatial memory in the Morris 
Water Maze as measured in a hippocampal-dependent task (Cui et al., 2008; Min et al., 
2009) and LPS infusion over 33 days in rats induced microglial activation which correlated 
with impaired performance in a Morris Water Maze task (Hauss-Wegrzyniak et al, 1999). 
More importantly, LPS infusion for 4 weeks in rats caused residual impairment in spatial 
working memory when they were tested a week later in a hippocampal-dependent T-maze 
(Hauss-Wegrzyniak et al., 1998), and a similar residual impairment in spatial working 
memory was observed in rats, when they were tested in a Morris Water Maze 37 days after 
cessation of LPS infusion over periods of 37 or 74 days (Hauss-Wegrzyniak et al., 2000). In 
my study, the absence of residual detrimental effects on learning and memory as measured 
in the hippocampal-dependent Morris Water Maze may have resulted from the different 
pyrogen we administered (FSL-1 vs. LPS), the route of administration (i.p. vs. infusion), or 
the frequency of pyrogen administration (single injection vs. chronic infusion vs. spaced 
single injections).   
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I administered FSL-1 for the first time to rats at an age of about 36 days, and again on 46 
and 56 days. The absence of detectable or residual effects of recurrent acute FSL-1 
administration to growing rats may have been specific to the stage of development at which I 
tested for those effects. Rats reach “puberty” at 40 to 60 days of age (Kohn and Clifford, 
2002), an age also comparable, on average, to that of an 11-12 year old child (Krisman-
Scott et al., 2002; Quinn, 2005). So the stage of development in the rats’ lives at which I 
tested the effects of recurrent FSL-1 administration on spatial learning and memory was 
equivalent to that of school-aged children during early adolescence. Other studies in rats 
have shown that neonatal exposure to LPS was associated with dramatic impairment of 
memory consolidation during development and in adulthood, when rats were exposed to 
another immune challenge (Bilbo et al., 2005b; Bilbo et al., 2005a; Bilbo et al., 2006). 
Moreover, neonatal administration of a single dose of LPS to rats resulted in a loss of 
hippocampal CA1-3 parvalbumin neurons in adulthood (Jenkins et al., 2009). So, recurrent 
administration of FSL-1 to neonatal rats may well have left residual effects on learning and 
memory.   
 
There is another life stage at which recurrent FSL-1 administration might leave residual 
effects on learning and memory, namely old age. Peripheral injection, or chronic infusion of 
LPS to aged rats, increased the number of activated microglia in the hippocampus, and 
induced a heightened inflammatory cytokine response in the hippocampus which resulted in 
atrophy of hippocampal neurons (Hauss-Wegrzyniak et al., 1999; Richwine et al., 2008). 
Furthermore, systemic infection, which activates microglial cells in the brains of humans 
(Lemstra et al., 2007) and other animals (Semmler et al., 2005), is thought to worsen the 
neurological symptoms in patients suffering from neurodegenerative diseases, such as 
Alzheimer’s disease, in which microglia already are activated (Perry et al., 2003; Perry et al., 
2007). Animal models of chronic neurodegeneration have shown that subsequent systemic 
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infection resulted in further activation of microglia, which in turn evoked exaggerated 
sickness behaviours (Combrinck et al., 2002; Cunningham et al., 2005). Because the 
hippocampus is one of the brain areas to show damage in neurodegenerative diseases (see 
(Jellinger, 1998; Jellinger and Bancher, 1998), recurrent systemic infections may aggravate 
the cognitive decline in patients with Alzheimer’s disease (Holmes et al., 2003). So, recurrent 
administration of FSL-1 to aged rats may have had a different outcome. However, a recent 
mice model of neurodegenerative disorders showed that recurrent systemic infection with 
Streptococcus pneumoniae did not affect the onset or the course of Alzheimer’s disease 
(Ebert et al., 2010). 
 
Though residual impairment of hippocampal-dependent learning and memory as a 
consequence of hippocampal damage may occur in neonatal rats, following recurrent 
injections of FSL-1, they did not occur in my “adolescent” rats. My findings in “adolescent” 
rats parallel those of Mouihate and Pittman (1998), who found no evidence for apoptotic cell 
death in several brain areas, including the hippocampus, in adult rats, after repeated (5 
consecutive days) i.p. injections of LPS, at a dose that induced sustained fevers for four 
days (Mouihate and Pittman, 1998). In mice, Terrazzino and colleagues (2002) also found 
no apoptotic cells in sections of the hippocampus, among other brain areas, two weeks after 
repeated (4 consecutive days) i.p. injections of LPS (Terrazzino et al., 2002). Although the 
above two studies also have simulated repeated infections (daily injections, not spaced 
injections), they did not measure spatial learning and memory, as I did. Tanaka and 
colleagues (2006), however, did find impaired spatial memory, but did not observe neuronal 
cell death in adult rats after repeated (5 consecutive days) administration of LPS into the 
hippocampal CA1 region (Tanaka et al., 2006). 
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Apart from contributing towards the understanding of impaired learning and memory as a 
sickness behaviour, I also have contributed new information about tolerance following 
repeated FSL-1 injections, though the phenomenon relates to a design requirement of my 
study rather than an outcome. Tolerance, the tachyphylaxis evident in the acute phase 
response following repeated activation, seems to develop after administration of the 
pyrogenic moieties of most, if not all, classes of infective organisms (Zeisberger and Roth, 
1998; West and Heavy, 2002; Cartmell and Mitchell, 2005; Biswas and Lopez-Collazo, 
2009), but at a rate and with a degree of completeness that depends on the number of 
injections, the interval between them and the route of administration (for example see 
Mouihate and Pittman, 1998, Voss et al., 2006; Greis et al., 2009).  Five injections of FSL-1, 
spaced 3 days apart and at a dose of 100 µg.kg-1, did not induce tolerance when the moiety 
was injected intra-arterially, but did so when it was injected intraperitoneally (Greis et al., 
2009). I now have shown that, in growing rats repeated administration of FSL-1 at a dose of 
500 µg.kg-1, spaced 10 d apart, generated recurrent fevers of similar magnitude and duration 
after each of three injections. Thus, even at the higher dose, there was no pyrogenic 
tolerance to repeated i.p. FSL-1 when injections were given at 10 day intervals. Also, the 
magnitude of the anorexia and lethargy that followed i.p. FSL-1 administration was the same 
after the three repeated injections, though these sickness behaviours lasted longer after the 
first injection than they did after subsequent injections. Presumably as a result primarily of 
the anorexia, but perhaps also because of the increased metabolic demand of the fever, the 
growth rates (Fig. 5.5B) of the rats were reduced by a similar magnitude over the first 24 h 
after each of the three injections of FSL-1. However, I did not observe sustained stunting, 
implying that the stunting which lasted for four days following a single injection of FSL-1 at a 
similar dose (see Fig. 3.5B, Chapter 3) was reversed by ten days, presumably by the slight 
but persistent daily increases in rate of mass gain relative to that following PBS 
administration (see Fig. 5.5B). Acute intratracheal inoculation with Mycoplasma 
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hyopneumoniae (strain P5722–3, 3 ml of 1 x 1010 units.L-1) also had no effect on growth in 
growing pigs (Escobar et al., 2004). However, growth failure did occur in guinea pigs given 
spaced repeated injections of muramyl dipeptide, a pyrogenic moiety of Gram-positive 
organisms (Madu et al., 2007).  
 
Though residual effects on learning and memory of solitary acute bacterial infections and 
chronic infections have been studied previously (Aubert et al., 1995; Hauss-Wegrzyniak et 
al., 1998, 2000; Sparkman et al., 2005b), I believe mine is the first study to measure residual 
learning and memory after simulated recurrent, acute infections. Also, previous studies have 
not addressed the issue of whether only learning and memory are affected, or whether any 
impaired learning and memory represents one component of a suite of residual sickness 
behaviours. Because I was interested particularly in the residual deficits in learning and 
memory that might persist, once the rats were apparently well after the effects of the last in 
their series of simulated infections had resolved, I assessed learning and memory at a time 
when no residual fever, anorexia or lethargy was present. Moreover, I used FSL-1 and 
‘adolescent’ rats in the current study because I wanted to assess the consequences of 
recurrent acute stimulation of innate immunity, such as would occur in growing children of 
school-going age subject to repetitive bouts of e.g., community-acquired pneumonia, 
commonly caused by Mycoplasma. I believe that my model of recurrent acute Mycoplasma 
infection has significant potential to be implemented in many other models of acute infection 
that occur recurrently. For example, recurrent acute fevers commonly occur in meningitis, 
malaria and influenza that are caused by other classes of organisms, including Gram-
positive bacteria, protozoa and viruses.  
 
In conclusion, though I cannot extrapolate directly the outcome of my study, which employed 
a pyrogenic moiety of Mycoplasma in rats, to the real infection caused by live organisms in 
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humans, the clinical implications of my study are encouraging. First, I did not find any 
residual histological damage to the hippocampus nor did I observe lasting detrimental effects 
on spatial learning and memory. Secondly, I did not observe permanent stunting in my rats. 
If I had observed these phenomena in the simulated infections there would have been a high 
likelihood of them occurring, and being aggravated, in the real infections. Ultimately, studies 
in children need to be undertaken in order to determine whether or not apparently-well 
children who have recovered from recurrent acute Mycoplasma infections have residual 
deficits in learning and memory.  
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Although Mycoplasma primarily causes respiratory disease, Mycoplasma pneumoniae has 
been implicated in life-threatening meningitis as well as memory deficits. Experimentally, 
very little still is known about Mycoplasma-induced sickness behaviour and no one 
previously has investigated its effect on learning and memory. I have investigated various 
sickness responses during acute and recurrent acute simulated Mycoplasma infection. I also 
was interested, particularly, in the consequences of recurrent acute infections, which seldom 
are being simulated in the laboratory. Mycoplasma is a common cause of recurrent 
infections. To avoid safety concerns and ethical issues arising from administration of 
pathogenic live organisms, such as Mycoplasma pneumoniae, to experimental animals (see 
e.g. Pietsch et al., 1994; Wubbel et al., 1998; Chu et al., 2003) I used a pyrogenic moiety 
from M. salivarium, namely fibroblast-stimulating lipopeptide-1 (FSL-1). Acute administration 
of FSL-1 in rats induces fever and sickness behaviours (Hübschle et al., 2006). I 
administered FSL-1 both acutely and recurrently to a different strain of rat (Sprague-Dawley 
vs. Wistar) and at a different dose (500 vs.100 µg.kg-1) previously used (Hübschle et al., 
2006). Contrary to the dose of 100 µg.kg-1, which Hübschle and colleagues (2006) used in 
Wistar rats, my pilot studies showed that, in my hand, administration of FSL-1 at doses of 
500 µg.kg-1 and higher, but not 100 µg.kg-1, induced pronounced fever and sickness 
behaviours (lethargy and anorexia) in Sprague-Dawley rats. 
 
Having established successfully an animal model of simulated acute as well as simulated 
recurrent Mycoplasma infection, I investigated fever, lethargy, growth and anorexia as well 
as learning and memory processes. After acute, parenteral administration of my higher dose 
of FSL-1 (i.e. 1 000 µg.kg-1) the sickness behaviours lasted for longer than that described by 
Hübschle and colleagues (2006): I observed four days of lethargy, three days of anorexia 
and at least four days of body mass stunting (Chapter 3), a phenomenon not reported by 
Hübschle and colleagues (2006). In fact, no one previously has observed stunting in 
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simulated acute Mycoplasma infection. I further investigated potential roles for pro-
inflammatory cytokines, interleukin-1 (IL-1β) and interleukin-6 (IL-6) in mediating 
Mycoplasma-induced sickness responses by measuring the concentrations of these two 
cytokines in the hypothalamus, required for eating behaviour and body temperature 
regulation. In rats, sickness responses induced by FSL-1, including fever, lethargy and 
anorexia appear to be mediated by peripherally-released pro-inflammatory cytokines, 
including IL-6 and tumor necrosis factor-α (TNF-α) (Hübschle et al., 2006). I have shown, for 
the first time, increased concentrations in the plasma and brain of another pro-inflammatory 
cytokine, namely IL-1β (Chapter 4), accompanying FSL-1-induced fever, lethargy and 
anorexia as well as stunting in rats (Chapter 3). 
 
I measured fever, lethargy and anorexia over a course of days whilst learning and memory 
were being assessed. As a test procedure, I chose to use a Morris Water Maze that tests a 
high component of cognitive function and where the responses are not simply reflexes. In 
Table 1 (Chapter 1) I summarized studies that have measured spatial learning and memory 
in a Morris Water Maze, after a single i.p. administration of a given moiety / pathogen-
associated molecular pattern (PAMP), either from typical bacteria (Gram-positive or Gram-
negative) or viruses. Using FSL-1, which simulates Mycoplasma infection, my studies extend 
what already is known about the effects of acute immune activation on learning and memory 
processes: I have shown, in rats, that a single i.p. administration of FSL-1, at doses of 500 or 
1 000 µg.kg-1, did not induce impairment in spatial learning and memory, as measured in a 
Water Maze as I have implemented it. Because the learning environment during Morris 
Water Maze testing can be manipulated in various ways, studies have found contradicting 
results with other PAMPs on memory processes. For example, following acute 
administration of a given PAMP, studies have reported impairment in spatial learning and/or 
memory (i.e. working memory) when the platform within the pool was relocated to a new 
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position throughout testing (Gibertini, 1996; Richwine et al., 2009; Zhang et al., 2009; Ito et 
al., 2010). However, when the platform remained in a fixed location in the Maze no 
impairment in spatial learning or memory (i.e. reference memory) was observed, after acute 
administration of the same PAMP (Gibertini, 1996; Ito et al., 2010). I also showed that 
reference memory was unaffected after acute administration of FSL-1 (Chapter 3), although 
I did not measure working memory. Moreover, water temperatures between 18-25 ºC have 
been used to induce stress conditions as means of interfering with acquisition rates and 
consolidation processes during memory formation (Gibertini, 1998; Akirav et al., 2001). For 
example, in a warm-water Maze (23 ºC) IL-1 appears to interfere with learning (Gibertini, 
1998), which is contrary to what I have found in my Water Maze in which the water 
temperature was kept constant between 25-26 ºC (based on the “standard” protocol of 
Morris, 1981) (Chapter 3 and 5). In addition to the manipulation of water temperature, the 
level of “emotionality” of animals that are tested in the Maze also can be manipulated or 
altered by using ‘massed’ or ‘spaced’ training protocols (Gibertini, 1998). Massed training 
typically consists of between 3-12 trials on one day, whereas spaced training consists of a 
limited number of trials (e.g. 4 trials) over a number of days (e.g. 3 days). Spaced training 
trials are considered to be more effective for the production of robust learning and memory 
than are massed training trials (Scharf et al., 2002). I therefore used spaced training trials of 
four trials per day over four days, during the acquisition phase in my Morris Water Maze, to 
ensure optimal learning and memory (Chapter 3 and 5).  
  
Unlike most previous authors I have assessed learning and memory in the full context of the 
acute phase response, in my case induced by Mycoplasma infection. I found that spatial 
learning and memory were spared at a time when the rats still were febrile, lethargic, 
anorexic and stunted (Chapter 3). I believe that the lack of impairment in learning and 
memory, and the dissociation from other brain-controlled sickness behaviours, is an 
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important finding, and therefore I measured concentrations of IL-1β and IL-6 in the 
hippocampus, required for spatial learning and memory. At the time of active learning in the 
Maze the rats had significantly elevated concentrations of IL-1β in both the hypothalamus 
and the hippocampus (see Chapter 4). Although increased concentrations of IL-1β in the 
hippocampus of rats have been associated with impairment in learning and memory (for 
review see Goshen and Yirmiya, 2007; Barrientos et al., 2009), in my study increased 
concentrations of IL-1β in the hippocampus were not associated with any impairments. 
Following i.p. administration of FSL-1 in rats, the concentration of IL-1β was slightly higher in 
the hypothalamus than in the hippocampus, albeit insignificantly (see Chapter 4). Thus, 
following FSL-1 administration to rats, the same concentration of IL-1β in the hypothalamus 
that seems to mediate fever and lethargy was not sufficient to induce impairment in 
hippocampal-dependent learning and memory (Chapter 3). Further investigations are 
required using other models of assessing learning and memory, such as the Y-maze and the 
T-maze, to confirm that learning and memory is spared in the face of other sickness 
behaviours following systemic administration of FLS-1. Studies also need to investigate 
whether or not FSL-1 can cross the blood-brain-barrier (BBB), after systemic administration. 
If FSL-1 crosses the BBB, studies need to characterise the brain areas in which receptors for 
FSL-1 (i.e. toll-like receptor 2/6; TLR2/6) are present. It is possible that some brain areas, 
including the hypothalamus, may be more ‘sensitive’ to the effects of FSL-1, than are other 
areas like the hippocampus. Ultimately, FSL-1 needs to be injected into the brain, for 
example using intracerebroventricularly (i.c.v.) injections, to confirm its effect on learning and 
memory processes.  
 
Following FSL-1 administration to rats, I measured cage activity as an index of lethargy and 
also to assess whether any diminished performance in the Water Maze could be attributed to 
lethargy rather than a decline in cognitive function. In my opinion, whether or not impairment 
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in learning or memory is observed in a Morris Water Maze following simulated, systemic 
infection depends on the pyrogen and the dose administered, the route of administration, 
and importantly, the time of testing in the Maze. If infected animals are tested in the Maze 
before resolution of the acute phase response, it may not be surprising that sickness 
responses, including lethargy, may affect locomotion or swimming speed and not necessarily 
learning or memory itself (see Cunningham and Sanderson, 2008). Although other measures 
of activity exists, I used biotelemetry to monitor physical activity of rats before, during and 
after they were exposed to training and testing in the Maze. Moreover, the use of 
biotelemetry also allowed me to monitor continuously body temperature of rats while they 
were swimming: not only hyperthermia (Ahlers and Riccio, 1987), but also hypothermia may 
cause anterograde memory loss (Richardson et al., 1983). Although hyper- or hypothermia 
and lethargy did not confound results in my study, I propose that biotelemetry be 
implemented together with the Morris Water Maze in future experiments, to exclude 
confounding factors, such as changes in body temperature and lethargy. 
 
Interestingly, I have shown that acute administration of my higher dose of FSL-1 (i.e.1 000 
µg.kg-1) abolished almost all spontaneous cage activity (also referred to as ‘house-keeping 
activity’) of rats, yet they swam competently in a Morris Water Maze (Chapter 3). I therefore 
hypothesize that the rats may have invoked both their motivation and capacity for activity 
that was unaffected by concurrent lethargy. However, a distinction between motivation and 
capacity in sickness behaviour has been discussed previously (e.g., see Maier and Watkins, 
1998; Larson and Dunn, 2001). Recently, the distinction between motivation and capacity for 
activity was reported in rats that showed impaired motivation for physical exercise 
(measured as voluntary wheel running), but less impairment in their capacity to be active, 
e.g. during normal house-keeping activity (measured as cage activity) (Hopwood et al., 
2009; Skinner et al., 2009). Because voluntary physical exercise (e.g. voluntary wheel 
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running) is optional, it is more likely to be impaired during sickness (Hopwood et al., 2009; 
Skinner et al., 2009). However, activity in a Water Maze is not optional and survival of the 
rats depends on escaping from the water. My observation that the rats swam competently, 
despite being lethargic, contributes to what already is known about activity during sickness: 
in a life-and-death juncture, such as occurs when rats are forced to swim (e.g. in a Water 
Maze) in order to survive, the sickness behaviour of lethargy may be suppressed, because if 
it was implemented it would have threatened survival. I therefore support previous evidence 
that the sickness behaviour of lethargy may be activity specific (Hopwood et al., 2009; 
Skinner et al., 2009). Moreover, motivation for survival may override many aspects of 
sickness behaviour and I believe that this phenomenon may have important implications for 
the behaviour of ill individuals who may find themselves in situations where survival is their 
only option. 
 
Many attempts to simulate chronic, sustained fevers experimentally have failed. However, I 
have shown that it is possible to simulate recurrent acute fevers, in my case during 
simulated recurrent Mycoplasma infection. In spite of their prevalence and importance, 
recurrent acute infections seldom are investigated in the laboratory. Following repetitive 
administration to rats of 500 µg.kg-1 FSL-1, 10 days apart, I observed recurrent fevers, 
recurrent lethargy and recurrent anorexia, but no body mass stunting (Chapter 5). I showed 
that FSL-1, which simulates Mycoplasma infection, is a reliable pyrogen that produces 
consistent, pronounced, recurrent acute phase responses experimentally in rats, without the 
development of tolerance to fever, lethargy or anorexia (Chapter 5), when it is administered 
at 10-day intervals. However, I did not observe residual impairment in learning and memory 
in rats, a finding consistent with recent evidence in mice that had received acute or repeated 
administration of Staphylococcal enterotoxin A (SEA) (Woodruff et al., 2010). My study is the 
first, I believe, to have assessed residual deficits in learning and memory in otherwise 
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healthy rats following recurrent acute stimulation of the innate immune system, i.e. spaced 
injections of a pyrogen with recovery between infections (Chapter 5). However, residual 
impairment has been detected in rats after repeated (i.e. daily injections with no recovery 
between infections) or chronic administration (i.e. continuous infusion) of lipopolysaccharide 
(LPS) (Aubert et al., 1995; Hauss-Wegrzyniak et al., 1998, 1999; Sparkman et al., 2005), 
which is different to my model of recurrent acute administration (i.e. spaced injections with 
recovery between infections). 
 
In addition to measuring residual learning and memory following simulated recurrent 
infection I investigated whether any observed impairments could be associated with 
apoptosis and necrosis in the hippocampus, the principal brain region involved in spatial 
learning and memory. For the histopathology, I used the technique of cresyl violet staining to 
identify apoptosis in the dentate gyrus of the hippocampus (see Pfister et al., 2000). 
However, it is advisable to use other staining methods, including Caspase assays, Annexin 
V assays, cell permeability assays or DNA fragmentation in conjunction with cresyl violet 
staining in future experiments. Although I did not observe any residual histological pathology 
in the hippocampus following simulated recurrent Mycoplasma infection (Chapter 5), it 
remains to be confirmed whether Mycoplasma infection may affect other aspects of 
hippocampal-dependent learning and memory, including non-spatial learning and memory. 
Recurrent, central Mycoplasma infections, rather than peripheral Mycoplasma infections, 
also may affect learning and memory processes. Moreover, it is possible that, in 
Mycoplasma infection, the genetic background of the host is an important determinant of 
whether or not the infected individual will have impairment in learning and memory (see Chu 
et al., 2006). Impairment also may depend on age, the type and severity of infection as well 
as the duration of the infection. A case study in a 7-year old girl has reported pervasive 
changes in memory following M. pneumoniae encephalitis (Benjamin et al., 2007), but 
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cognitive impairment does not seem to be significant in adults or aged individuals who suffer 
from M. pneumoniae encephalitis (Hokkanen et al., 1996a,b). Therefore, if other behavioural 
paradigms that assess other types of hippocampal-independent non-declarative learning 
and/or memory are employed in addition to a Morris Water Maze, we ultimately may be able 
to identify the mechanisms involved in Mycoplasma-induced cognitive impairment and 
whether the impairment is specific to a certain age group or not. Recurrent Mycoplasma 
infection, which affects all age groups, could have long-term detrimental cognitive 
consequences. Therefore, there could be value in repeating my experimental procedures to 
simulate Mycoplasma infection in very young and very old rats. I believe that my model of 
recurrent acute infection has significant potential to be implemented in other experimental 
models of infection, including influenza, malaria and meningitis, which often occur acute 
recurrently. The potential consequences of different types of infections on various aspects of 
learning and memory that might persist once the infected host had recovered from recurrent 
infections require more investigation. 
  
Before any hypotheses are constructed about the consequences of recurrent infection in 
children, based on the outcome of my studies, the factors influencing acute phase responses 
in children, rather than rats, will have to be considered. For example, in humans helminthic 
infections might affect immune reactions to concomitant infections (e.g. tuberculosis) that 
occur with high frequencies in helminth-endemic areas. In the host, helminthic infections 
induce immune hypo-responsiveness to subsequent infections, which is characterized by 
elevated T-helper cell type 2 (Th2) cytokines and IgE production (Bentwich et al., 1999; 
Bundy et al., 2000). Studies also have shown that intestinal helminth infections could impair 
cognitive ability (see Watkins and Pollitt, 1997; Dickson et al., 2000a; Dickson et al., 2000b).  
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Although no direct extrapolation of the outcome of my acute, recurrent study in rats can be 
made to humans, the clinical implications of my study are hopeful in that I did not observe 
permanent stunting in rats. Equally importantly, I did not find any residual histological 
damage to the hippocampus of rats nor did I find lasting detrimental effects on spatial 
learning and memory. Nonetheless, Mycoplasma infection still is a major problem especially 
in developing countries and affects many children. Therefore, studies in children are needed 
to determine whether or not apparently-well children who have recovered from recurrent 
acute Mycoplasma infections have residual deficits in learning and memory. 
 
Not only are Mycoplasma infections prevalent in developing countries, but emerging 
evidence also has implicated Mycoplasma pneumoniae in facilitating allergic airway 
diseases, such as asthma (Sutherland and Martin, 2007; Schroder et al., 2008), with 
increasing incidence in developed countries (European Community Respiratory Health 
Survey, 1996). The increased incidence of respiratory tract infections in developed countries 
presumably is because of lifestyle changes and improved general hygiene in those 
industrialized countries (ISAAC Steering Committee, 1998), a phenomenon often referred to 
as the ‘hygiene hypothesis’ (Strachan, 1989). According to the hygiene hypothesis, reduced 
exposure to micro-organisms may be associated with increased prevalence of allergic 
conditions (Strachan, 1989; Strachan et al., 1994, 1996, 1997). Thus, early childhood 
exposure to pathogens, typically within households, may protect against allergic sensitization 
(see Gangal and Chowgule, 2009). A more recent hypothesis, which parallels the hygiene 
hypothesis, is the ‘parasite-stress hypothesis’, which proposes a positive relationship 
between exposure to infectious disease, albeit at low levels, and high intelligence (see Eppig 
et al., 2010). My observation with regard to sparing of learning and memory during acute and 
recurrent acute simulated Mycoplasma infection not only is encouraging, it also may be in 
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line with the ‘parasite-stress hypothesis’, although we should not equate “normal” learning 
and memory to high intelligence. 
 
FUTURE PERSPECTIVES AND RECOMMENDATIONS 
 
Because of its robustness, I implemented the Morris Water Maze for measuring learning and 
memory in my studies. The Maze also has been adapted for studies in humans. The use of 
advanced 3D-computer technology as well as the implementation of virtual water tasks (i.e. 
the “Virtual Morris Water Maze”) allows researchers to test spatial navigation and memory 
ability in humans under laboratory conditions (Astur et al., 1998, 2001, 2004; Hamilton et al., 
2002). The virtual mazes have proven highly sensitive when used in the assessment of 
cognition in children (Overman et al., 1996; Leplow et al., 2003), novel treatments for age-
related cognitive decline (for review see Lindner, 1997; Driscoll et al., 2003), gender 
differences in cognitive ability and spatial navigation in both adults (Moffat et al., 1998; Astur 
et al., 1998; 2004; Mueller et al., 2008; Woolley et al., 2010) and in children (Newhouse et 
al., 2007), cognitive processes in children with Fetal Alcohol Syndrome (Hamilton et al., 
2003), cognitive ageing (Newman and Kaszniak, 2000), hippocampal damage or dysfunction 
(Astur et al., 2002) as well as the involvement of the hippocampus in spatial navigation 
(Aquirre et al., 1996; Astur et al., 2004; Goodrich-Hunsaker et al., 2010). In the clinical 
setting, the virtual mazes seem to have advantages over the traditional spatial memory 
paradigms in terms of their flexibility, generalizability and experimental control (see Astur et 
al., 2004), although some still prefer the traditional methods (Grigoleit et al., 2010). Although 
the virtual mazes have not been used in humans to study learning and memory processes 
as part of infection-induced sickness responses, their use should be considered.  
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Studies investigating infection-induced learning and memory impairment are crucial, 
because exposure to pathogens is inevitable. Children, in particular, are at risk of recurrent 
infections and of developing chronic infectious diseases, which may have detrimental 
outcomes for cognition. Mycoplasma-induced community-acquired pneumonia is prevalent in 
children in both developing countries as well as in industrialized, developed countries. 
Although M. pneumoniae classically has been considered an extracellular (or membrane-
associated) organism, accumulating evidence suggests that this pathogen and other strains 
of the Mycoplasmas may colonize, exist and replicate as intracellular pathogens within 
human cells (Dallo and Baseman, 2000; Meseguer et al., 2003). Thus, the ability of the 
Mycoplasmas to act as intracellular pathogens may contribute to their pathogenicity. 
Because cytokines appear to mediate the acute phase response to many infections, 
including Mycoplasma infection, studies of cytokine antagonism for therapeutic intervention 
will be critical. Agents that block the actions of cytokines already are available clinically and 
may be used in studies of cytokine-mediated fever and sickness behaviours during real, or 
simulated, Mycoplasma infection. Furthermore, using endogenous antagonism of the 
biological action of cytokines, the actual role of various pro-inflammatory cytokines in 
mediating Mycoplasma-induced fever and sickness behaviours can be confirmed. In 
simulated acute Mycoplasma infection in rats I have shown that increases in concentrations 
of the pro-inflammatory cytokine, IL-1β, in both the plasma and brain accompany fever, 
lethargy, anorexia and body mass stunting without affecting learning and memory (Chapter 
3 and 4).  
 
My finding that learning and memory (as measured with a Morris Water Maze) were spared 
in the presence of an increased concentration of IL-1β is at odds with the findings of others. 
Infection-induced over-expression of pro-inflammatory cytokines, including IL-1β in the brain, 
has been associated strongly with learning and memory impairment (Oitzl et al., 1993; 
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Rachal Pugh et al., 1999; Song et al., 2004; Song and Horrobin, 2004). Consequently, 
studies are needed to clarify whether altered concentrations in the CNS of individual 
cytokines result from a pathological condition, or whether altered expression of cytokines 
results as a consequence of a disorder. In simulated Mycoplasma infection, induced by FSL-
1, investigations also are needed to determine what high plasma concentrations of IL-6 
achieve if there are no changes in brain concentrations of this cytokine (Chapter 4).  
 
Cytokine antagonism also could be used to investigate the roles of pro-inflammatory 
cytokines, including IL-1β, IL-6 and TNF-α, in learning and memory processes. In contrast to 
fever, lethargy and anorexia that are well established sickness responses to many infections, 
learning and memory impairment is not an inevitable consequence of infection, as I and 
others have shown (Thomson and Sutherland, 2006; Huang et al., 2010; Woodruff et al., 
2010; Chapter 3). The question remains why the same pyrogenic moiety (e.g., IL-1β or LPS) 
in the same species sometimes impairs learning and memory in the same task (i.e., Morris 
Water Maze) and sometimes not (refer to Table 1, Chapter 1). Whether the latter 
phenomenon also is true for other pyrogenic moieties needs to be explored, because during 
infection brain regions required for fever may be affected differentially from those brain 
regions required, specifically, for learning and memory. 
   
In situations where learning and memory are critical for survival of the host, sickness 
behaviours may be suppressed. In Chapter 3 I have shown that learning and memory, 
competencies which were crucial for survival of rats in a Morris Water Maze behavioural test, 
were unaffected in spite of the sickness behaviour of lethargy the rats had experienced. 
Further studies are needed to investigate the effect of other sickness behaviours, including 
anorexia, on learning and memory during life-and-death situations. Whether anorexia will be 
suppressed, in order to enhance survival, has clinical relevance particularly for children in 
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resource-poor, developing countries who suffer simultaneously from infection and 
malnutrition. Although nutrition is crucial for mental development (Lynn, 1990, 1993), the 
nutritional status of children also may affect intelligence in the absence of infection (Barber 
et al., 2005). Therefore, experiments in food-deprived animals are needed to determine 
whether cognitive function, including learning and memory will be spared if it could increase 
chances for survival. Similarly, it needs to be investigated whether learning and memory take 
priority over fever or the sickness behaviour of, for example hyperalgesia, when survival 
behaviour is employed during illness. These questions can be addressed by injecting 
species-specific neutralizing antibodies against those cytokines mediating the particular 
infection. For measuring learning and memory, the Morris Water Maze may be used in 
conjunction with other models of learning and memory, which do not necessarily depend on 
physical activity, such as swimming. Sickness behaviours, including lethargy may confound 
results in those models that rely on physical activity, such as the Morris Water Maze. 
 
Because learning/memory impairment appears to be a common, albeit not ubiquitous, 
consequence of immune activation, the question remains whether there is an adaptive 
purpose to illness-induced cognitive impairment? In my view, the type of infection (e.g., 
bacterial vs. viral vs. fungal), the site of infection (e.g., local vs. systemic vs. central) as well 
as the severity and duration of the inflammation may be important predictors for illness-
induced cognitive impairment. It is possible that a longer-lasting, severe, CNS infection may 
increase the chances of cognitive impairment, as opposed to a mild, one-day, local infection. 
The frequency of the infection (i.e., once-off, repeatedly or recurrently) also may be a critical 
predictor of whether cognitive impairment is likely to occur or not. Chronic or recurrent 
activation of the immune response may render the brain more susceptible for neurologic 
sequelae, including cognitive deficits. Other factors, such as old age or health status, i.e., 
patients with HIV, tuberculosis, brain injury or neurodegenerative diseases (e.g. Alzheimer’s 
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disease) also may predispose patients to cognitive decline during infection. All these factors 
may clarify, or even contribute, to the existence of illness-induced cognitive impairment, but 
the adaptive purpose thereof still is incomprehensible.   
 
Moreover, activation of the host’s immune system may result in latent vulnerability to 
subsequent activation and recurrent inflammatory challenges may uncover, or even 
exacerbate existing clinical symptoms. Mycoplasma infection is not the only type of infection 
that occurs recurrently. The bacterium Streptococcus pneumoniae is a common cause, if not 
the main cause, for recurrent pneumonia throughout infancy and childhood (e.g., see Stein 
and Cauduro Marostica, 2007). Other recurrent infections, including meningitis, malaria and 
influenza could have long-term detrimental consequences, such as growth retardation or 
cognitive retardation after resolution of the recurrent infection. If residual detrimental effects 
of infection persist, they need to be investigated experimentally. Management requires an 
understanding of the physiological processes which link the infecting pathogen to the 
sickness behaviour, particularly so that targets for intervention can be identified. When 
simulating infections, experimentally, the use of pyrogenic moieties from organisms should 
be considered instead of using live pathogenic organisms. While I have used FSL-1 derived 
from M. salivarium (which appears to have a lower pyrogenicity compared to M. 
pneumoniae), moieties from other species in the genus, such as MALP-2 from M. 
fermentans (Mühlradt et al., 1997) or FAM20 from M. pneumoniae (Shimizu et al., 2008) also 
should be considered to simulate recurrent infections caused by the Mycoplasmas. So too 
should moieties form other causative pathogens, particularly pneumolysin from S. 
pneumoniae (e.g., see Hirst et al., 2004), be used for future research into simulating 
infections that occur recurrently.  
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Finally, in contrast to simulating chronic infections in the laboratory, there appears to be no 
barrier for simulating recurrent infections experimentally. These studies ultimately will help 
us elucidate whether recurrent acute infections indeed have lasting detrimental outcomes. 
Growth retardation, loss of motivation for life-sustaining activities and cognitive retardation 
may have a devastating impact on the infected individual’s welfare. 
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